SACHS ASSOCIATES

11TH ANNUAL

EUROPEAN LIFE SCIENCES CEO FORUM

FOR PARTNERING & INVESTING IN BIOTECH & PHARMA INDUSTRY

26TH-27TH FEBRUARY 2018
HILTON ZURICH AIRPORT HOTEL
SWITZERLAND

CONFERENCE GUIDE

www.sachsforum.com

SACHS ASSOCIATES ARE DELIGHTED TO WELCOME YOU TO THE:

11TH ANNUAL

EUROPEAN LIFE SCIENCES CEO FORUM

FOR PARTNERING AND INVESTING IN BIOTECH & PHARMA INDUSTRY

26TH – 27TH FEBRUARY 2018
HILTON ZURICH AIRPORT HOTEL
SWITZERLAND

Sachs Associates are delighted to welcome you to the 11th Annual European Life Science CEO Forum for Partnering & Investing in Biotech & Pharma Industry. Back for its 11th Annual edition, this global bio-pharma industry forum addresses through its conference programme the main challenges for 2018 in investment, partnering and alliance management. Key players contribute their insights in panels which cover the macro picture as well as innovation in the different therapeutic sectors. The forum also features keynote speeches, about 50 selected corporate presentations from established (public and private) and emerging biotechs seeking to promote investment and partnering opportunities. There is also a focus on early stage innovation and an elevator session with up 20 presentations by start-ups from BioMed and Digital Health.

GENERAL INFORMATION

• The registration desk is open from 7.30 am on the first day and from 8.30 am on the second day, although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.

• Wireless Internet connection is available throughout the venue for the duration of the event. Please ask for an access code at the registration desk.

• The one-to-one meetings are being held in the La Place A and B, as well as in room London downstairs. Please note that partnering room is not available during these times: 14:00-16:00 on 26th and 12:00-13:00 and 15:00-16:00 on the 27th. Please bring with you a copy of your diary.

Should you have any queries about your schedule, the team member situated by the meeting tables is available for your assistance.

REQUEST FOR PRESENTATIONS

Please use the agenda to mark off presentations that you are interested in and email your request to Silvia@sachsforum.com after the conference. We will endeavor to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter.

Please note that we DO NOT have copies of the slides that are shown during the conference.

EVENTS DIARY

For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Silvia Kar on Silvia@sachsforum.com.

SACHS BIOCAPITAL USA FORUM

FOR PHARMA – BIOTECH PARTNERING & INVESTMENT OPPORTUNITIES

21ST MARCH 2018 • NEW YORK ACADEMY OF SCIENCES • USA

Returning to New York in March 2018, Sachs Associates is pleased to announce the Sachs BioCapital USA Forum. Building on the success of Sachs forums in Europe and the USA, we decided to combine the 2nd Neuroscience BioPartnering & Investment and the 5th Cancer BioPartnering & Investment forums and make one event - Sachs BioCapital USA Forum (BCUSA) that will take place on the 21st of March at the at the New York Academy of sciences. The BCUSA showcases biotechs with advanced therapeutics and brings them together with pharma partnering executives and institutional investors, bankers and advisers. The programme features panels on pharma-biotech dealmaking, advances in different therapeutics areas and a keynote and roundtable on investment. We anticipate up to 250 delegates and around 25 company presentations (public and private) and an emerging company track. There is also a focus on early stage innovation and an elevator session with 10 companies.

4TH ANNUAL IMMUNO-ONCOLOGY: BD&L & INVESTMENT FORUM

1ST JUNE 2018 • WALDORF ASTORIA CHICAGO HOTEL • USA

Taking place on the first day of ASCO, the 4th Annual Immuno-Oncology: BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment.

6TH ANNUAL MEDTECH & DIGITAL HEALTH FORUM

3RD OCTOBER 2018 • CONGRESS CENTER BASEL • SWITZERLAND

This year again we will be holding our 6th MT&DH Forum one day before our 18th Annual BEF Forum, on 3rd of October at the Congress Center Basel. The programme is designed to highlight the latest industry developments and showcase emerging and innovative technology companies seeking finance and partnerships. The delegates are comprised of Healthcare, MedTech, Healthcare IT and Digital Health companies as well as consultants, bankers and corporate & financial investors. We expect over 250 delegates and 25 presenting companies plus presentations by seed companies.

18TH ANNUAL BIOTECH IN EUROPE FORUM

4TH – 5TH OCTOBER 2018 • CONGRESS CENTER BASEL • SWITZERLAND

18th Annual BEF Forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry. This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe's pharmaceutical and biotech industry, this event will once again be covered by our regular media partners. We expect over 650 delegates and over 100 presenting companies plus presentations by seed companies.

The forum will be held for the fifth time in Basel to be close to the largest biopharma hub in Europe and the Congress Center provides meeting space capable of handling several thousand one-to-one meetings as well as significant exhibition space. The programme will feature number of plenary panels/workshops covering BD & Licensing in the main therapeutic areas.

ONLINE ONE-2-ONE MEETING SYSTEM AVAILABLE AT ALL SACHS EVENTS

In order to offer the best possible provision for networking opportunities and deal making Sachs Associates provides all delegates access to our online one-to-one meeting system, allowing you to set up, accept or decline private one to one meetings with other conference attendees. These meetings last for 20 minutes in duration. Individual passwords and logins are provided to allow immediate access and ensure full security.

EUROPEAN INVESTMENT FUND

ADELAIDE CRACCO

Head of Life Sciences

Adelaide Cracco is Head of Life Sciences Competence Centre of the Venture Capital Division at the European Investment Fund (EIF). As part of her responsibilities she oversees EIF's fund of fund VC investment activities and portfolio in the life sciences industry which presently represents over EUR 1.8 bn in commitments. Prior to joining the EIF, Adelaide was Managing Director of the Finaves seed capital funds linked to IESE Business School, investing both in ICT and med tech startups. Before working for Finaves Adelaide was a member of the founding management team and CFO of the Mixta Africa Group an impact venture promoting social and economic housing in Africa and backed by Morgan Stanley and the IFC (World Bank Group). Adelaide developed most of her early career in corporate finance and private equity starting off at the Interamerican Investment Corporation and later joining Clairfield International where she focused on the chemical, healthcare and pharmaceutical industries. Adelaide holds a Master of Sciences in Economics and International Relations from the University of Louvain (Belgium) and an MBA from IESE (Spain).

NXR BIOTECHNOLOGIES GMBH

ALAIN VERTES

Managing Director

Dr. Alain Vertès is Managing Director at NxR Biotechnologies, a boutique global consulting firm based in Basel, Switzerland, where he advises clients on strategy, business development, in/out-licensing, entrepreneurship and investment. He brings to this role extensive experience in the pharmaceutical and industrial biotechnology sectors, in Europe, North America and Asia and in different functions including research, manufacturing, contract research, and strategic alliances. NxR's track record comprises projects with big pharmas, biotechs, generics companies, financial investors, CROs, academia, and start-ups. Prior to NxR Biotechnologies, Dr. Vertès held positions of increasing responsibility in pharmaceuticals at Lilly and Pfizer, and led the global cell therapeutics strategy and implementation team from 2007-2010 at Roche. In addition, he has worked in petrochemicals at Mitsubishi Chemical Corporation, public research at the Institut Pasteur and RITE/Kyoto, contract research at Battelle Memorial Institute and PPD|BioDuro, and has done consulting for the Australian Strategic Policy Institute. With a focus on innovation commercialization, he has been a key player in the evaluation, selection, deal making, implementation and alliance management of numerous novel products and emerging technologies.

Dr. Vertès received his M.Sc. degree from the University of Illinois at Urbana-Champaign, his Ph.D. from the University of Lille Flandres Artois, and is a Sloan Fellow from London Business School (MBA/M.Sc.). Dr Vertès is a lead editor of several science and strategy books in the fields of regenerative medicine and sustainable chemistry.

BASELAUNCH

ALETHIA DE LEON

Managing Director

Alethia is leading BaseLaunch, a leading Swiss healthcare start-up accelerator in Basel. She is also the CEO and founder of Senes Science GmbH, whose mission is to develop medical technologies improving elderly quality of life. Previously, she was at Novartis heading globally the search and evaluation Business Development Activities for the Neuroscience Unit of Novartis Pharmaceuticals AG. She was also part of the Strategy team of Novartis Pharmaceuticals, and previously had product development and business development roles in biotech and in Investment Management in private equity.

Alethia has an MBA from Harvard Business School, and a Masters and Bachelor´s degree in Chemical Engineering from the Massachusetts Institute of Technology.

F.HOFFMANN-LA ROCHE LTD.

ALEXANDER BREIDENBACH

Global Head Neuroscience, Ophthalmology & Rare Diseases Partnering

Alexander Breidenbach has over 19 years of experience in R&D, management, and partnering within pharma, currently as a Global Business Development Director Neuroscience in Roche Pharma Partnering, Basel. He has lead a number of in-licensing and M&A deals to complement Roche's neuroscience pipeline.

Alexander is an accomplished Healthcare Industry professional, with extensive experience in Business Development and Research and Development. He is German, trained in Pharmacology, and holding an MBA.

NOVARTIS VENTURE FUND

ANJA KÖNIG

Managing Director

Dr. Anja König is a Managing Director of the NVF in Basel, Switzerland. She is active in the UK, Switzerland and the rest of Europe. Prior to joining NVF, she was an Associate Partner at McKinsey and Company in New York, a global consultancy, where she worked with healthcare companies in the US, Europe and Emerging Markets. Anja holds a PhD in physics from Cornell University. She currently serves on the boards of Bicycle Therapeutics, F2G and Forendo Pharma and led the investments in Covagen (sold to J&J), Heptares (sold to Sosei) and Nabriva (NASDAQ: NBRV).

MISSION THERAPEUTICS LTD.

ANKER LUNDEMOSE

Chief Executive Officer

In a biopharma career spanning over twenty five years, Dr. Lundemose brings extensive international experience in areas of management, business development, corporate development, M&A strategy, and execution, financing as well as R&D in key therapeutic areas including oncology, neuroscience, diabetes, obesity and anti-infectives. He is a serial entrepreneur and founder of several successful biotech companies, and has a broad international pharma, biotech and investor network. He is currently on the board of Inthera Therapeutics and Antag Therapeutics.

Prior to joining Mission Therapeutics, Dr. Lundemose was CEO of publicly listed Bionor Pharma, and owner and Managing Partner of BioTesch Advice & Consultancy. Previously he was co-founder and CEO of Prosidion, the UK spin-out of OSI Pharmaceuticals' diabetes and obesity assets, which was subsequently reversed into OSI Pharmaceuticals, Inc. At OSI Pharmaceuticals, Dr. Lundemose held several senior management roles, most latterly as Executive Vice President Corporate Development & Strategy Officer, OSI, New York. Notably he was responsible for the acquisition of the DP-IV patent estate from Probiodrug generating a 30 times return on investment. He was also involved in the sale of OSI Pharmaceuticals to Astellas Pharma for $4 billion.

Dr. Lundemose has been involved in a total of six biotech exits/IPOs and has held Board positions on over 12 Biotech Companies.

Dr. Lundemose is a qualified medical doctor and has a D.M.Sc and a Ph.D from the University of Aarhus, Denmark.

SEVENTURE PARTNERS

ANNEGRET DE BAEY-DIEPOLDER

Venture Partner

Annegret de Baey-Diepolder is a Venture Partner of the Life Sciences Department of Seventure responsible for investment opportunities in the DACH region. Formerly she was co-founder and CEO of RNA-based immunotherapeutics company Rigontec GmbH, now Merck & Co., Inc..

As a life science industry consultant and former partner at private equity and venture capital companies TVM Capital and Gimv NV, she brings more than 15 years of experience in the life science and venture capital sector. Prior to joining the VC industry, she led a research group developing therapeutic vaccines at Micromet AG, now Amgen.

Annegret de Baey-Diepolder was trained as a dermatologist and allergologist at the department for Dermatology and Allergology of the academic Hospital LMU in Munich. She studied medicine at Georg-August University of Göttingen and the Technical University of Munich.

Annegret de Baey-Diepolder holds a MD in human genetics from Ludwig-Maximilians-University Munich. She received her postdoctoral training as a fellow of the German Research Foundation at the Basel Institute for Immunology (Basic research institute Hoffmann-La Roche).

EUROPEAN INVESTMENT BANK

ARI-PEKKA LAITSAARI

Senior Investment Officer

Ari-Pekka Laitsaari has been involved with several growth-stage companies in Europe as independent advisor to with core competence in building the path to market and commercialization of innovations and science. While educated in Heidelberg, Germany, his professional expertise spans some 30 years covering investment and corporate banking as well as venture capital throughout Europe. Mr. Laitsaari is an astute advocate of hands-on management believing in strong management teams creating growth stage success stories. In his capacity in various boards as shareholder, chairman and executive board member, he has focused on growth strategies, deal structuring and execution guiding each of the companies he is involved with to get to market successfully. Mr. Laitsaari has been a regular speaker and panellist in European Venture and Private Equity events and was in the Boards of five Finnish and one Swiss Life Sciences companies before returning to Luxembourg to spearhead equity-type co-financing structures in life sciences with European Investment Bank.

MEDEX CAPITAL

BARTJAN VAN HULTEN

Founder

As an investment professional, Bartjan van Hulten has been involved with the healthcare sector for close to 20 years. He currently runs the Medex Healthcare Fund, a healthcare equities fund he founded and which is focused on delivering returns uncorrelated to the market.

Prior to Medex, he was at Fidelity Investments as a healthcare team head, responsible for equity investments in excess of $5bn within US and International portfolios. Prior to that, he led the healthcare research team at MeesPierson (ABNAmro), covering European and US healthcare companies. He has a MSc in Physics from Delft University of Technology, a MBA from Insead, and is a CFA charter holder.

BAYER HEALTHCARE PHARMACEUTICALS, LLC

BERTHOLD HINZEN

Head BD&L General Medicine

Berthold Hinzen is Vice President and Head of Business Development & Licensing (BD&L) at Bayer AG Pharmaceuticals and has 19 years of experience in the pharmaceutical industry. Before joining the BD&L group, he was Senior Director Strategic Marketing Cardiology and Director in Medicinal Chemistry. Berthold Hinzen holds a Ph.D. in Chemistry from the ETH Zurich, Switzerland. After a Post-Doc at the University of Cambridge, UK, he joined Bayer HealthCare Pharmaceuticals Research in 1998.

Since 2008, Berthold Hinzen is a member of the Board of Proteros.

ORYZON GENOMICS SA

CARLOS BUESA

Chief Executive Officer & Founder

Dr Buesa holds a PhD in Biochemistry (Molecular Biology) from the University of Barcelona. He was EU post-doctoral fellow in the Faculty of Medicine at the University of Ghent in Belgium and later Senior Investigator at the Flemish Institute of Biotechnology (VIB). In 1997, he was Group Leader in the Signal Transduction Group of the UB. In 2000, he founded Oryzon Genomics and in 2002 leaved the Academy to focus exclusively in its tasks as CEO. Later he has also taken the executive education programme (PADE) at the IESE Business School in Barcelona and several other additional educational programs in BD and finances.

Under his leadership the company became a pioneer in epigenetic drugs and after a transforming partnering deal in 2014 with Roche, licensing its anti-tumoral ORY-1001 in a deal of +$500 M, Dr Buesa leaded the company public listing in 2015 in Madrid Stock exchange in Spain securing €16,5M in equity ($19M) complemented with €15.5M ($17M) of non-senior, non-convertible debt. In 2016, Oryzon was selected as one of the 3 Finalists in healthcare for the 7th Annual Most Innovative EU Biotech SME Award. In 1Q2017 he leaded a successful 18.2M€ Pipes ($20m) offering that included institutional investors specialized in healthcare and life sciences from the US, Spain and rest of Europe. The company has a second molecule ORY-2001 in Phase II in MS and AD

Dr. Buesa maintains an intense presence in the US Biotech-biopharma circuit, visiting frequently the sectoral hubs like Boston and San Francisco but also relevant cities such as New York City, Chicago or Miami. He has been presenting the Company at Investment Bank Health Care Conferences like Jefferies, Stifel, JMP Securities, Roadman Renshaw or events like BioCEO-NY or BioPharm America and many others and also to more pure scientific Conferences like CTAD, AAIC, ASH, AAN and others.

HBM PARTNERS AG

CHANDRA LEO

Investment Advisor

Dr. Leo has more than 20 years of professional experience in venture capital, clinical practice and biomedical research. He is a member of the private equity team at HBM, a healthcare-focused investment group managing >USD 1.5 billion in assets. In this role, Dr. Leo has been responsible for more than a dozen healthcare investments across the US and Europe and serves or has served as a board representative at companies including CardiacAssist, Gynesonics, i-Optics, Symbiomix, ChemoCentryx and ESBATech.

Dr. Leo completed his medical studies in Berlin and London and holds a doctoral degree from the Freie Universität Berlin (Charité) as well as an MBA degree with distinction from INSEAD. Before joining HBM, he worked as a principal at Wellington Partners, as a physician at the University Hospital Leipzig and as a postdoctoral scientist at Stanford University.

ABBVIE VENTURES

CHARLES KUNSCH

Director

Chuck has over twenty five years of experience in biomedical R&D, business development and corporate venture capital investing. Since 2013, Chuck has been a member of AbbVie's Venture team and is based in Cambridge, MA where his focus is on early-stage investments in therapeutic biotech companies. Chuck is responsible for sourcing, evaluating and transacting venture investments and serves on the board of several AbbVie portfolio companies. Prior to joining the Ventures team, he served as a Director in Abbott's Global External Research organization where he led the identification and implementation of early-stage partnerships across Abbott's therapeutic areas. Prior to joining Abbott in 2009, he served as Vice President of Discovery at AtheroGenics, Inc and started his career in biotech as one of the first scientists with Human Genome Sciences where he led a team of scientists to fully sequence the genomes of several medically important bacterial pathogens. Dr. Kunsch obtained his B.S. in Biological Sciences from Drexel University and Ph.D. from Penn State's College of Medicine in Microbiology and Immunology. He performed his postdoctoral work at the Roche Institute of Molecular Biology and is an inventor on dozens of patents and has authored more than 125 peer-reviewed manuscripts, reviews and book chapters.

LIFESCI ADVISORS, LLC

CHRIS MAGGOS

Managing Director, Europe

Chris established in 2015 the European headquarters for LifeSci Advisors, a New York City based investor relations and communications firm, which provides unparalleled access for life science companies to investors and media around the world. He is founder of BioConfidant Sàrl, a strategic consultancy for investor relations, communication and business development. Chris sits on the board of directors of genome-scale variant analysis company Saphetor SA. As a member of the executive committee at Addex Therapeutics (SIX:ADXN), Chris held the positions of Head of Investor Relations & Communication (2007-2010) and Director Business Development (2010-2013). Chris also worked as: a journalist (2001-2007) at a leading biotechnology trade publication BioCentury; an investor (1997-2000) at a NYC-based biotechnology hedge-fund, Casdin Life Science Partners, which was backed and housed by Hambrecht & Quist (now JP Morgan); and a molecular neurobiologist studying drug dependence at The Rockefeller University (1993-1997), where he co-authored twelve peer-reviewed publications. Chris earned a BA in English Literature and completed pre-medical studies at Yale University.

WELLINGTON PARTNERS GMBH

CHRISTIAN JUNG

Principal

Christian joined Wellington Partners in 2016 as a Principal in the Life Sciences Team.

Christian obtained his MSc degree in Molecular Biotechnology from the Technical University of Munich and was awarded a PhD with distinction in Medical Science and Technology from the Technical University of Munich for his work on patient-specific induced pluripotent stem cells. The key articles generated in the context of his PhD were published in the New England Journal of Medicine, EMBO Molecular Medicine and FASEB Journal and have so far been cited more than 1000 times. In 2013, the thesis was recognized with the "Outstanding PhD thesis award" by the Luxembourg National Research Fund. During the course of his PhD, Christian was supporting the Life Science Team of Atlas Venture in Munich.

Prior to joining Wellington, Christian was a Senior Investment Manager with High-Tech Gründerfonds, the largest german seed investor with 576 Mio. € under management, where he completed and led the early-stage investments in coramaze technologies, WISEneuro, Amal Therapeutics, CuneSoft, PS Biotech, perora, Senostic, Rigontec and Dolosys. Christian was serving as a Board Director at coramaze technologies , as well as a Board Observer at Amal, WISEneuro and Rigontec.

NOVO HOLDINGS A/S

CHRISTINA TROJEL-HANSEN

Senior Investment Associate

Christina serves as Senior Investment Associate at Novo Seeds, the early stage investment arm of Novo Holdings. Her primary focus is identifying promising research projects and building companies.

Prior to joining Novo Seeds, Christina served as Senior Business Development manager in Novozymes' Business Creation and M&A division. Additionally, Christina has been working as patent agent at one of Europe's largest patent and IP consulting firms, Zacco where she led the efforts of building the IP intelligence division. Additionally, Christina has worked as analyst within the area of emerging nanobiotechnologies. Christina has also been serving as start-up mentor at Indiebio (CA) and Breakout Labs (CA).

Christina has a background in the field of nanobiotechnology and cancer drug discovery. She completed her post-doctoral training at the leading european cancer Centre, Institute Gustave Roussy (INSERM) within the field of immuno-oncology. Christina holds a PhD from University of California, Berkeley and an MSc from the iNANO Centre at University of Aarhus.

Christina has received several awards and she was in 2017 nominated as one of Denmark's top business talents.

BOSTON PHARMACEUTICALS, INC.

CONSTANTINE CHINOPOROS

Chief Business Officer

He joins Boston Pharmaceuticals from Sanofi, where he was Vice President and Chief Licensing Officer, responsible for the global business development function since 2014. In addition, the North American and European regional Business Development teams reported to him. Some of the notable transactions he was directly responsible for included Sanofi's $2.5 billion Immuno-Oncology pact with Regeneron, acquisition of the Rx to OTC rights for Cialis from Eli Lilly, and the purchase of Priority Review Vouchers from Biomarin and Retrophin.

Constantine brings extensive experience in Business Development with nearly 20 years of working in external innovation-focused roles in the biotech and pharma industries. He joined Sanofi following its acquisition of Genzyme in 2011, and assumed the role of regional head of Business Development for Sanofi's North American Pharmaceutical division. Prior to this position, he was a Vice President in Genzyme's Corporate Development group, which he joined in 2001.

Before Genzyme, Constantine served in various capacities at Eli Lilly and Company over a twelve year period, including roles in Corporate Finance & Investment Banking as well as the Office of Alliance Management.

Constantine received an undergraduate degree in History as well as an MBA from Cornell University.

HALIODX

CORINNE DANAN

EVP, Partnerships BU

Corinne leads the Partnerships Business Unit at HalioDx a French diagnostic company. HalioDx is an immuno-oncology diagnostic company, founded in 2015 by Corinne and 4 others co-founders.

Her focus is to develop partnerships with Pharma, by including HalioDx proprietary assays in Pharma clinical trials to demonstrate potential predictive value. HalioDx has the capabilities & experience to partner with Pharma from early stage to Companion Diagnostic commercialization.

Corinne worked during 15 years in Pharma (Lilly), and during 10 year in the Diagnostic Industry.

Corinne has a MBA from Insead.

TOUCHSTONE INNOVATIONS

DANI BACH

Healthcare Investment Director

Dani joined Innovations in January 2016 from Aravis, where as managing partner he co-led the design of the investment strategy, fund raising and investment process. He focuses on early stage, at times matching technologies with passionate management teams. His areas of investment have ranged from medical devices to protein therapeutics.

Prior to Aravis, Dani worked at Index Ventures, helping build companies such as Acutus Medical, Levicept, and Versartis.

Dani holds a PhD in molecular biology from the University of Barcelona and an executive MBA from the Escuela de Organización Industrial (Madrid).

JOHNSON & JOHNSON INNOVATION

DECLAN JONES

VP, Neuroscience Lead

Declan N.C. Jones, PhD joined Janssen Neuroscience in 2013 as Vice President, Neuroscience External Innovation, located at the J&J Innovation Centre in London. He is responsible for identifying Neuroscience opportunities across Europe and Asia-Pacific regions, and coordinates mood disorders opportunities across the Innovation Centres. He is an in vivo psychopharmacologist by training (>77 papers and book chapters). He previously worked for GSK's Centre of Excellence for External Drug Discovery (CEEDD) as Global Head of Research and was responsible for creating scientific strategies, identifying external opportunities, and managing programs from preclinical to Phase II programs across all therapeutic areas. Prior to this, he spent 14 years in GSK's Neuroscience R&D, finishing as Head of In Vivo Neurobiology and Strategy Leader for schizophrenia and bipolar disorders within the Psychiatry Centre of Excellence for Drug Discovery. His group helped identify >12 psychiatry clinical development candidates, and provided scientific support for marketed assets, including Seroxat, Lamictal, Wellbutrin and Requip. Declan received a significant R&D Pipeline award for leadership of a schizophrenia program with a successful Phase II outcome. He received his PhD from the University of Bradford and did post-doctoral work at Emory University and Glaxo. He served as a Neuroscience panel member on the UK's BBSRC grant committee, is a founding Executive Team member for the Dementias Platform UK (DPUK), the Wellcome Trust Neuroimmunology in Mood & Alzheimer's Consortium, is a JSC member for the J&J/Karolinska Institute alliance, and is a SAB member for the South London and Maudsely Mental Health Biomedical Research Centre at the Institute of Psychiatry, Psychology, and Neuroscience. Declan also works closely with our corporate venture team, JJDC, and J&J funded innovators such as Dementia Discovery Fund, JLINX, Apollo Therapeutics, and FutuRx – which incubate novel science emerging from academia. Declan is also the Neuroscience Lead for the Asia-Pacific J&J Innovation Centre.

ASCENEURON SA

DIRK BEHER

Chief Executive Officer

Dirk Beher is the chief executive officer, a founder and member of the board of directors of Asceneuron SA. Since its inception he has strategically positioned Asceneuron as an emerging leader in the field of orally bioavailable drugs for treating tauopathies. Under his leadership the company has raised over CHF 40 million from leading venture capital firms and successfully moved the novel modifier of tau pathology ASN120290 from early discovery into the clinic.

Dirk brings more than 25 years of experience in the field of Alzheimer's disease and neurodegeneration. He has spent over 19 years in pharmaceutical drug discovery including senior research positions around the globe at Merck Sharp & Dohme (Merck & Co.; UK), Amgen (US) and Merck KGaA (CH). Dirk holds a Ph.D. and a Diploma (M.S.) in Biology from the Ruprecht-Karls University Heidelberg, Germany. He is an inventor of seven patents and currently the author of 49 peer-reviewed publications and reviews.

GRABULOVSKI CONSULTING SERVICES

DRAGAN GRABULOVSKI

Chief Executive Officer & Founder

Dr. Dragan Grabulovski is an advisor in pharmaceutical biotechnology at Grabulovski Consulting Services (CH). He was previously chief scientific officer and co-founder of Covagen AG, a Swiss biotech company acquired in 2014 by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson.

As Covagen's CSO, he was responsible for developing and overseeing the execution of the overall strategy for research and development. He was a main inventor of the Fyno-mer technology, established a portfolio of novel bispecific FynomAb product candidates and managed the internal and collaboration pipeline. As a member of Covagen's executive management team, Dr. Grabulovski was instrumental in Covagen's trade sale to Johnson & Johnson, and in the closing of Covagen's CHF 45M ($44.5M) Series B round in 2014 with the participation of renowned investors such as GIMV, Edmond de Rothschild Investment Partners, Novartis Venture Fund and other prestigious funds.

Dr. Grabulovski received his master's degree in pharmaceutical sciences and Doctor of Sci-ences from ETH Zurich (CH). He is a co-author of several peer-reviewed articles, reviews, book chapters, poster abstracts, patent applications and granted patents.

PDC*LINE PHARMA SA

ERIC HALIOUA

President & Chief Executive Officer

Eric Halioua is President and CEO of PDC*line Pharma. He is as well Board member of the biotechnology company Bioxodes, HairClone, Vitricell and Innobiochips. He has raised more that €80 million over the course of his career and has had numerous successes in the sale and initial public offering of biotechnology companies. He is co-Inventor of the first GMP approved mobile manufacturing unit for cell therapy. Eric is co-founder of four biotechnology called Myosix (bought by Genzyme mid-2002), Murigenetics, HairClone and Digital Orthopaedics. Eric was also a Board Member of a French public biotechnology company called Valneva, which specializes in the development and commercialisation of vaccines and monoclonal antibodies. He was as well principal of the life sciences practice of Arthur D. Little in Paris and Boston during 11 years. He also worked as project leader in the corporate R&D centre of Astra-Zeneca. Eric holds two master degrees (DEA and Magistère) in Pharmacology and Molecular Biology and a MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair.

ETH ZURICH (IMSB)

ERNST HAFEN

Director of Studies

Ernst Hafen, PhD, is a Professor of Systems Genetics at ETH Zurich and former President of ETH. In addition to over 30 years of academic research, he has founded and advised several biotechnology companies. He is the president of the BIO-TECHNOPARK Schlieren-Zurich. Ernst Hafen endeavors to assist scientific discovery and its efficient translation into products that help society and the economy. As a trained geneticist, he has a strong interest in human genetics and personalized medicine. He posits, that an individual's control over his or her personal health data, will be a key asset for better and more effective health care.

In 2012 he acted as a founding member of the Association Data and Health and is the president of MIDATA.coop (https://www.midata.coop) which he co-founded in 2015. Citizen-owned personal data cooperatives enable citizens to securely store, manage and control access to their personal data and form the basis for a fair and sustainable personal data economy.

TARGIMMUNE THERAPEUTICS AG

ESTEBAN POMBO-VILLAR

Chief Executive Officer

Dr. Esteban Pombo-Villar is the Chief Executive Officer of TargImmune Therapeutics, and has 30 years of experience in leading biopharmaceutical R&D, business development and alliance management. Previously he was Chief Operations Officer (COO) for Oxford BioTherapeutics, and a Member of their Boards of Directors. He was responsible for the development data and manufacturing activities of their lead antibody and antibody-drug conjugate projects and their collaboration projects. Prior to joining Oxford BioTherapeutics, Dr. Pombo-Villar was at Novartis and Sandoz for over 23 years, the last 12 years engaged in Business Development and Alliance Management, most recently as Head of Alliance Management at the Novartis Institute for Biomedical Research (NIBR), for alliances in all therapeutic areas up to proof-of-concept in man. Prior to that he led Medicinal Chemistry efforts in the Neuroscience group as Chemistry Expert, and was Laboratory Head and Chemistry Project Leader for multiple projects. He obtained a PhD, MSc and BSc in organic chemistry from the University of Warwick (UK), was visiting researcher at the University of Newcastle upon Tyne (UK) and completed postdoctoral studies at the ETH in Zurich. Dr. Pombo-Villar is a Fellow of the Royal Society of Chemistry, and member of several scientific societies, and has completed executive business studies at IMD (MTE, Lausanne), Harvard Business School (US), and the Tuck School of Business (Dartmouth, US). Dr. Pombo has been on the faculty of the European Course for Biobusiness Development (University of Basel and ETH Zurich, 2007-2009), lectured in many conferences and workshops and is a member of the Licensing Executive Society.

PHARMAVENTURES LTD.

FINTAN WALTON

Chief Executive Officer

In 1992 Dr Walton co-founded CONNECT Pharma, a predecessor company to PharmaVentures focused on assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making. In 1997 this company became PharmaVentures.

Since its inception, PharmaVentures has worked with blue chip clients on a global basis, delivering more than 700 assignments for companies in 38 countries. Clients have included major pharmaceutical and biotechnology companies as well as diversified chemical corporations, medical device, generic and OTC companies. Its clients have included major banks, investment/merchant banks, and private equity and venture capital groups.

In 1996 he also founded PharmaDeals, the leading database and publishing business related to dealmaking. Thousands of customers from around the world have either bought or subscribed to these PharmaDeals publications. PharmaDeals was sold to IMS Health in Aug 2012.

Educated at Trinity College (Dublin, Ireland), Fintan subsequently gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

INKEF CAPITAL

FIONA MACLAUGHLIN

Director

Fiona joined Inkef Capital as a Director in 2017 with >20 years of experience in Life Sciences, in particular founding companies and financing early stage life science technologies. She is a Director of Calypso Biotech BV. Previously, Fiona was an Associate at Advent Life Sciences, during which time she co-founded Boston-based Arrakis Therapeutics Inc and helped build companies Capella Therapeutics, Levicept and CoCo Therapeutics. Her interest in innovation came from her prior role as a Business Development Manager in the Technology Transfer Division of the Wellcome Trust. There she evaluated early stage product development opportunities and investments for Translational Funding, established and ran the £45M "R&D for Affordable Healthcare" fund, a joint venture with the Indian Government supporting development of new technologies in India, and was part of the founding team with Merck & Co Inc, a joint venture leading to the formation of the Hilleman Laboratories, Delhi. Fiona has historically held senior operational roles as Head of Strategic Business and Product Development at RepRegen™ Ltd, Head of R&D at Gendel Ltd, and scientific roles at Phaeton Ltd and US-based gene therapy company Valentis Inc. In parallel, she was an Advisor to Tiber Creek Partners, a US-based boutique consultancy advising life science companies of opportunities in sourcing non-dilutive capital. Fiona is a Pharmacist by training and has a PhD in drug delivery (Nottingham University).

INSERM TRANSFERT INITIATIVE

FRANCOIS THOMAS

Partner

EDUCATION

MIT Sloan School of Management, Boston

Master in Management and Sloan Fellow, 1995

Paris School of Medicine

- "Habilitation à diriger des recherches". (Equivalent to a Ph.D), 1994.
- Board certification in medical oncology, 1987 (revalidated in 2013)
- Master in Science (human biology), 1986
- Medical Doctor (MD), 1984

Foreign Medical Graduate Examination in the Medical Sciences (ECFMG, US), 1984

Investment Manager Certificate of the UK society of Investment Professionals, 2004

EXPERIENCE

September 2017- to date: Venture Partner, Sofimac Innovation, Paris

2015- 2017: President and Managing Partner, Inserm Transfert Initiative (ITI), Paris

ITI is a leading seed fund investing in Biotech companies. ITI has been financed by Inserm, the French Investment Bank (BPI), and 9 Pharmaceuticals companies.

Portfolio companies raised more than 100 million Euros in 2015 with VC firms such as Versant, Orbimed, NEA, EdRIP, Sofinnova, BPI, Kurma, Morningside...

Non-executive irector of 8 portfolio companies

1995- To date: Founder and managing director of the consultancies Bioserve Ltd, Cambridge (U.K) and Thomas Conseil SPRL (Belgium)

Clients: more than 80 Pharma and Biotech companies, public research institutions, and Biotech investors in Europe and North America.

Main assignements were on: drug development programs, strategy and market research for anticancer drugs and therapeutic proteins; technical assessment, valuation and structuring of (in- and out-) licensing deals and academic spin-offs; strategic advice, design of business plan and private placements for start-up/biotech companies.

2013: Visiting Physician, department of medicine, Bordet cancer center, Brussels (Be)

Studies on the role of next generation sequencing on cancer drug development and prescription

2011- June 2012: President and CEO of Cytheris (Paris),

Development of recombinant interleukin-7 (in phase II) in viral infections

2006-2007: Senior Advisor, in charge of healthcare corporate finance, Bryan Garnier,

A French investment bank, leader in the financing of innovative companies

Led the IPO of Innate Pharma (11/06), the follow-on offerings of Transgene (Euros100M; 06/07), and Bioalliance Pharma (40M Euros; 07/07), all on Euronext

2002-2006: Partner, Atlas Venture LP, London (Senior advisor 2006-2007)

A leading US venture capital firm with $2.3Bn assets under management at that time.

In charge of the French and Benelux Life Sciences activities (2002-2005), and responsible for: new investments (Axovan (sold to Actelion), Newron (listed on the Swiss stock exchange), and Novexel (spin-off of Aventis sold to AstraZeneca) and other portfolio companies (Cropdesign latter sold to BASF, Neurotech, IDM, latter sold to Takeda...)

1999-2001: Vice-President Licensing and Pharmacogenomics and CMO, Genset, Paris

A leading genomics company (listed on NASDAQ, sold in 2002 to Serono)

Responsible for pharmacogenomics programs partenered with Pharma companies (Sanofi, Abbott, Pharmacia) and academia (in France and US).

1989-1994: Vice-President, clinical development, Ipsen, Paris

VP for R&D portfolio management (1989 to 1991), then CMO of Ipsen Biotech (1991 to 1994), responsible for the development and registration of the peptides triptorelin and lanreotide in Europe, latter registered worldwide

1987-1988: Guest Researcher, US National Institute of Health, Bethesda

Studies on the molecular biology of lung cancer at the US National Cancer Institute

1986-1989: Assistant professor of oncology, Gustave Roussy Cancer Institute, Villejuif

Care of patients with and clinical research on lung and breast cancers and lymphomas

1981-1986: Resident and fellow, Hospitals affiliated to the Paris Medical School

Interne des Hopitaux de Paris

2002-2017: Boards

Former independant director of DNA therapeutics, Epixis, Eurogentec (sold to Taneka), YMB (listed on NYSE, sold to Gilead) and Zentech.

Independant director of Gamamabs and Cardiawave.

Past representative of Atlas at the board of 5 European biotech companies.

Representative of ITI at the boards of Aelis Pharma, Annapurna (until the merger with NASDAQ-listed Avalanche in 2016), Biomodex, Eyevensys, Inotrem, Sensorion (listed on Euronext), Step Pharma, Therachon.

Former member of the SAB of the fondation Fournier/Majoie (Belgium) and of Ipsen, and of the advisory committee for tech transfer of the Curie Institute (France)

SCIENTIFIC ASSOCIATIONS AND PUBLICATIONS

- Member: American Association of Clinical Oncology, American Association for Cancer Research, American Society of Hematology, European Society of Medical Oncology.
- Former editorial board member: Expert Review of Molecular Diagnostics, Biodrugs.
- 70 publications in peer-reviewed journals

ADRENOMED AG

FRAUKE HEIN

Chief Business Officer

Dr. Frauke Hein, Co-Founder and Chief Business Officer (CBO) of Adrenomed AG, is Biologist with decades of experience in the diagnostic and biotechnology industry. Before establishing Adrenomed she was at BRAHMS AG / Thermo Fisher Scientific responsible for strategic global R&D projects, in the field of cardiology, liver disease, sepsis and neurodegeneration. Dr. Hein is Executive Board Member of the InfectControl 2020 Consortium, Member of the Board of Trustees of Technology Foundation Brandenburg and was Jury Member of the Berlin-Brandenburg Business Innovation Award.

TAKEDA PHARMACEUTICALS

GABRIELE PROETZEL

Director, Regenerative Medicine

Gabriele Proetzel, PhD is Director of Regenerative Medicine at Takeda Pharmaceuticals, based in Cambridge, MA. In her current role she is focused on cell and gene therapy therapeutic approaches and strategic alliance management.

Prior industry appointments were at Scil Proteins, Halle Germany, Deltagen Inc., San Carlos, California and Boehringer Mannheim/Roche Penzberg, Germany. Before joining Takeda, Gabriele held the position of Associate Director of Technology Transfer at The Jackson Laboratory, Bar Harbor, Maine, USA.

Gabriele earned her Master degree in Life Sciences from the Ludwig-Maximilian University of Würzburg, Germany, and a Ph.D. from University of Cincinnati, Ohio studying homologous recombination in embryonic stem cells in order to develop mouse models for disease. She did her postdoctoral training in the laboratory of Prof. Peter Gruss at the Max Planck Institute for Biophysical Chemistry in Göttingen, Germany.

JEFFERIES INTERNATIONAL LIMITED

GIL BAR-NAHUM

Managing Director

Dr. Gil Bar-Nahum is a Managing Director in the Global Healthcare Investment Banking Group at Jefferies and is based in London. He leads the Jefferies' International Biotechnology team with a primary focus on innovative companies in Europe and Israel. Dr. Bar-Nahum has over 18 years of investment banking experience and has executed transactions for biotechnology, pharmaceutical, medical technology, and life science tools companies. In the last 4 years Dr. Bar-Nahum has led the execution of more than 40 financings, including 22 IPOs for foreign private issuers (16 on NASDAQ), raising more than US$4Bn.Dr Bar-Nahum has also advised on more than 10 cross-border M&A transactions in the last several years, including most recently advising Advanced Accelerator Applications in its $3.9bn sale to Novartis. From 2002-2009 Dr. Bar-Nahum was part of UBS Investment Bank's Global Healthcare Group, based primarily in the US. Prior to that, Dr. Bar-Nahum worked as an Equity Research Analyst for UBS where he served as an Associate Director covering companies in the Life Science Tools and Biotechnology space. Dr. Bar-Nahum received his PhD in Basic Medical Sciences from the Department of Biochemistry at the Sackler Institute of New York University School of Medicine. The subject of Dr. Bar-Nahum's doctorate work was published twice in the journal Cell. Dr. Bar-Nahum also received an MS from New York University's School of Medicine in Cell and Molecular Biology and a BS from the University of Illinois in Microbiology.

CANTARGIA AB

GÖRAN FORSBERG

Chief Executive Officer

Dr Göran Forsberg has been CEO for Cantargia since 2104 and was responsible for Cantargias IPO in 2015. In total more than 40 M€ has been raised. Cantargias lead project is an immuno-oncology antibody in phase I/IIa clinical development focused on non-small cell lung cancer and pancreatic cancer. Dr Forsberg has a PhD in biochemistry, and is an associate professor and author of over 40 scientific publications. He has worked for pharmaceutical and biotechnology companies for 30 years in various positions, including at KabiGen, Pharmacia, Active Biotech and the University of Adelaide, Australia. He has a large amount of drug development experience, with a special focus on oncology. Dr .Forsberg also has significant experience in business development from previous engagement as Chief Business Officer at Active Biotech AB. Since 2011, he is also a board member of Isogenica Ltd.

JOHNSON & JOHNSON

GREGOR J. MACDONALD

Senior Director, Neuroscience Scientific Licensing

Dr. Gregor Macdonald graduated with a B.Sc. (Hons.) degree in Organic Chemistry from Edinburgh University in 1992, before joining the Wellcome Foundation in London within the Medicinal Chemistry department. In 1994, he moved to the University of York where he obtained his Ph.D. in natural product synthesis in 1997. Between 1997 and 2004, he worked for SmithKline Beecham and then GlaxoSmithKline, playing a prominent role in leading discovery programs within both the Psychiatry and Neurology disease areas. Over this period, he was successfully involved in identifying several clinical stage drug candidates, including the 5-HT6 antagonist, SB742457, which progressed to Phase III clinical trials as a cognitive enhancer in Alzheimer's disease

In 2004, Dr. Macdonald joined Janssen Pharmaceutica in Belgium, to lead the Psychiatry 1 Medicinal Chemistry team and then later a combined Psychiatry group. During this period, he co-led the discovery program aimed at identifying Fast Dissociating D2 antagonists for the treatment of schizophrenia, resulting in the identification of JNJ37822681, which has progressed to late stage clinical trials. From 2007 to 2016, Dr. Macdonald was head of the Neuroscience Medicinal Chemistry team in Europe, leading teams in Beerse (Belgium) and Toledo (Spain) in the identification of multiple clinical candidates from the Janssen mGluR and PDE programs, together with supporting significant research efforts to develop disease modifying treatments for Alzheimer's disease, including BACE inhibitors and gamma-sectretase modulators. In 2016, Dr. Macdonald moved into Janssen Business Development to lead Neuroscience Scientific Licensing.

Throughout his time within Janssen, Dr. Macdonald has been involved in managing several external drug discovery collaborations, including those with Addex Therapeutics, the Vanderbilt Centre for Neuroscience Drug Discovery, Shionogi, Neurosearch and Evotec. He is a co-author and co-inventor on over 100 scientific publications and patents and has been an invited speaker and panelist at several international conferences.

BIOARCTIC AB

GUNILLA OSSWALD

President and Chief Executive Officer

In current position since 2014, employed since 2013. Gunilla Osswald has more than 30 years of experience from drug development. She has successfully brought projects from pre-clinical and clinical development to regulatory approval and market introduction as well as managed in- and outlicensing of drug projects. In leading positions at Astra/AstraZeneca during 1985-2013, including Vice President with the responsibility of the product portfolio in neurodegenerative diseases Education: Pharmacist and Ph.D. in biopharmacy and pharmacokinetics at Uppsala University, Sweden.

ABIVAX

HARMUT EHRLICH

Chief Executive Officer

Physician and entrepreneur with >30 years in the bio-pharmaceutical industry, having lived and worked in the US, The Netherlands, Germany, Switzerland, Austria and France.

Current role: CEO of Paris-based ABIVAX since its creation in 2013. ABIVAX is targeting the immune system to develop novel treatments that eliminate viral (e.g. HIV, Dengue and Ebola) and inflammatory diseases (e.g.. ulcerative colitis) as well as cancer. In June 2015, ABIVAX accomplished the most successful Biotech IPO at Euronext Paris ever by raising 57.7 Mio Euro. ABIVAX' lead compound, ABX464, is the first drug that has ever shown a reduction of the HIV reservoir in immune cells, and is being developed as a potential functional cure for HIV/AIDS.

Previously VP and Head of Global R&D and Medical Affairs, Baxter BioScience (2006-2013). Drove the global regulatory approval of >10 biologics in the areas Hemophilia, Thrombosis, Immunology, Neurology, Oncology, BioSurgery and Vaccines. Served as Baxter's principal investigator on a grant from US DHHS (BARDA), which paid $ 242 Mio (2006 – 2013) for the development of cell-culture derived seasonal and pandemic influenza vaccines.

Authored and coauthored >120 peer-reviewed articles and book chapters, incl. a first authorship in NEJM and a senior authorship in The Lancet.

VAXIMM AG

HEINZ LUBENAU

Chief Operating Officer

Heinz Lubenau co-founded VAXIMM in 2008 and currently serves as Chief Operating Officer leading all the development activities of the Company. Prior to this, 2003-2008, he was Global Project Manager Biosimilar G-CSF and Head of Preclinical and Clinical Development at BioGeneriX AG, where he led the development work of the first biosimilar G-CSF Ratiograstim® from preclinical studies through European marketing approval and launch and of the 2nd generation G-CSF Lonquex from project implementation to clinical Phase 2. In 1994 he joined Servier Forschung und Pharmaentwicklung GmbH as Junior Project leader and rose to Clinical Research Manager and Project Director Internal Medicine in 2001. In this role he was responsible for Servier Phase 1 to Phase 3 clinical trials in Germany, Austria and Switzerland for cardiology, diabetes and hypertension, including the registration trials of Preterax® and Procoralan®. At this time, he also led clinical project teams and was responsible for hiring clinical project staff. Heinz Lubenau gained his PhD in pharmacy from Johannes-Gutenberg-University, Mainz.

ADAPTIMMUNE THERAPEUTICS

HELEN TAYTON-MARTIN

Chief Business Officer

Dr. Helen Tayton-Martin has over 25 years of experience working within the pharma, biotech and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence and business development. She co-founded Adaptimmune from the former company, Avidex Limited, where she had been responsible for commercial development of the soluble TCR program in cancer and HIV from 2005 to 2008.

Dr. Tayton-Martin transitioned to become Adaptimmune's Chief Business Officer in March 2017, having served as its Chief Operating Officer since 2008, a role in which she oversaw the transition of all operations in the company from 5 to 300 staff, through transatlantic growth, multiple clinical, academic and commercial collaborations and private and public financing through to its NASDAQ IPO. Today, she is responsible for optimizing the strategic and commercial opportunity for Adaptimmune's assets, leading on business development and commercial activities. Her role encompasses all aspects of pipeline and technology assessment, strategic portfolio analysis, integrated program management and commercial planning and partnerships, including the company's strategic partnership with GSK.

Dr. Tayton-Martin also serves as a non-executive director of Trillium Therapeutics Inc. (NASDAQ and TSX: TRIL). She holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London Business School.

MERCK KGAA

HOLGER SCHWARZ

Director, Global Head of Search & Evaluation Discovery Technologies

Holger Schwarz transitioned to Merck Serono as 'Director Innovation Opportunities Europe' from Merck Chemicals, where he was 'Director Innovation Management' in the Technology Office Chemicals, covering both, Merck's Performance Materials division and Merck Millipore. Before Millipore has been acquired by Merck KGaA, Holger joined Millipore's BioScience Division in Danvers, MA, USA, as a 'Director Business Development'. In 2006 he became a member of the Corporate Technology Office as a 'Director Alliances & Technology' in Merck Millipore's headquarters in Billerica, MA. While he has been a member of the Corporate Technology Office, Holger has been elected to become an 'Executive Committee Member' of the Biomedical Diagnostics Institute (BDI) in Dublin, Ireland, and later he has had a seat at the BDI Governance Committee.

Previously, Holger has been an independent consultant and worked as a 'Manager Business Development' at EMBLEM in Heidelberg, Germany, and as 'Product Development Manager' and 'Laboratory Manager' at QIAGEN in Hilden, Germany.

In academia, Holger has been a visitor at the EMBL in the laboratory of Dietrich Suck and worked at the Max Planck Institute for medical research in the groups of Kenneth C. Holmes and Nobel Laureate Bert Sakmann. Holger earned his Dipl. Biol. (Master equivalent), and Dr. rer. nat. (Ph. D. equivalent) degrees at the University of Heidelberg, Germany.

ORBIMED ADVISORS, LLC

IAIN DUKES

Venture Partner

Iain D. Dukes, D.Phil., is a Venture Partner with OrbiMed. Iain also serves on the Board of Lion Biotechnologies. Most recently Iain was a Senior Vice President, Business Development & Licensing Merck where he oversaw all licensing deals for Merck Research Laboratories, including external research, out-licensing, regional deals and academic alliances. Iain has more than 20 years of experience in pharmaceutical research, drug discovery, scientific and technology licensing, start-up company leadership, as well as consulting for numerous biotech and venture capital organizations. Before joining Merck, he served as vice president of External Research and Development at Amgen. He has also held positions as president and CEO of Essentialis Therapeutics and as Vice President, Scientific and Technology Licensing at GlaxoSmithKline. Iain received his D.Phil. degree from the University of Oxford where he also received a B.A. in Jurisprudence.

F. HOFFMANN-LA ROCHE LTD.

ISABEL FERREIRA

Director Global Business Development

Isabel joined Roche Partnering in 2015 as Director Global Business Development in Neurosciences, Ophthalmology and Rare Diseases (NORD). In this role, she has broad responsibility across the BD process including strategy, search, evaluation, senior stakeholder management, due diligence and negotiation. Recently, Isabel successfully led the deal team and the cross-functional Due Diligence team to license BMS`s anti-myostatin for the treatment of Duchenne's Muscular Dystrophy.

Before joining Roche, Isabel worked as Senior Director Business Development at Prosensa. She was instrumental in managing Prosensa's IPO and subsequent acquisition by BioMarin and held roles of increasing responsibility within licensing, equity financing and corporate development.

Previously, Isabel worked at Janssen-Cilag (J&J), at OctoPlus (The Netherlands) and Theravance (USA) in commercial, drug development and scientific roles.

Isabel holds a PhD in Biochemistry from the University of Groningen and an MBA from the Rotterdam School of Management (RSM), Erasmus University.

TAKEDA PHARMACEUTICALS INTERNATIONAL AG

ISABELLE HEIT

Director Global Alliance Management

Dr Isabelle Heit joined Takeda Pharmaceuticals International AG as Director of Global Alliance Management after Takeda acquired Nycomed in 2012.

In this role she manages global and cross regional strategic development and commercial alliances in different therapeutic areas. She is a core team member of the Center of Excellence for Alliance Management at Takeda and contributed significantly to its design and implementation. Furthermore, she was also engaged in the integration of the Nycomed alliance portfolio. Takeda earned the Alliance Program Excellence Award of the Association of Strategic Alliance Professionals' (ASAP) in 2013 and 2015.

Prior to joining Takeda in 2012, Isabelle had different responsibilities at Nycomed GmbH and the former ALTANA Pharma AG, Germany in In-licensing, Project-Management and Early Research.

She has a Ph.D. in Chemistry from the University of Mainz in Germany.

F. HOFFMANN-LA ROCHE LTD.

JAKOB BUSCH-PETERSEN

Intrapreneur

Dr. Jakob Busch-Petersen is an Intrapreneur in Roche's External Innovation Group (Therapeutic modalities) where he is responsible for scouting, developing and executing novel early stage therapeutic and technology programs with external partners. Before joining Roche in 2015, he worked in a similar capacity in GlaxoSmithKline's Discovery Partnerships with Academia. Jakob started his industrial career in 2000 as a medicinal chemist at Smith-Kline-Beecham. His track record includes the marketed muscarinic antagonist umeclidinium bromide (Anoro/Incruise) as well as the late stage CXCR2 antagonist danirixin for which he was the project leader and sole inventor. Jakob holds a Ph.D in organic chemistry from the University of Hawaii and conducted post-doctoral research with Nobel laureate with E. J. Corey at Harvard University.

JOHNSON & JOHNSON INNOVATION

JEANNE BOLGER

Vice President, Venture Investments

Jeanne joined Johnson & Johnson Development Corporation (JJDC) as Vice President, Venture Investments, in February 2013. She is based in London, UK at the Johnson & Johnson Innovation Centre. Jeanne's responsibilities are focused on investing in and managing portfolio investments in the pharmaceuticals and biotechnology areas in Europe.

Jeanne has over 25 years of pharmaceutical industry experience in management roles across R+D, Commercial and Business Development. She spent 11 years in Licensing and Acquisition, most recently as Global Head of Scientific Licensing for Johnson & Johnson's Pharmaceutical business, having joined the Johnson & Johnson Family of Companies in 2005 from the Business Development group at GSK.

In 2009, Jeanne became VP Alliance Management and Board Director at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan on immunotherapies targeting beta amyloid for Alzheimer's disease.

Jeanne received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). She has served as the sole pharmaceutical industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.

ELI LILLY & COMPANY

JENNIFER LAIRD

Senior Director, Search & Evaluation

Jennifer Laird, Ph.D., D.Sc. is Senior Director, Search & Evaluation at Eli Lilly and Company, based at Lilly's European Headquarters near London. The Search & Evaluation team complements Lilly's internal R&D efforts by evaluating and in-licensing assets and technologies and by collaborating with external partners to advance molecules through discovery and development. Dr. Laird joined Lilly in 2012; prior to that, she spent 10 years at AstraZeneca as Executive Director heading the Translational Science department and Project Director leading preclinical and early development projects. Dr. Laird received doctorates from Bristol University and University of Alicante, Spain, serves as an Editorial Board member of Neuropharmacology and European Journal of Pain and holds an honorary appointment as Professor of Pharmacology at McGill University, Canada.

EMERALD HEALTH PHARMACEUTICALS, INC.

JIM DEMESA

Chief Executive Officer

Dr. DeMesa has been a practicing physician and has served as a senior executive with several international pharmaceutical and biotech companies, both public and private, in the areas of corporate management, regulatory affairs, and pre-clinical and clinical pharmaceutical and medical device product development. In addition to his role at Emerald, Dr. DeMesa is currently on the Board of Directors of OncoSec Medical, a cancer company (NASD:ONCS) and Induce Biologics, a regenerative medicine company. In 2008, Dr. DeMesa retired from his role as President, Chief Executive Officer and a director of Migenix Inc., a public biotechnology company focused on infectious and neurodegenerative diseases. From 1997 to 2001, he was President, Chief Executive Officer and a director of GenSci Regeneration Sciences Inc., a public biotech company involved in regenerative medicine (now part of Integra LifeSciences, NASD: IART). During his tenure at these companies, Dr. DeMesa led the acquisition of several technologies and companies and completed multiple strategic partnership transactions with companies such as J&J, Astellas Pharmaceuticals, United Therapeutics, and Cadence Pharmaceuticals. He also led multiple successful financings totaling over $150 million. From 1992 to 1997, he was Vice President, Medical and Regulatory Affairs at Biodynamics International, Inc. (now part of RTI Surgical, NASD: RTIX), and from 1989 to 1992 was Vice President, Medical and Regulatory Affairs of Bentley Pharmaceuticals (now part of Teva Pharmaceuticals, NYSE: TEVA). Dr. DeMesa is a cofounder of CommGeniX, a medical communications company, and MedXcel, a medical education company. Dr. DeMesa attended the University of South Florida where he received his B.A. (Chemistry), M.D. and M.B.A. degrees and did his medical residency at the University of North Carolina.

LSP

JÖRG NEERMANN

Partner

Jörg Neermann, PhD, joined LSP in 2007 as Partner. Jörg's prime focus and responsibility within LSP is to invest in unlisted securities. Prior to joining LSP, Jörg was the Managing Director of Deutsche Bank's DVC, where he ran its healthcare investment franchise. Previously, he worked at Atlas Ventures in Germany where he also invested in the healthcare sector. Jörg brings a strong scientific background and hands-on finance and investment expertise to the LSP team. He has been appointed a Director at a large number of companies, all of which he has helped with his scientific expertise, biotechnology experience and global networks. Among others, Jörg is currently a Director at Probiodrug, a German biotech company that went public on Euronext Amsterdam in 2014 and is active in the development of novel, disease modifying therapeutics against Alzheimer's disease. Jörg holds a Master's degree and a PhD in Biotechnology from the Technical University in Braunschweig and MIT in Cambridge, US. He also studied economics at Harvard Business School, US.

SANIONA AB

JØRGEN DREJER

Chief Executive Officer

Jørgen Drejer, Ph.D., is CEO and founder of Saniona and has during the past 30 years been engaged in drug discovery and development and worked as a Biotech entrepreneur. Dr. Drejer took his Ph.D. in 1982 from the Royal Danish School of Pharmacy and worked until 1984 as a Postdoctoral fellow at the Medical Faculty, University of Copenhagen before going into Biotech. Dr. Drejer was a co-founder of NeuroSearch in 1989 serving as Executive Vice President and Director of Drug Discovery. He also co-founded - or assisted in founding - several other Biotech companies, including, NsGene, Sophion, Antalium (Canada); Painceptor (Canada); Poseidon Pharmaceuticals, Azign. Atonomics, Ataxion and most recently Initiator Pharma and Scandion Oncology. He held a board seat at the Danish National Research Council for Independent Research and is a member of the Danish Academy for Technical Sciences. Dr. Drejer is the author of more than 75 peer-reviewed papers.

APOGENIX AG

JUERGEN GAMER

VP Business Development

Juergen Gamer joined Apogenix AG as VP, Business Development in January 2006 responsible for partnering and licensing activities. Throughout his career, Juergen built a successful track record of transactions including alliances, licensing, and M&A agreements with major pharmaceutical and biotechnology companies in the US, Europe, and China.

From 2000 to 2005 he worked for Graffinity AG / Santhera Pharmaceuticals AG as VP, Business Development and Project Management aquiring deals and leading alliance management. In the years from 1998 to 2000 Jürgen Gamer served at Clontech Lab. Inc., USA as Head of Business Development Europe where he was responsible for the licensing business in Europe. His industrial career started at BASF Pharma from 1995 to 1998 in the life science department. He obtained his Ph.D. in 1995 with highest honors from the “Zentrum für Molekulare Biologie” Heidelberg (ZMBH) at the University of Heidelberg.

JANSSEN RESEARCH AND DEVELOPMENT, LLC

JULIAN BERTSCHINGER

VP, Head Therapeutic Platform Innovation

Julian Bertschinger is VP, Head Therapeutic Platform Innovation at Janssen R&D and Managing Director of Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Prior to Covagen’s acquisition by Johnson & Johnson in August 2014, Julian Bertschinger was Covagen’s Chief Executive Officer and successfully developed and executed Covagen’s business and R&D strategy. He raised CHF 58.9 million of venture capital, entered a strategic collaboration and licensing agreement with Mitsubishi Tanabe Pharma (Osaka, JP), and advanced Covagen’s lead asset to Phase I/IIa clinical trials.

Julian Bertschinger studied molecular biology and biochemistry and obtained his PhD from ETH Zurich, Switzerland. He serves on the legal entity board of Actelion and other Johnson & Johnson companies in Switzerland.

MERCK VENTURES

KENO GUTIERREZ

Investment Director

Keno Gutierrez, PhD, MBA, joined the Healthcare team as an Investment Director in 2017. Previously, he worked at Omega Funds, where he invested in public and private healthcare companies, participating in direct investments and secondaries. Before joining Omega in 2014, Keno was an associate at Piper Jaffray's Healthcare Investment Banking group, advising biopharma and medtech companies on corporate finance, cross-border M&A and licensing. Prior to joining Piper Jaffray in 2010, he spent four years as a consultant at IMS Health, advising pharma clients on portfolio strategy and commercial operations. Keno is a Fellow of the Royal Society of Medicine, holds a PhD in Genetics from University College in London and an MBA from INSEAD. His research in lipid metabolism has been published in the top scientific journal Nature. Keno is based in Amsterdam.

STALICLA SA

LYNN DURHAM

Chief Executive Officer and Founder

Lynn is a biotech entrepreneur and the founder of STALICLA SA. Her lifelong involvement with the Autism community has brought her to develop a unique patient centric vision of Drug Development to address the unmet medical needs of patients with Autism Spectrum Disorder. Fostering on a strong network within the neuroscience, clinical research and data science communities, she launched STALICLA in May 2017 and is leading its early fast-paced growth. The company has secured capital and competence to develop its innovative algorithm-based platform (DEPI) that uses robust sets of clinical signs and symptoms with big data analytics to characterize subgroups of patients with ASD. By identifying these subgroups and through its strong IP strategy, STALICLA is advancing repurposed drugs to fast-track personalized treatment options for patients with ASD. Lynn has extensive experience in Business development and has worked in the past for the World Economic forum, venture capital & start-up promoting initiatives. Lynn holds a degree in economic history and a post graduate degree in Drug Discovery and Clinical Development from the Faculty of medicine of the University of Geneva.

MSD

KHATEREH AHMADI

Executive Director, Oncology BD&L

Dr. Khatereh Ahmadi has worked in the biotech/pharma industry for 14 years. Previous to her current role at MSD/Merck as Executive Director in BD&L, she was a co-founder and CEO of reViral Ltd, leading a Series A round of $21M with EdRIP and Orbimed. She played a significant role in the spin out of Piramed Ltd, and subsequently became head of business development culminating in a significant deal with Genentech and acquisition of Piramed by Roche in 2008. She has consulted for a number of EU and US companies in the oncology field. She obtained a PhD in biochemistry from King's College London and held a post-doctoral position at the Ludwig Institute for Cancer Research in London working in the PI 3-kinase field. Dr. Ahmadi was awarded her MBA from Henley Management College.

ELI LILLY & COMPANY

JENNIFER LAIRD

Senior Director, Search & Evaluation

Jennifer Laird, Ph.D., D.Sc. is Senior Director, Search & Evaluation at Eli Lilly and Company, based at Lilly's European Headquarters near London. The Search & Evaluation team complements Lilly's internal R&D efforts by evaluating and in-licensing assets and technologies and by collaborating with external partners to advance molecules through discovery and development. Dr. Laird joined Lilly in 2012; prior to that, she spent 10 years at AstraZeneca as Executive Director heading the Translational Science department and Project Director leading preclinical and early development projects. Dr. Laird received doctorates from Bristol University and University of Alicante, Spain, serves as an Editorial Board member of Neuropharmacology and European Journal of Pain and holds an honorary appointment as Professor of Pharmacology at McGill University, Canada.

EMERALD HEALTH PHARMACEUTICALS, INC.

JIM DEMESA

Chief Executive Officer

Dr. DeMesa has been a practicing physician and has served as a senior executive with several international pharmaceutical and biotech companies, both public and private, in the areas of corporate management, regulatory affairs, and pre-clinical and clinical pharmaceutical and medical device product development. In addition to his role at Emerald, Dr. DeMesa is currently on the Board of Directors of OncoSec Medical, a cancer company (NASD:ONCS) and Induce Biologics, a regenerative medicine company. In 2008, Dr. DeMesa retired from his role as President, Chief Executive Officer and a director of Migenix Inc., a public biotechnology company focused on infectious and neurodegenerative diseases. From 1997 to 2001, he was President, Chief Executive Officer and a director of GenSci Regeneration Sciences Inc., a public biotech company involved in regenerative medicine (now part of Integra LifeSciences, NASD: IART). During his tenure at these companies, Dr. DeMesa led the acquisition of several technologies and companies and completed multiple strategic partnership transactions with companies such as J&J, Astellas Pharmaceuticals, United Therapeutics, and Cadence Pharmaceuticals. He also led multiple successful financings totaling over $150 million. From 1992 to 1997, he was Vice President, Medical and Regulatory Affairs at Biodynamics International, Inc. (now part of RTI Surgical, NASD: RTIX), and from 1989 to 1992 was Vice President, Medical and Regulatory Affairs of Bentley Pharmaceuticals (now part of Teva Pharmaceuticals, NYSE: TEVA). Dr. DeMesa is a cofounder of CommGeniX, a medical communications company, and MedXcel, a medical education company. Dr. DeMesa attended the University of South Florida where he received his B.A. (Chemistry), M.D. and M.B.A. degrees and did his medical residency at the University of North Carolina.

LSP

JÖRG NEERMANN

Partner

Jörg Neermann, PhD, joined LSP in 2007 as Partner. Jörg's prime focus and responsibility within LSP is to invest in unlisted securities. Prior to joining LSP, Jörg was the Managing Director of Deutsche Bank's DVC, where he ran its healthcare investment franchise. Previously, he worked at Atlas Ventures in Germany where he also invested in the healthcare sector. Jörg brings a strong scientific background and hands-on finance and investment expertise to the LSP team. He has been appointed a Director at a large number of companies, all of which he has helped with his scientific expertise, biotechnology experience and global networks. Among others, Jörg is currently a Director at Probiodrug, a German biotech company that went public on Euronext Amsterdam in 2014 and is active in the development of novel, disease modifying therapeutics against Alzheimer's disease. Jörg holds a Master's degree and a PhD in Biotechnology from the Technical University in Braunschweig and MIT in Cambridge, US. He also studied economics at Harvard Business School, US.

BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

KLAUS MENDLA

Global Head of CNS Business Development & Licensing

Dr. Mendla received his PhD degree in Biochemistry and Pharmacology from the University of Muenster (Germany) and completed a postdoctoral fellowship in Neuropathology at the University of Heidelberg.

Since joining Boehringer Ingelheim (BI) in 1985, he has held several positions in Research and Development within the corporation. Before joining BI's global Business Development and Licensing organization, Dr. Mendla was director of the company's neurodegenerative diseases research group.

Dr. Mendla currently acts as Global Head, Business Development & Licensing CNS at Boehringer Ingelheim. He is member of BI's CNS Therapeutic Area Leadership Team and heads up the cross-functional CNS Licensing Advisory Team which is responsible for BI's global partnering and licensing activities in the therapeutic area CNS Diseases.

The strategic partnering focus of Dr. Mendla and his team is on compounds and novel therapeutic approaches for the treatment of neuropsychiatric diseases (including Alzheimer's disease, schizophrenia and depression).

AXOVANT SCIENCES

MARK ALTMEYER

President & Chief Commercial Officer

Mr. Altmeyer is Chief Commercial Officer of Axovant Sciences GmbH and joined our company in March 2015. He has 30 years of experience leading successful drug commercialization efforts as a pharmaceutical executive, with a focus on therapies for central nervous system disorders. Previously, he served as Chief Executive Officer and President of Otsuka America Pharmaceutical, Inc., where he led 1,700 employees and grew total revenues from $2.6 billion to over $5 billion. He led the launch of Abilify®, the top-selling CNS drug in history and the number-one selling drug in the United States in 2013. Earlier in his career, Mr. Altmeyer held a number of executive leadership roles at Bristol-Myers Squibb, including Senior Vice President, Global Commercialization, and Senior Vice President, Neuroscience Business Unit.

Mr. Altmeyer received an M.B.A. from Harvard Business School and a B.A. in economics from Middlebury College.

AGLAIA BIOMEDICAL VENTURES

MARK KRUL

Director

Mark has been involved in anticancer drug development since 1993 and has a background in molecular biology and immunology. Before founding Aglaia BioMedical Ventures in 2003 he was Program Director of the NDDO Research Foundation. He held several positions at NDDO Oncology BV (formerly the EORTC New Drug Development Office) with respect to oncology drug development strategies (1997-2002). From 1993 till 1997 Mark has been Research Manager of the European Cancer Center and headed the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection from 1989 till 1993.

Aglaia Biomedical Ventures currently has three Funds under management, all focused on the development of innovative anticancer drugs.

COMPLIX NV

MARK VAECK

Chief Executive Officer

Dr. Mark Vaeck has more than 25 years of experience in the biotech and pharma industry and has raised over €80 million in venture financing for his companies. In 2008 he co-founded the biopharmaceutical company Complix (Belgium) and was appointed as its CEO in May 2010. Before that, from 2006 until 2010 he was the founding CEO of ActoGeniX (Belgium). From 2001 until 2006 he was the CEO of Ablynx (Belgium), which he co-founded in June 2001. Prior to joining Ablynx, Mark was Chief Operating Officer of Ceres Inc (US). From 1993 until 1998 he served as Director Business Development and thereafter as CEO of Keygene (The Netherlands). Between 1983 and 1993 he held several research management and business development positions in the biotech and pharma industry.

Mark has a PhD in Immunology from the University of Brussels (1982).

BIOMEDPARTNERS AG

MARKUS HOSANG

General Partner

Dr. Markus Hosang is a General Partner and Managing Director at the life sciences venture capital firm BioMedPartners in Basel. He has strong experience and broad knowledge in strategic and operational aspects of the VC business, as well as in pharmaceutical and diagnostics R&D. Before joining BioMedPartners, Dr. Hosang was a Venture Partner at MPM Capital, where he managed their European office and was co-responsible for their European deal flow. Previously, at Roche in Basel, he held several senior management positions of increasing importance in its global Pharma R&D organization, and was directly involved in major strategic transactions, including the acquisition of Genentech. Dr. Hosang obtained his Ph.D. in Biochemistry from the ETH Zurich. He serves on the boards of several biotech and medtech companies, many of which have already been exited highly successfully.

MERCK KGAA

MATTHIAS MUELLENBECK

Director Global Licensing & Business Development Oncology

Dr. Matthias Müllenbeck is Director Global Licensing & Business Development at Merck Biopharma, responsible for leading strategic partnering initiatives in the field of oncology and immuno-oncology.

Throughout his career at Merck, Matthias concluded successfully negotiations on various partnerships for asset-, technology-, and diagnostic-licensing deals.

Matthias holds a PhD in immunology from the Humboldt-University of Berlin. He worked during this time as a scientific project leader at the Max-Planck Institute for infection biology Berlin, Germany, and the Albert-Schweitzer Hospital in Lambaréné, Gabon. He is married and lives in Frankfurt.

ORIGENIS GMBH

MICHAEL ALMSTETTER

Chief Executive Officer

Michael Almstetter studied chemistry at the Technical University of Munich. He wrote his thesis about "Simulation and Optimisation of Multi Component Reactions with the Use of Genetic Algorithms" at the Organic Chemistry department of Prof. Dr. Ivar Ugi. He applied these theories in an internship at Roche AG. Michael Almstetter laid the fundaments for the later MOREsystem® with the invention of MolMind® as Head of Discovery Chemistry at Morphochem AG. He applied MOREsystem® to a variety of drug discovery projects with success. Together with Michael Thormann and Andreas Treml, he initiated and orchestrated the successful management buy-out from Morphochem AG to form Origenis in October 2005.

CELLESTIA BIOTECH AG

MICHAEL BAUER

Chief Executive Officer

Chief Executive Officer and Board member of Cellestia Biotech AG, Basel, Switzerland. Michael is a senior drug development professional with over 20 years' experience in the life sciences industry and research. He served in senior leadership positions across disciplines such as clinical and preclinical drug development, project & portfolio management, regulatory affairs and metabolism research. He has many years of experience in leading global development projects, covering the full range of drug development, from early stage preclinical through Phase I, II and III clinical development, including IND and NDA submissions. Most recent assignments were with Novartis Pharma AG, Translational Medicine Oncology, working as Senior Global Program Manager Development and Polyphor Ltd., where he served as Head of Clinical Development. Under his leadership, several new oncology drugs were brought into clinical development and reached clinical proof of concept. Michael holds a Ph.D. in Biotechnology and M.Sc. in Chemistry.

METYS PHARMACEUTICALS AG

MICHAEL SCHERZ

Founder & Chief Executive Officer

Michael Scherz is chief executive officer of Metys Pharmaceuticals AG and a member of the company's board of directors. He founded Metys Pharmaceuticals in 2013, bringing more than 25 years of drug development and drug discovery expertise, and executive management experience to his role within the company. To date he has raised CHF 2.5 million in seed investment from private investors.

Michael Scherz manages drug development and drug discovery activities at Metys Pharmaceuticals, and is spear-heading the company's search for Series A investors. He is responsible for managing the corporate budget, and for the selection of suitable consultants for Metys' drug development and drug discovery activities. He is responsible for Metys' clinical, preclinical, and CMC development plans for MP-101, a newly-patented orally-active Phase II-ready small molecule intended for the treatment and prevention of neuropathic pain, in a first clinical trial for the prevention of chemotherapy-induced peripheral neuropathy. Since creating Metys Pharmaceuticals, Scherz has worked to share Metys' vision and strategy with its investors and consultants.

Michael Scherz graduated in 1989 from the University of Oregon with a PhD in synthetic and medicinal chemistry. Previously, Scherz served as vice president and life cycle leader at Actelion Pharmaceuticals, where he was responsible for the multi-functional development teams entrusted with the Phase I to Phase III clinical development of several novel therapeutic agents; he served his first four years at Actelion as one of four members of the drug discovery management team. His focus on innovation, team performance, and clear communication, led to the discovery of novel and diverse candidate therapeutic agents: urotensin-II antagonists, sphingosine-1-phosphate agonists, and novel calcium channel blockers; and significant advancements of the clinical projects he led: orexin receptor antagonists for insomnia, sphingosine-1-phosphate agonists for multiple sclerosis and psoriasis, and calcium channel blockers for hypertension and cardiac conduction abnormalities. Prior to Actelion, Scherz was section head of cardiac research at Procter & Gamble Pharmaceuticals in Cincinnati, Ohio, USA; and post-doc at Hoffman-La Roche AG in Basel, Switzerland.

GENEURO SA

MIGUEL PAYRÓ

Chief Executive Officer

Miguel has worked in corporate finance since 1985, first in various Swiss banks and then in industry since 1991, working in strong growth environments, initially with Unilabs SA, a European leader in clinical laboratory testing, for which he was in charge of the Swiss IPO and of numerous M&A transactions and international development. From 2003 to 2015 he was Chief Financial Officer of the Franck Muller luxury watch group in Switzerland, where he led, amongst other things, numerous M&A, tax and shareholder transactions, before joining GeNeuro in 2015 as CFO. Miguel graduated from the University in Geneva with a degree in business administration.

F. HOFFMAN-LA ROCHE LTD.

MIRO VENTURI

Global Head - Diagnostics Biomarkers

After receiving his PhD from the Max-Planck Institute of Biophysics in Frankfurt, Miro specialized in molecular medicine, virology and immunology at the National Institutes of Health, Bethesda, USA. In 2002, Miro joined the pharmaceutical industry as a Biomarker Laboratory Head and project team representative at Pharmacia Corp (later Pfizer Inc.) at the Oncology R&D site located in Nerviano, Italy. In this role, he initially established the biomarker laboratories and actively contributed to the development of numerous oncology programs focusing on small molecular weight kinase inhibitors, including the early development of sunitinib (Sutent) as well as research and exploratory biomarker strategies for several preclinical programs, from lead optimization until PoC clinical studies. In 2005, Miro was invited to join the faculty of the University "Vita Salute San Raffaele" in Milan as Adjunct Professor of preclinical and early clinical development of biopharmaceuticals. In 2007 Miro moved to Novartis as Divisional Head in Biomarker Development, supervising a team of scientists developing assays and supporting project teams in the realization of personalized medicine strategies across the portfolio, with a focus on biologics and oncology programs. His team has contributed to the development of nilotinib (Tasigna) and early programs in both solid tumors and hematological malignancies. Since 2009, Miro joined Roche Oncology where he has contributed the biomarker and personalized medicine strategies and directed the execution for global drug development programs with companion diagnostics, including the development and approval of Perjeta in breast cancer. In 2011, he was appointed Site Head for Oncology Biomarkers within the DTA Oncology Dept, under the leadership of William Pao, and based in Penzberg, Germany. Miro has then been appointed Global Head of Diagnostics Biomarkers at Hoffmann-la Roche and is based at the Company´s headquarters in Basel.

Miro has contributed to several drug research and scientific development projects and published in a number of relevant scientific journals, including Nature, Cell, PNAS and others.

NOVO VENTURES

NANNA LUNEBORG

Partner

Nanna is a Partner with Novo Ventures, based in Copenhagen.

She joined Novo Holdings in 2012, initially as part of Novo Seeds, where she helped build a strong portfolio of seed and Series A stage companies, primarily in Scandinavia. She led the initial investments and served on the Boards of IO Biotech, Inthera, Glionova, MinervaX, and Pcovery, and as an Observer with Forendo and Galecto.

Nanna joined Novo Ventures in 2016, and currently serves on the Boards of Epsilon-3 Bio, Orphazyme and Inventiva, and was previously on the Board of ObsEva.

From 2008-2012, Nanna was part of the Life Science investment team at Apposite Capital, a London-based venture fund, where she participated in both primary and secondary investments, with multiple portfolio companies leading to highly successful exits for the fund, including Ulthera, Conver-gence and Cancer Partners UK. Earlier in her career, she worked at Cancer Research UK as a research analyst, and as a consultant to various biotech and healthcare venture projects during her MBA.

Nanna received her PhD in Neuroscience from University College London as a Wellcome Trust Scholar. She holds an MBA with distinction from Uni-versity of Cambridge, where she was a Sainsbury Scholar, and a 1st class BA from University of Oxford.

PFIZER, INC.

NATHALIE TER WENGEL

European Head External R&D and Innovation

Nathalie ter Wengel, a medical doctor, is the European Lead Global Scouting External R&D and Innovation at Pfizer, where she is responsible for establishing new collaborations and exploring licensing and other corporate development opportunities across all therapeutic areas. She has an international background and a broad knowledge in the medical field, having worked in the hospital with extensive experience in internal medicine. Nathalie started her commercial career as European Medical Manager at Pfizer, where she successfully led ambitious international projects, combining a business perspective with her medical knowledge. It was this experience, coupled with her father's illness, that convinced her of the urgent need for change in the pharmaceutical industry. Consequently, she started up a company called myTomorrows focused on compassionate use, and served as Chief Medical Officer before joining Galapagos as Business Development Director, where she played a key role in the very successful NASDAQ IPO and in partnering filgotinib.

ACTELION, A JANSSEN PHARMACEUTICALS COMPANY OF JOHNSON & JOHNSON

NICHOLAS FRANCO

Executive Vice President & Chief Business Development Officer

Nicholas Franco has over 25 years of pharmaceutical leadership and experience in research, marketing, sales and business development across several therapeutic areas and geographies.

Prior to joining Actelion as Executive Vice President and Chief Business Development Officer, he was Senior Vice President, International Commercial Operations at Axcan Pharma based near Paris, France where he was responsible for ex-North American operations (including Marketing, Operations and Partnering).

Prior to that, he was Head of Market Access Region Europe for Novartis Pharma AG in Basel, Switzerland, where he has held various management positions since 1991, including President of Novartis Ophthalmics, Global Head, Business Development and Licensing Negotiations, Global Head, Neuroscience Franchise and Global Brand Director for gastrointestinal products.

Nicholas holds a BsC in Biochemistry and Masters in Business Administration, Strategic Planning and Marketing from McGill University (Canada).

SILICON VALLEY BANK

NOOMAN HAQUE

Managing Director, Life Sciences & Healthcare

Nooman Haque is the Managing Director of Life Sciences and Healthcare at Silicon Valley Bank's UK Branch. He leads a team dedicated to supporting early, growth-stage and established multinational businesses in all sectors of life sciences. Nooman is responsible for expanding the bank's business in this key sector and working with the global life sciences team to support companies with all aspects of their business, beyond financing. He is actively involved within the sector, sitting on the BIA's Finance and Tax Committee and is a frequent panelist, writer and spokesperson for the industry.

Nooman joined Silicon Valley Bank from a venture capital firm in London and previously worked at a sovereign wealth fund in Saudi Arabia largely focused on healthcare. His background includes management consulting and corporate finance.

Nooman has a Bsc in psychology and an Msc in economics, both from the University of London, and an MBA (finance) from Imperial College.

RENEURON GROUP PLC

OLAV HELLEBO

Chief Executive Officer

Olav Hellebo was appointed as Chief Executive Officer in September 2014. A highly experienced, international pharmaceutical executive he has broad commercial experience gained at both major pharmaceutical and small biotechnology companies. He has particular experience of the clinical development, out-licensing, commercialisation and marketing of new therapeutics.

Prior to ReNeuron, Olav held the role of CEO at Clavis Pharma ASA, a Norwegian, oncology focused, listed biotechnology company. At Clavis, Olav built a multi-national leadership team, taking the company's lead programme through Phase III clinical development as well as completing substantial fundraising and out-licensing transactions for the business. Prior to Clavis, Olav headed up the global biologics franchise at UCB Pharma and was head of the UK commercial operations of Novartis. Olav started his pharmaceutical career in 1992 at Schering-Plough, where he held a number of senior commercial roles in Europe and the US, including leading its US commercial operations in the areas of oncology, cardiovascular and hepatitis-C, representing annual sales in excess of $2 billion. Olav has an MBA from the IESE Business School in Spain and a Bachelor of Business Administration from Hofstra University, USA.

EDMOND DE ROTHSCHILD INVESTMENT PARTNERS S.A.S.

OLIVIER LITZKA

Partner

Olivier joined the EdRIP Life Sciences team based in Paris in 2006. Before that he worked with 3i in Venture Healthcare, with the first four years in Munich and the last two years in Paris. Prior to that, Olivier was a consultant with Mercer Management Consulting in Munich and Paris. Olivier holds a PhD in Biology from the Munich Institute für Genetik und Mikrobiology and has performed his scientific research in Munich and Oxford University. Olivier is a Director of Allecra Therapeutics, JenaValve, Noxxon Pharma, SuperSonic Imagine, Autonomic Technologies and MedLumics, and was a director of Novexel, Endosense, Sapiens and Probiodrug up until their respective acquisitions or listings.

ADOCIA

OLIVIER SOULA

Deputy General Manager, R&D Director

Olivier Soula has a PhD in polymer science, graduated from ENSC Mulhouse, and has an MBA from IAE, Lyon.

He worked for 8 years at Flamel Technologies as Director of the Nanotechnologies department. He led the development of Medusa, a platform for sustained delivery of therapeutic proteins and successfully conducted clinical trials on diabetes and hepatitis C.

Since founding Adocia in December 2005 and as part of his role of Deputy General Manager and Research & Development Director, he continues to design innovative protein formulations for chronic diseases with a particular focus on diabetes and insulin. Adocia aims to deliver "innovative medicine for everyone, everywhere". Adocia has developed a portfolio of 9 products including an ultra-fast formulation of insulin ready-o-enter in Phase 3.

Olivier is co-author of nearly 40 patents relating to protein delivery. He has worked for 16 years on insulin formulation.



JANSSEN, PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON

PATRICK BENZ

Senior Director Alliance Management

Patrick Benz, Senior Director Alliance Management, Janssen Business Development. In this role Patrick manages all global commercial and R&D key alliances for Neuroscience in all different global regions.

Patrick joined Johnson & Johnson Family of Companies in 1998 at Janssen Switzerland. He progressed through several commercial roles into the board of the Swiss Operating Company as Business Unit Director CNS, and then moved to Italy, holding several commercial roles at board level, advancing to EMEA Franchise Leader for Neurology, overseeing the entire EMEA Neurology Franchise. Since October 2008, Patrick has been a member of the Janssen Business Development team. In this group he was holding the position of Senior Director, Business Development & Licensing for the Neuroscience Franchise until 2013, where he was negotiating several transactions for commercial as well as R&D assets.

Patrick holds a Master Degree in Pharmacy and a PhD in Organic Chemistry. Before joining Janssen Switzerland in 1998, Patrick did work for Gebro Pharma AG, Switzerland, and for Boehringer Mannheim/Roche.

OXFORD UNIVERSITY INNOVATION LTD.

PAUL ASHLEY

Head of Technology Transfer

Paul is the Head of Technology Transfer, Life Sciences at OUI. Paul has an undergraduate degree in Zoology and research experience in neuro-physiology and behaviour. Paul's PhD and post-doc roles investigated mood disorders and pain. Moving away from the bench, Paul became the CEO of a spin-out company, commercialising remote monitoring and biotelemetry technology developed at the Defence Science Technology Laboratory. Following this, Paul took up a role at AstraZeneca as a member of the management team at the company's environmental risk assessment facility. Paul joined Oxford University Innovation as a Deputy Head of Technology Transfer in July 2011 and has overseen a team of life science Technology Transfer Managers commercialising large numbers of technologies across the breadth of the life sciences, licensing and creating companies in fields including biotech and drug discovery, medical devices, diagnostics, genomics and digital health.

BIRD & BIRD LLP

PAUL HERMANT

Partner

Paul Hermant is a corporate & finance partner at Bird & Bird LLP, specialised in the life sciences sector and based in Brussels. He heads the firmwide corporate life sciences group.

He assists clients in their corporate and financial transactions and provides the full range of advice in these fields. He has particular expertise in mergers and acquisitions, private equity, venture capital, joint ventures, strategic alliances, securities offerings, take-over bids, as well as project and acquisition finance. Paul also represents clients in corporate and financial litigation, including shareholders disputes, directors' liability and cases relating to financial products and services.

He graduated from the University of Brussels (Master in Law 1988; Master in Business Law 1989) and from the Solvay Business School (Master in Business Administration 1992). He joined Bird & Bird LLP in 2000, coming from Loeff Claeys Verbeke (now Allen & Overy).

He has written and spoken widely on corporate and financial law topics and teaches at the University of Brussels. He also serves on the Board of the Solvay Business School Alumni.

J&J INNOVATION

PAVITHRA SUNDARESAN

Senior Director of New Ventures and Transactions

Pavithra is a Senior Director and the New Ventures and Transaction Lead at Johnson & Johnson Innovation, London, responsible for identifying and transacting new opportunities for the Immunology pipeline.

Pavithra brings over 12 years of commercial experience in the Life Sciences industry, joining Johnson & Johnson from UCB Pharma where she was Director of Global Business Development, leading a wide range of licensing and collaboration activities for the Immunology and Neurology franchises. Previously, Pavithra was based in Geneva as an Associate Director of Business Development at Merck Serono, supporting Immunology and Neurology therapeutic areas. Prior to her business development roles, Pavithra was based at Atlas Venture in London, responsible for deal sourcing, investment analysis, and portfolio support. Pavithra started her business career at L.E.K. Consulting providing corporate strategy advice to biopharma and private equity clients. .

Prior to transitioning to the commercial side, Pavithra performed post-doctoral research at the University of Cambridge where she also obtained her PhD in Biochemistry.

ALLIGATOR BIOSCIENCE AB

PER NORLÉN

Chief Executive Officer

Per Norlén, MD, PhD, board certified clinical pharmacology physician and associate professor in clinical pharmacology at Lund University. Dr Norlén has 25 years of pharmacology research experience and 15 years of experience in clinical drug development with a focus on translational medicine and clinical phase I/II studies, including 4 years at AstraZeneca R&D as Sr Clinical Pharmacology Physician and Global Discipline Leader of Clinical Pharmacology Physicians. Dr Norlén joined Alligator in 2010 as Chief Medical Officer, and was appointed CEO in 2015.

CRESCENDO BIOLOGICS LTD.

PETER PACK

Chief Executive Officer

Peter Pack has 25 years of experience in the successful establishment and growth of international life science companies. For 18 years, he was CEO and Managing Director of product-oriented companies ranging from early stage up to international commercialization and profitability with several thousand certified products; predominantly working in Germany, the UK and Poland. He raised over € 73 m in venture capital, worked on several Boards and headed companies with up to 400 employees.

He started his career in the initial team of MorphoSys AG (1993-1999) as co-inventor of the commercially most successful phage library and was co-founder and CEO of the cancer diagnostics company mtm laboratories (1999-2008). The companies for which Peter worked in central positions were either successfully sold (mtm laboratories, Polytech Ophthalmologie, Signature Diagnostics), highly profitable (LGC Standards, Polytech) and/or went public (MorphoSys AG).

MSD

PHIL L'HUILLIER

Head, European Innovation Hub

Phil is Head of Business Development, Europe for Merck, Sharpe & Dohme (MSD), based in London. He is a seasoned business development professional with 15+ years' experience in the biotech/pharma industry, in R&D, licensing/partnering, new company formation and M&A, and corporate development. Prior to joining MSD, Phil was an Executive Director at Cancer Research Technology Ltd.

Phil has previously been a director of numerous start-ups including Achilles Therapeutics, Artois Pharma, PsiOxus Therapeutics and BliNK BioMedical. Prior to CRT, Phil headed up global licensing at BioFocus Discovery Ltd, an AIM-listed integrated early stage drug discovery company. Phil holds an MBA, and a PhD in cellular and molecular biology.

LONZA AG

SARAH HOLLAND

Global Head of Licensing

Sarah joined Lonza in August 2017 to build and lead a new business unit aimed at growing and accelerating the company's portfolio of in- and out-licensing programs. With a focus on new modalities such as mRNA, cell and gene therapy, bio conjugates, and end-to-end manufacturing, she is responsible for scouting new technology, as well as creating value from Lonza's internal R&D.

Sarah knows the innovation and finance landscape in pharma and biotech well having previously helped lead Sanofi's external science and partnering programme. Prior to Sanofi, Sarah managed teams in several roles at Roche and AstraZeneca and has overseen M&A transactions, integrations, spinouts and global brand launches.

Sarah holds a DPhil from Oxford University and an MBA from Manchester Business School, where she was also a Visiting Fellow. She is a firm supporter of initiatives supporting women in science and innovation careers.

EURONEXT

SØREN BJØNNESS

Director – Switzerland Representative

Søren Bjønness is a Director and Switzerland Representative for Euronext, supporting Swiss Tech companies and tech ecosystem. He started his career in 1988 in the Royal Norwegian Navy, where he became a Second Lieutenant. Posts in his career include environmental management, corporate banking, securitization and management buyouts at UBS, Private Equity at 3i, corporate incubation at Sulzer, venture capital at New Value, Corporate Finance and Capital Markets at PwC. Søren holds a Degree in Leadership, Organisation, Finance and Economic Policy from the University of Fribourg and completed a doctorate in Leadership and Change in SMEs at the University of Basel.

CELL MEDICA

STEFANOS THEOHARIS

SVP, Partnering and Corporate Development

Stefanos joined Cell Medica to lead our partnering activities, bringing a combination of academic, business development, project management and finance skills.

Following his PhD, Stefanos worked as a post-doctoral researcher at Imperial College, whilst also working for six years in parallel as a paid consultant to the London Technology Network, a government-funded organization bridging the gap between industry and academia. Subsequently, Stefanos joined Lazard, the investment bank, as a member of the life science M&A team and then Roche Partnering, as Director of Emerging Technologies, where he participated in multiple licensing deals, with a focus on novel innovative technologies. He then joined Antisense Pharma as Head of BD. Prior to joining Cell Medica, Stefanos was CBO for apceth in Munich, where he was responsible for business development on the company's first-in-man engineered cell therapy platform and its GMP manufacturing business, as well as project management, and communications.

Stefanos holds a PhD in gene therapy and immunology and a MSc in Molecular Medicine both from Imperial College.

GAMAMABS PHARMA SA

STÉPHANE DEGOVE

Chief Executive Officer

Stéphane is CEO and co-founder of Gamamabs Pharma, a clinical-stage immuno-oncology biotech. Gamamabs developed a portfolio of innovative drugs in oncology whose lead compound, GM102, is a first-in-class immuno-enhancer drug in clinical development. GamaMabs has also announced in November 2017 a collaboration and license agreement with Medimmune for the development of an ADC.

Stephane is a biotech entrepreneur and has a finance background. Graduated from ESCP Europe (majoring in Finance), started its career at Sanofi in Finance and was co-founder of Endotis Pharma, a biotechnology company in cancer and thrombosis.

TORREYA PARTNERS (EUROPE) LLP

STEPHANIE LÉOUZON

Principal and Head of Torreya Partners Europe

Stephanie Léouzon is Partner and Head of Europe for Torreya Partners, a life sciences boutique advisory firm which she joined in 2012. Previously she worked in healthcare investment banking in the US and Europe from 1989 to 2010, most recently at Credit Suisse in London as a Managing Director and Senior Advisor.

She has advised life sciences clients on more than 25 strategic transactions, valued at over

$65 billion, and has been involved in over 45 financing transactions to provide over $10 billion to healthcare clients.

Stephanie earned an MBA degree from the Darden Graduate School of Business at the University of Virginia in 1989 and a BA degree, cum laude, from Mount Holyoke College in 1985.

GLAXOSMITHKLINE

SVEN KILI

VP & Head of Gene Therapy Development

Dr Sven Kili is the VP and Development Head for the Gene Therapy division of GSK where he leads the teams developing ex-vivo Gene Therapies for a variety of genetic disorders. They are currently developing solutions for a number of diseases including ADA-SCID; WAS; Metachromatic Leukodystrophy (MLD) and Beta-Thalassemia. Prior to this, he was Senior Director, Cell Therapy and Regenerative Medicine for Sanofi (Genzyme) Biosurgery where he led the clinical development and medical affairs activities culminating in the granting of the first combined ATMP approval in the EU for MACI®. His team also prepared and submitted regulatory filings for Australia and the US, including health technology assessments and he was responsible for late stage developments for Carticel® and Epicel® in the US. Before joining Genzyme, Sven worked for Geistlich Pharma where, in addition to leading the cell therapy medical activities, he oversaw all UK regulatory functions and was the QPPV for the EU. Sven trained as an Orthopaedic surgeon in the UK and South Africa and since leaving full-time clinical practise has developed expertise Cell and Gene Therapy in clinical development, regulatory compliance, value creation, risk management and product safety, product launches and post-marketing activities. He sits on the board of a Swedish Stem Cell company and still maintains his clinical skills in the UK NHS and serves as an ATLS Instructor in his spare time.

BPIFRANCE

THIBAUT ROULON

Investment Director

Thibaut started his career as a scientist in a US biotech company developing cancer immunotherapeutics.

In 2005 he joined Bioam Gestion, a venture capital firm investing in life science companies. In 2010, Bioam merged with Bpifrance Investissement (formerly known as CDC Entreprises), a leading French investment firm investing in SMEs and mid-Tier companies. Bpifrance Investissement manages several funds dedicated to life science investments, including InnoBio. InnoBio is a EUR 173 million venture capital fund with investors such as Sanofi, GSK, Roche, Novartis, Pfizer, Lilly, Ipsen, Takeda and Boehringer-Ingelheim.

Thibaut is in charge of investments in life sciences companies at various stages (Seed, Venture, IPO, PIPE).

He is a graduate of the Ecole Centrale de Paris and holds a PhD from the Pierre & Marie Curie University.

ABINGWORTH LLP

TIM HAINES

Managing Partner

Tim has more than 25 years of international management experience in the life sciences industry in both public and private companies. During his time at Abingworth Tim has taken board roles in a number of companies including Astex, Fovea, GammaDelta Therapeutics, MEDIAN Technologies, PowderMed, Proteon Therapeutics, Sientra and VirionHealth.

Before joining Abingworth in 2005 he was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. Tim was with Astex for over five years and was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe, including CEO of Thackray Inc and General Manager Baxter UK. Tim has a BSc from Exeter University and an MBA from INSEAD.

ASTRAZENECA

TIMOTHY HERPIN

Vice-President, Head of Transactions, Business Development

Timothy Herpin Ph.D., Vice President, Head of Transactions, Business Development, AstraZeneca.

Timothy Herpin heads a group of business development professionals involved in all aspects of transactions negotiation and execution at AstraZeneca. Tim joined AstraZeneca in 2011 as Vice-President, Strategic Partnering and Business Development, initially for CNS& Pain and more recently for Oncology. Prior to AstraZeneca, Tim spent eight years in the business development organization at Bristol-Myers Squibb covering both search and evaluation as well as transaction in multiple disease areas. Before his business development career, Tim worked in R&D at Bristol-Myers Squibb, Aventis and Pharmacopeia. Tim grew up in Paris and is a graduate of Ecole Polytechnique in France. He also holds a Ph.D. in organic chemistry from University College London and an MBA in Finance from NYU Stern.

INTHERA BIOSCIENCE AG

ULRICH KESSLER

Chief Executive Officer

Ulrich Kessler has more than 15 years of experience in life science R&D, drug discovery and pharma business development in the US and Switzerland. Since 2013 he is the CEO of Inthera Bioscience, for which he raised more than USD 15 million. Inthera is developing small molecule transcription modulators that reprogram cancer cells. Before, Ulrich worked for F. Hoffmann La Roche AG's oncology franchise as International Product/ Business Manager and the healthcare franchise of the Boston Consulting Group, advising large pharma customers on R&D operations and product launch strategies. Ulrich holds a MSc in pharmaceutical sciences, a PhD in applied biosciences from ETH Zurich and completed a postdoctoral fellowship at the Institute of Chemistry and Cell Biology at Harvard Medical School, focusing on chemical genetics approaches and identification of novel cell cycle inhibitors.

DOCDOK.HEALTH AG

ULRICH MUEHLNER

Chief Executive Officer

Ulrich Mühlner is the Founder and Managing Director of GrowthCube Partners LLC, a global firm he started in June 2016 to enable life-changing healthcare innovations by joining forces with scientists, innovators, and entrepreneurs, and - together - translating groundbreaking ideas, discoveries, and inventions into services and products that make a real difference to people's lives.

Ulrich is a trained scientist, experienced top management consultant, and former senior pharma executive with strategic and operational experience. He is an active startup investor & entrepreneur (co-founder docdok.health Ltd) and serves globally as senior executive (CEO, CBO), board member, and advisor to biopharma and digital health companies, international organizations, and leading academic institutions. Ulrich is a frequent speaker at international healthcare conferences.

Before starting GrowthCube Partners, Ulrich spent seven years at Novartis AG and had global roles of increasing responsibilities. He joined Novartis in August 2009 as Director Corporate Strategy and led, in addition to the annual group-wide strategic planning process, key initiatives in areas such as emerging markets, digital health, innovation driven growth opportunities, and novel R&D approaches. Until April 2013, Ulrich was Global Head Corporate Strategy and led the development of the portfolio strategy resulting in the fundamental transformation of the Novartis business portfolio through multibillion dollar asset deals. He also led and managed Novartis' LP investments into two China healthcare VC funds. Until end of May 2016, Ulrich was Global Head Outcomes Technologies Incubator (NOVAE) at Novartis. In this operational role, he spearheaded the digital health activities across entire Novartis and led programs and partnerships aiming at increasing the value of the Novartis portfolio through "beyond-the-drug" (digital-/health-) technologies and solutions. Examples of such initiatives include the "smart lens" licensing deal with Google(x) Life Sciences (Verily), the collaboration with the "smart pill" company Proteus Digital Health, several projects to develop real-world outcomes solutions for the heart failure drug Entresto, and the partnership with IBM Watson Health in oncology. In total, Ulrich successfully executed deals with a volume of $350+ million.

Prior to Novartis, Ulrich spent ten years with The Boston Consulting Group (BCG) serving clients in the biopharmaceuticals, medtech & diagnostics, venture capital/private equity, and chemical industries across Europe, USA, and Asia. He successfully led and executed more than fifty projects covering areas such as biopharma R&D, innovation, business model development, corporate development, business transformation, value management, carve-outs, and strategic/financial investments. His projects generated tangible impact at business (P&L) and organizational (business set-up, structures & processes, culture) levels.

Ulrich studied Biochemistry in Hannover and Munich, and earned a PhD degree in Biochemistry and Molecular Biology based on his research on molecular mechanisms of blood vessel formation and signal transduction in cancer development at the Research Institute of Molecular Pathology (I.M.P.) in Vienna.

ANIMA BIOTECH LTD.

YOCHI SLONIM

Chief Executive Officer

Yochi Slonim is a serial entrepreneur with a track record of over 30 years in software and biotech. He co-founded Anima in 2005 and as CEO has been driving its drug discovery platform and pipeline.

Prior to Anima, Yochi has built several companies from their early stage, through all stages of product development, marketing and sales and eventually turned them into successful large exits.

He was a co-founder of Mercury Interactive. As CTO and VP R&D from the company's early days he created product vision and strategy and led a multi-product organization of 200 developers. After going public and reaching revenues of over $1B annually, Mercury was acquired by HP for $4.5B.

As Senior VP of products and marketing for Tecnomatix, a public NASDAQ company, he led a 500 people organization of 4 divisions that generated revenues of $100m until the company was acquired by UGS for $230m.

In 2000, Yochi was founder and CEO of Identify. The company reached revenues of $50m in in less than 5 years and was acquired by BMC in 2006 for $150m in cash.

Yochi founded ffwd.me (www.ffwd.me), a unique startup acceleration program where he led a team that worked with over 25 startups in diverse areas and technologies, developing strategy, products and go to market operations while raising multiple rounds of financing from VCs and private investors.

As one of Israel's leading speakers on the subject of startup positioning and company building, several of Yochi's approachable and amusing lectures can be found on Youtube ("Youtube Yochi Slonim")

SOFINNOVA PARTNERS

ZHIZHONG (JOEL) YAO

Associate

Zhizhong Yao joined Sofinnova Partners in 2015 and focuses on investments in the biotech/biopharm sector. Prior to Sofinnova, Zhizhong was a Human Frontier Science Program cross-disciplinary fellow at the French National Institute of Agricultural Research. Zhizhong received his PhD in Chemistry and Chemical Biology from Harvard University. At Harvard, he developed quantitative single-cell methods to study gene-drug interactions in microbial systems at the Department of Systems Biology and Systems Pharmacology. Zhizhong graduated with a BA in Chemistry and Molecular Engineering from Peking University where he graduated with Honors. Zhizhong was a teaching fellow and life-science residential advisor at Harvard College. His original research and review articles have appeared in peer-reviewed journals such as PNAS, Molecular Cell, PLoS Genetics and Annual Review of Microbiology.

4D Lifetec
DNA Damage Detection & Diagnostics

ADDRESS
Gewerbestrasse 8
6330 Cham
Switzerland

WEBSITE
www.4dlifetec.com

E-MAIL
info@4dlifetec.com

PHONE
+41 41 747 25 52

COMPANY TYPE
Private

SECTOR
Biotechnology
Bioinformatics
Diagnostics
Medical Devices

YEAR FOUNDED
2014

4D LIFETEC AG

COMPANY PROFILE

4D Lifetec is a company developing and promoting test and screening systems for molecular diagnostics including the production of related consumables. 4D Lifetec developed the 4D Lifetest™ – an innovative,

standardized, cost effective ultra-precise Integral Liquid Biopsy (ILB) assay. ILB is measuring the activity level of oncogenes in

white and red blood cells, which reliably correlates with primary tumor affection at an early stage.

4D Lifetest™ has the potential to measure 10'000 data points per day at a cost level of approximately 10 USD per point and has already proven its ability to detect early-stage cancer in general in patients affected by any kind of cancer.

Clinical trials have shown its potential as a simple, single, cost-efficient empirical assay to select any early-stage cancer (Early Cancer Diagnostics).

MANAGEMENT TEAM

Dr. Arne Faisst
Nick Mijnssen
Marco Zingg
Oliver Schicht
Giancarlo Rizzoli

FINANCIAL SUMMARY

Business Plan October 2017 available

ABIVAX

ADDRESS
Rue de la Baume 5
75008 Paris
France

WEBSITE
www.abivax.com

PHONE
+33 1 53 83 08 41

COMPANY TYPE
Public

TICKER
[EPA: ABVX]

SECTOR
Biotechnology

YEAR FOUNDED
2013

ABIVAX

COMPANY PROFILE

ABIVAX, a clinical stage Biotech company listed on Euronext Paris, is developing drugs to treat severe viral and inflammatory diseases as well as cancer. The company leverages three technology platforms for drug discovery: an antiviral platform, an immune enhancer platform and a polyclonal antibody platform. ABX464, its most advanced compound, is the first compound ever that was shown in clinical trials to reduce the viral reservoir of HIV patients and is currently in Phase 2 clinical trials for providing a sustained viral remission or functional cure for these patients. It is a first-in-class oral small antiviral molecule which blocks HIV replication through a unique mechanism of action and also has strong anti-inflammatory activities. Based on the latter effect, ABX464 is now also in a phase 2 proof-of-concept (POC) study in patients with moderate to severe ulcerative colitis. In addition, ABIVAX is advancing ABX196, an INKT agonist, into a POC clinical trial in patients with hepato-cellular cancer. ABIVAX' early stage portfolio is comprised of a number of compounds derived from its antiviral platform that have shown activity against additional viral targets (e.g. Respiratory Syncytial Virus (RSV), Influenza and Dengue).

MANAGEMENT TEAM

Prof. Hartmut Ehrlich, M.D., CEO
Didier Blondel, CFO
Jean-Marc Steens, M.D., CMO
Pierre Courteille, VP Business Development and Commercial
Dr. Paul Gineste, VP Clinical Operations
Dr. Jerome Denis, VP Process Development and Manufacturing
Didier Scherrer, VP R&D
Prof. Jamal Tazi, Ph.D., CNRS Director
Bernard Fanget, VP Regulatory Affairs



ADDRESS
Chemin des Aulx 12
Plan-les-Ouates
Geneva, 1228
Switzerland

WEBSITE
www.addextherapeutics.com/en

EMAIL
info@addextherapeutics.com

PHONE
+41 22 884 1555

COMPANY TYPE
Public

TICKER
[SWX: ADXN]

SECTOR
Biotechnology

YEAR FOUNDED
2002

ADDEX THERAPEUTICS LTD.

COMPANY PROFILE

Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for central nervous system disorders.

Addex lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase 2A POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter Phase 2B for PD-LID. In parallel, dipraglurant's therapeutic use in dystonia and treatment esistant depression is being investigated. Addex second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc. Addex also has several preclinical programs including: ADX71441 (GABAB receptor PAM) which has received regulatory approval to start Phase 1 and is being investigated for therapeutic use in Charcot-Marie-Tooth (type 1A) disease, alcohol use disorder and nicotine dependence; mGluR4 PAM for drug abuse and dependence, Parkinson's disease and other neurodegenerative diseases; mGluR2 NAM for treatment resistant depression and cognitive deficits; mGluR7 NAM for psychosomatic disorders, TrkB PAM for neurodegenerative disorders; and GLP1 PAM for type 2 diabetes.

Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.

Founded in 2002, Addex is headquartered in Geneva and listed on the SIX Swiss Stock Exchange under the trading symbol ADXN.

MANAGEMENT TEAM

Tim Dyer, CEO

Roger Mills, Chief Medical Officer

Robert Lutjens, Head of Discovery

FINANCIAL SUMMARY

2017 Half Year Report

https://www.addextherapeutics.com/files/4815/1266/0227/Addex_financial_statements_H1_2017.pdf

PIPELINE GRAPHIC



ADDRESS
Chemin des Aulx 12
Plan-les-Ouates
Geneva, 1228
Switzerland

WEBSITE
www.addextherapeutics.com/en

EMAIL
info@addextherapeutics.com

PHONE
+41 22 884 1555

COMPANY TYPE
Public

TICKER
[SWX: ADXN]

SECTOR
Biotechnology

YEAR FOUNDED
2002

PIPELINE PRODUCT 1:

Dipraglurant-IR (mGluR5 NAM) : Phase 2
Dipraglurant-ER (mGluR5 NAM) : Phase 1

PIPELINE PRODUCT 1:

Dipraglurant-IR (mGluR5 NAM) : Parkinson's disease levodopa-induced dyskinesia
Dipraglurant-ER (mGluR5 NAM) : Focal cervical dystonia

PIPELINE PRODUCT 2:

ADX71441 (GABAB PAM) : Preclinical
(GABAB PAM) : Preclinical

PIPELINE PRODUCT 2:

ADX71441 (GABAB PAM) : Addiction
(GABAB PAM) : CMT 1A neuropathy

PIPELINE PRODUCT 3:

ADX71149 (mGluR2 PAM) : Phase 1

PIPELINE PRODUCT 3:

ADX71149 (mGluR2 PAM) : Epilepsy

ADRENOMED

ADDRESS
Neuendorfstr. 15a
Hennigsdorf, 16761
Germany

WEBSITE
www.adrenomed.com

E-MAIL
info@adrenomed.com

PHONE
+49 3302 20 77 80

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2009

ADRENOMED AG

COMPANY PROFILE

Adrenomed AG is a privately-financed biopharmaceutical company with a clear mission: to improve survival by improving compromised vascular integrity in critically ill patients.

Clinical lead product is the first-in-class drug candidate Adrecizumab, a humanized monoclonal antibody targeting Adrenomedullin, an essential hormone that controls endothelial barrier function and prevents vascular leakage, a pathology that serves a variety of medical conditions.

The groundbreaking Mode of Action combines high efficacy in a variety of preclinical models mimicking standard of care treatment on ICU with excellent safety and tolerability in clinical Phase 1a/1b. Adrecizumab effectively counteracts loss of vascular integrity and edema formation, a hallmark of a variety of severe acute indications with high unmet need and the final common path of all severe infections. Adrecizumab is currently tested in a Phase II study in patients with early septic shock, which are stratified by measuring the biologically active target. A second Phase II study in acute congestive heart failure is planned to start in 2018.

Adrecizumab and related antibodies are effectively protected by a variety of granted patents (US, EU) in any indications and ready for partnering with the pharmaceutical industry.

Adrenomed was established in 2009 by former executive managers of BRAHMS AG which successfully changed the standard of care in sepsis by developing Procalcitonin (PCT), which is the current diagnostic gold standard sepsis biomarker.

MANAGEMENT TEAM

Gerald Moeller, PhD, CEO

Andreas Bergmann, PhD, CSO

Frauke Hein, PhD, CBO

FINANCIAL SUMMARY

Adrenomed AG is a privately-financed biopharmaceutical company.

PIPELINE PRODUCT 1:

Clinical lead product is the first-in-class drug candidate Adrecizumab, a humanized monoclonal antibody targeting Adrenomedullin, an essential hormone that controls endothelial barrier function and prevents vascular leakage, a pathology that serves a variety of medical conditions.

We demonstrated that Adrecizumab effectively counteracts loss of vascular integrity and edema formation, a hallmark of a variety of severe acute indications with high unmet need and the final common path of all infections. The groundbreaking Mode of Action combines high efficacy in a variety of preclinical models mimicking standard of care treatment on ICU with excellent safety and tolerability in clinical Phase 1a/1b. Adrecizumab showed dose -dependend efficacy on clinical scores in patients with systemic inflammation induced by LPS administration. Adrecizumab is currently tested in a Phase II study in patients with early septic shock, which are stratified by measuring the biologically active target. A second Phase II study in acute congestive heart failure is planned.

ADRENOMED

ADDRESS
Neuendorfstr. 15a
Hennigsdorf, 16761
Germany

WEBSITE
www.adrenomed.com

E-MAIL
info@adrenomed.com

PHONE
+49 3302 20 77 80

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2009

OPPORTUNITY 1:

Adrecizumab and related antibodies are effectively protected by a variety of granted patents (US, EU) in any indications and ready for partnering with the pharmaceutical industry after Phase 2 PoC planned for 2019.

ALLIGATOR bioscience

ALLIGATOR BIOSCIENCE AB

ADDRESS
Medicon Village
Scheelevagen 2
Lund, 223 81
Sweden

WEBSITE
www.alligatorbioscience.se/en

E-MAIL
info@alligatorbioscience.com

PHONE
+46 4 62 86 42 80

COMPANY TYPE
Public

TICKER
[STO: ATORX]

SECTOR
Biotechnology

YEAR FOUNDED
2001

COMPANY PROFILE

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes four lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527). ADC-1013 (JNJ-64457107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. For more information, please visit www.alligatorbioscience.com.

MANAGEMENT TEAM

Per Norlén, CEO
Christina Furebring, SVP Research
Charlotte Russell, CMO
Per-Olof Schrewelius, CFO
Peter Ellmark, VP Discovery

PIPELINE PRODUCT 1:

ADC-1013 Phase I

PIPELINE PRODUCT 1:

ATOR-1015 Preclinical

PIPELINE PRODUCT 2:

ATOR-1017 Preclinical

PIPELINE PRODUCT 2:

ALG.APV-527 Preclinical

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

ATOR-1015

OPPORTUNITY 1:

ATOR-1015 is a bispecific (CTLA-4 and OX40) antibody developed for tumor-targeted treatment of metastatic cancer, as either a single therapy or in combination with other immunotherapies, such as PD-1 blockers. The antibody has been created using Alligator's unique bispecific fusion format.

ATOR-1015 binds to two different immunostimulatory receptors – to the checkpoint receptor CTLA-4, and to a costimulatory receptor OX40. In preclinical studies, the bio-specificity has been shown to cause a significant increase in the immunostimulatory effect and is expected be achieved mainly in environments where both target molecules are expressed at elevated levels, such as in a tumor.

In 2017, preclinical data was presented to support the described mechanism of action for ATOR-1015, i.e. that it causes immunostimulation in the tumor environment but not in the rest of the body, which is the goal of the treatment. New data has also demonstrated effects in multiple experimental tumor models, and additional data has confirmed that the stimulation is effectively localized to the tumor.

ADDRESS
Medicon Village
Scheelevagen 2
Lund, 223 81
Sweden

WEBSITE
www.alligatorbioscience.se/en

E-MAIL
info@alligatorbioscience.com

PHONE
+46 4 62 86 42 80

COMPANY TYPE
Public

TICKER
[STO: ATORX]

SECTOR
Biotechnology

YEAR FOUNDED
2001

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 2: ATOR-1017

OPPORTUNITY 2:

ATOR-1017 is an immunostimulating antibody (IgG4) that binds to the costimulatory receptor 4-1BB (CD137) in tumor-specific T cells. 4-1BB has the capacity to support the immune cells involved in tumor control, making 4-1BB a particularly attractive target for cancer immunotherapy.

ATOR-1017 is differentiated from other 4-1BB antibodies, partly because of its unique binding profile, but also because its immunostimulating function is dependent on cross-linking to Fc gamma receptors in immune cells. This localizes the immunostimulation to the tumor region where both 4-1BB and Fc gamma receptors are expressed at elevated levels – totally in line with the treatment strategy for Alligator's drug candidates. The aim is to achieve effective tumor-targeted immune stimulation with minimum side effects.

ANIMA BIOTECH LTD.

ADDRESS
10 Hanechoshet st.,
Tel Aviv 69710,
Israel

WEBSITE
www.animabiotech.com

E-MAIL
anima@animabiotech.com

PHONE
+972 72 214 8770

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2006

COMPANY PROFILE

Anima Biotech is pioneering Translation Control Therapeutics, a new class of drugs that control protein translation. Our novel technology platform enables for the first time to visualize and specifically control the synthesis of target proteins. By targeting the proteins that specifically regulate the translation of mRNA, we discover molecules that either decrease or increase a given protein's production, enabling a strategy against hard and undruggable targets.

The platform is applicable to over 80% of known proteins and our pipeline is quickly expanding. Currently we run programs in Fibrosis (inhibiting the synthesis of Collagen type I), Viral infections (RSV – interfering with viral protein synthesis), Oncology (C-Myc translation inhibitors) and Huntington's disease. Discovered molecules are in the validated hit to lead stage.

Funding: $28m, including $10m in NIH research grants.

Technology Validation: our protein synthesis monitoring (PSM) technology was originally developed over 7 years in close collaboration with the ribosome biochemistry lab at Penn university. Over the last 5 years, we have built a network of 17 scientific collaborations, resulting in 13 peer reviewed publications. Our platform has 5 granted patents and 2 patents pending.

Business strategy: We expand to additional areas on our own and through partnering with Pharma in their drug discovery programs. We drive our pipeline forward to the clinic while partnering in additional areas.

MANAGEMENT TEAM

Mr. Avi Eliassaf: Vice president, Operations
Dr. David Sheppard: Head of Chemistry
Dr. Iris Alroy: Vice President, R&D
Mr. Yochi Slonim: Co-founder & CEO
Mr. Yossi Oulu: Vice president, Digital technologies
Dr. Zeev Smilansky: Co-founder & CSO

FINANCIAL SUMMARY

10.05.2007: 10.00 (USD in millions)
03.09.2015: 12.00 (USD in millions)
01.01.2018: 6.00 (USD in millions)

PIPELINE GRAPHIC:

Program	Indication	Assay Development	Hit Generation	Hit-to-lead	Preclinical
Collagen I – Target1	Lung Fibrosis				
Collagen I – Target2	Liver Fibrosis				
Collagen I – Target3	Scleroderma				
Respiratory Syncytial Virus	RSV				
Myc	Oncology/Longevity				
Huntingtin	HD				

ADDRESS
10 Hanechoshet st.,
Tel Aviv 69710,
Israel

WEBSITE
www.animabiotech.com

E-MAIL
anima@animabiotech.com

PHONE
+972 72 214 8770

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2006

PIPELINE PRODUCT 1:

Fibrosis Collagen I translation inhibitors - Lung, NASH, Scleroderma
Phase: Hit-to-Lead Optimization

PIPELINE PRODUCT 1:

The main underpinning of Fibrosis is the overproduction of collagen I. We discovered molecules that selectively inhibit the synthesis of Collagen. This is a new therapeutic strategy applicable to many types of Fibrosis.

PIPELINE PRODUCT 2:

RSV - Inhibiting the production of viral proteins
Phase: Hit optimization

PIPELINE PRODUCT 2:

Instead of targeting the viral protein that is subject to mutations, we focus on cellular targets that viruses hijack and use to control the translation of their proteins. These targets are in the host cell and therefore are not impacted by the mutation of the virus itself.

PIPELINE PRODUCT 3:

Oncology - C-Myc translation inhibitors
Phase: HCS assay transfe

PIPELINE PRODUCT 3:

Our platform can monitor C-Myc protein translation in tumor cells and identify novel regulators of its translation.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

C-Myc Translation Inhibitors
Compounds that selectively inhibit the translation of C-Myc, an undruggable target involved in many types of cancer

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 2:

Collagen translation inhibitors - Fibrosis - Scleroderma, NASH Liver & lung
Compounds that selectively inhibit the translation of Collagen I.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 3:

RSV translation inhibitors
A new strategy against RSV - we discovered compounds that inhibit the translation of the virus by the host cell's ribosomes.

APOGENIX AG

ADDRESS
Im Neuenheimer Feld 584
69120 Heidelberg
Germany

WEBSITE
www.apogenix.com

E-MAIL
contact@apogenix.com

PHONE
+49 6221 58608 0

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2005

COMPANY PROFILE

Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signaling pathways, thereby restoring the anti-tumor immune response. Since its inception in fall 2005, Apogenix has raised more than 90 million euros in financing rounds, public grants, as well as upfront and milestone payments from licensing agreements. The company is based in Heidelberg, Germany.

Apogenix' lead drug candidate APG101 is a fully human fusion protein that consists of the extracellular domain of the CD95 receptor and the Fc domain of an IgG antibody. The substance inhibits the CD95 ligand which plays an important role in the progression of solid tumors. Depending on the target cell – immune cell or tumor cell – the interaction between the CD95 ligand and the CD95 receptor induces either apoptotic cell death or invasive growth of cells. With this unique dual mode of action, APG101 is being developed for the treatment of solid tumors and malignant hematological diseases. So far, the substance has been successfully evaluated in clinical trials for the treatment of glioblastoma and myelodysplastic syndromes (MDS).

Better than antibodies – Apogenix' HERA-technology: Apogenix' proprietary HERA technology platform enables the construction of novel hexavalent TNFSF receptor agonists for the treatment of cancer. Preclinical experiments have shown that these agonists effectively stimulate the immune system, marking them as promising candidates for the treatment of solid tumors.

ADDRESS
EPFL Innovation Park
Bâtiment B
Lausanne, 1015
Switzerland

WEBSITE
www.asceneuron.com

PHONE
+41 21 693 8242

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2012

ASCENEURON SA

COMPANY PROFILE

Asceneuron is an emerging biotech company specializing in the discovery and development of groundbreaking small molecule therapeutics for neurodegenerative diseases.

We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases.

To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP).

Our lead product, the O-GlcNAcase inhibitor ASN120290 which has been demonstrated to modulate tau pathology in preclinical studies, has entered human clinical testing in healthy volunteers. The O-GlcNAcase inhibitor is being developed for the orphan tauopathy Progressive Supranuclear Palsy (PSP).

ADDRESS
Christophstr. 32
Tübingen, 72072
Germany

WEBSITE
www.atriva-therapeutics.com

E-MAIL
info@atriva-therapeutics.com

PHONE
+49 7071 859 7673

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2015

ATRIVA THERAPEUTICS GMBH

COMPANY PROFILE

Atriva Therapeutics GmbH is a company based on patented research on the benefit of MEK inhibitors in the treatment of viral and bacterial infections and located in Tübingen, Germany, a mainstay in European anti-infective research (Curevac, supported by gates foundation, Inmatics).

The novel ATRIVA approach is targeting host cell structures and not viral structures, so being a universal mechanism that the virus cannot escape e.g. through surface alterations.

Key advantages are that there will be no resistance development unlike standard of care. Our approach will be active against all known or upcoming strains of influenza viruses and has the potential open a longer therapeutic time window, compared to standard of care.

We focus on Influenza as lead, but have established the foundation to build a pipeline of additional preclinical projects on negative-strand RNA viruses: Hanta (Orphan Disease!), RSV and Corona (MERS, SARS), for none of them an effective cure existing so far.

Our technology finds strong interest at US-American NIH and BARDA. We recently agreed with NIH a test program for an array of viral targets causing serious respiratory diseases and hemorrhagic fevers.

Influenza viruses are the immediate focus for our required funding to achieve the clinical milestones with our lead compound ATR-002, an investigational MEK-inhibitor and a small molecule, coming with a smart oral delivery form.

We are currently finalizing the remaining preclinical development path for intended use as potent anti-influenza drug. We plan to file an IND in Q4-2018 in Europe. We aim to complete the clinical phase 2 studies in mid 2020 based on viral challenge study approach. 2020 will thus be a major transaction event for the company.

ATR-002 carries a strong potential to be the first compound active against the so-called Influenza-like-Illness syndrome (ILI), a serious disease of the respiratory tracts caused by an array of viruses, including RSV, influenza and rhino virus, especially dangerous for elderly with concomitant heart or lung disease.

We discovered more recently that MEK inhibitors show an inhibitory effect on certain bacteria causing bacterial super-infections following the viral infections, e.g. nosocomial S.aureus strains (MRSA), an exciting early-stage finding which we are currently further exploring in preclinical development after having the IP globally secured.

Our technology is protected by a solid global IP base of 5 patent family including use and application patents for a broader array of RNA viruses, causing serious diseases.

In late 2016 we have closed a € 3 Mn seed round to push our lead compound into clinical phase 1 development. We benefit from an internationally versed private and institutional investor base, including the renowned German Hightech-Gründerfond, Europe's largest seed fund.

In first half 2018 we invite new investors to join our venture round of up to € 14 Mn funds, sufficient to achieve our clinical milestone phase 2 objectives.

ADDRESS
Christophstr. 32
Tübingen, 72072
Germany

WEBSITE
www.atriva-therapeutics.com

E-MAIL
info@atriva-therapeutics.com

PHONE
+49 7071 859 7673

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2015

This is now the chance to be part of this exciting story and to enjoy a high return on your investment in only three years.

There is still the opportunity to participate in an extension of the seed round at very favorable conditions for investors being decided within the next 10 weeks to invest at least € 500k.

MANAGEMENT TEAM

Dr. Rainer LIchtenberger, CEO
Prof. Oliver Planz, CSO
Dr. Chrsitian Wallasch, COO
Dr. Sebastian Canisius, CMO
Dr. Henrik Lueßen, CBO

FINANCIAL SUMMARY

Founders round 2015 €200k Seeed
round 2016 - 2017 € 3 Mn
Venture round of up to € 14 Mn open

AUREALIS PHARMA

ADDRESS
Hochbergerstrasse 60C
CH-4057 Basel
Switzerland

WEBSITE
www.aurealispharma.com

E-MAIL
info@aurealispharma.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Pharmaceuticals/Licensing
Regenerative Medicine

YEAR FOUNDED
2015

AUREALIS PHARMA AG

COMPANY PROFILE

Aurealis Pharma is a Swiss-Finnish private biopharmaceutical company developing novel three-in-one combination biologics for chronic inflammation and cancer. Technology is based on safe food-grade lactic acid bacteria delivering multiple human therapeutic proteins in target tissue. Lead product AUP-16 is entering phase I in chronic wound patients in 2018 (diabetic foot ulcer and vascular leg ulcer). Immuno-oncology program has 14 lead candidates being tested for in vivo potency.

MANAGEMENT TEAM

Mr. Juha Yrjänheikki, CEO, PhD

Mr. Thomas Wirth, CSO, PhD

Mr. Dirk Weber, CMO, MD, PhD

FINANCIAL SUMMARY

Our goal is to raise 8MCHF in Q1-Q3/2018 to advance AUP-16 into phase 1 in chronic wound patients in Q4/2018 and oncology lead into non-clinical efficacy.

We have raised up to date 16MCHF in Seed A-C and Series A rounds.

PIPELINE PRODUCT 1:

AUP-16 is currently at clinical trial application submission. Entering phase 1 patient trial in Q4/2018.

PIPELINE PRODUCT 1:

AUP-16 is the lead product from Aurealis Pharma “combination biologics in one product” technology platform. It is a genetically engineered lactococcus lactis bacteria expressing human basic fibroblast growth factor, interleukin-4 and macrophage colony stimulating factor. AUP-16 is topically applied on chronic wounds and covered by wound dressing (e.g. in diabetic foot ulcers, venous leg ulcers and pressure ulcers). In the wound AUP-16 acts as millions of bioreactors producing the therapeutic proteins, which are designed to i) halt chronic inflammation in the wound, ii) induce growth of new blood vessels, and iii) promote granulation tissue formation and skin re-epithelization – all in one product. AUP-16 is currently produced at GMP level, passed GLP safety and toxicity studies, and is planned to enter phase 1 patient trial in Q4/2018. It has passed EU regulatory authority scientific advice and is showing superior efficacy in non-clinical efficacy studies in non-healing diabetic wounds.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

AUP-16 CTA ready

OPPORTUNITY 1:

AUP-16 is the lead product from Aurealis Pharma “combination biologics in one product” technology platform. It is a genetically engineered lactococcus lactis bacteria expressing human basic fibroblast growth factor, interleukin-4 and macrophage colony stimulating factor. AUP-16 is topically applied on chronic wounds and covered by wound dressing (e.g. in diabetic foot ulcers, venous leg ulcers and pressure ulcers). In the wound AUP-16 acts as millions of bioreactors producing the therapeutic proteins, which are designed to i) halt chronic inflammation in the wound, ii) induce growth of new blood vessels, and iii) promote granulation tissue formation and skin re-epithelization – all in one product. AUP-16 is currently produced at GMP level, passed GLP safety and toxicity studies, and is planned to enter phase 1 patient trial in Q4/2018. It has passed EU regulatory authority scientific advice and is showing superior efficacy in non-clinical efficacy studies in non-healing diabetic wounds.

AYOXXA BIOSYSTEMS GMBH

ADDRESS
BioCampus Cologne
Nattermannallee 1.
50829 Köln,
Germany

WEBSITE
www.ayoxxa.com

PHONE
+49 0 221 222529 0

COMPANY TYPE
Private

SECTOR
Biotechnology
Laboratory Equipment

YEAR FOUNDED
2010

COMPANY PROFILE

AYOXXA's products and services enable customers to have greater success in translational proteomics - in every setting from research lab to clinical study. LUNARIS™ is AYOXXA's proprietary multiplex assay platform for advanced protein analysis. With advantages in quality, flexibility, robustness and efficiency, LUNARIS™ enables scalable quantitative protein analysis from tiny amounts of biological samples. Partners are already using the AYOXXA technology to develop clinically-useful assay panels and to validate biomarkers in the context of drug discovery and development. AYOXXA is commercializing a growing portfolio of standardized ready-to-use biomarker analysis assays, with a focus on the biology of inflammation and immune response. AYOXXA is currently raising its Series C financing with an anticipated close in mid-2018.

MANAGEMENT TEAM

Rodney Turner - CEO

Wolfgang Kintzel - co-CEO

Markus Zumbansens - CTO

Andreas Richter - CFO

FINANCIAL SUMMARY

AYOXXA is currently raising its Series C round anticipated to close in mid-2018. Proceeds will help expand the menu of consumable products, execute on pharma and clinical research collaborations, and support partnerships for the development of clinical assays.

AYOXXA is supported by leading venture capital firms, including Wellington Partners, BioMed Partners, NRW Bank, Creathor Ventuers, and b-to-v Partners.

BAYOOMED MEDICAL SOFTWARE

ADDRESS
Robert-Bosch-Strasse 7
D-64293 Darmstadt
Germany

WEBSITE
www.bayoomed.com

E-MAIL
info@bayoo.net

PHONE
+49 0 6151 86 18 0

COMPANY TYPE
Private

SECTOR
Biotechnology
Bioinformatics
Consulting Services
Diagnostics
Drug Delivery
Medical Devices
Other

YEAR FOUNDED
2001

COMPANY PROFILE

BAYOOMED is specialized in the development of medical apps and medical software for life science industry. With more than 250 person years of project experience in software development in the regulated medical and pharmaceutical environment and over 800 medical & pharma customers, we are among the most experienced medical software developers in Europe.

As a certified legal manufacturer of medical devices we offer full service packages for product developers and innovators from pharmaceutical and biotechnology companies who are not permitted to place a medical device in the market.

Thereby our customers can concentrate on their business like drug discovery and development while BAYOOMED will engineer the corresponding medical software like computerized systems for preclinical studies and clinical investigation, risk management software, pain diary logs, dosage or drug delivery apps as well as software to control medical devices like insulin pumps, respirator or medical laser systems.

BAYOOMED is highly professional in the regulated CE & FDA environment. Our Quality management processes certified by TÜV Hessen according to ISO 13485 are a testament to our passion for sustainable solutions and distinct customer focus. We design, develop, test, validate and document medical software and MHEALTH / EHEALTH apps in accordance with the regulatory standards IEC 62304, ISO 14971, IEC 62366 as well as the FDA Guidance for Mobile Medical Applications.

We could offer Due Dilligence Services for medical device classifications, usability engineering, risk management, technical documentation and FDA and CE registration.

Our customers have been entrusting us with their sensitive projects for 16 years and have recommended our services many times. We are delighted about this and it also gives us further motivation to show each and every new customer what we can do for them.

MANAGEMENT TEAM

Stefan Becher, CEO

Frank Manger, CEO

BIOARCTIC

ADDRESS
Warfvinges Vaeg 35
Stockholm, 112 51
Sweden

WEBSITE
www.bioarctic.se/en

E-MAIL
info@bioarctic.se

PHONE
+46 8 695 69 30

COMPANY TYPE
Public

TICKER
[STO: BIOA-B]

SECTOR
Biotechnology

YEAR FOUNDED
2003

BIOARCTIC AB

COMPANY PROFILE

BioArctic AB (publ) is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. BioArctic's B-share is listed on Nasdaq Stockholm Mid Cap (STO:BIOA B). www.bioarctic.com

PIPELINE GRAPHIC



BIOLINGUS AG

COMPANY PROFILE

BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) delivery of peptides and proteins for chronic diseases and immune-therapies.

Lead projects are : oral liraglutide (currently fundraising), exenatide, oral exenatide+insulin, oral IL-2 for auto-immune diseases (in particular delaying onset in type I diabetes).

We are interested in collaborations on oral delivery of peptides or oral delivery of immuno-active compounds for auto-immune and inflammatory disorders.

BioLingus has won several innovation awards, amongst other the European CEO award for “most innovative biotech” company 2016, Gamechanger Award 2017 and nominated for Red Herring Top 100 in 2018

ADDRESS
Grossmatt 6
CH-6052 Hergiswil NW
Switzerland

WEBSITE
www.biolingus.ch

E-MAIL
info@biolingus.ch

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2013

BRASTER S.A.

ADDRESS
PGE Narodowy
Al. Ks. J. Poniatowskiego 1
03-901 Warsaw
Poland

WEBSITE
www.braster.eu

E-MAIL
braster@braster.eu

PHONE
+48 22 295 03 50

COMPANY TYPE
Public

TICKER
[BRA:WSE]

SECTOR
Biotechnology
Medical Devices
Diagnostics

YEAR FOUNDED
2008

COMPANY PROFILE

Braster was founded by a group of medical doctors and scientists, developed a state-of-the-art technology called a "contact thermography" which has been clinically proven effective in early breast cancer detection. Braster is the only company that has developed a method of manufacturing liquid crystal matrices used for breast cancer diagnostics. Thanks to this Braster created medical device that enables women to perform regular breast examinations at home and detect symptoms of breast cancer. In record time of 18-months company designed and manufactured its device. In October 2016 Braster launched on the Polish market (B2C) its innovative medical device.

All business values are geared towards the future and long-term development strategy in the field of telemedicine. In the 2017 the company announced the strategy of international expansion.

Braster System is an innovative mHelath soultion for in-home breast examination. It is dedicated to all women regardless of age and breast tissue type. Braster System consists of a high-tech medical device class IIa, mobile application, artificial intelligence algorithms detecting potential abnormalities in breasts and a telemedical centre with high class medical experts supervising the process. High efficacy of the system was proven in observational trials. The examination is painless, radiation free and safe for women.

MANAGEMENT TEAM

Marcin Halicki - President of the Management Board, CEO

Konrad Kowalczuk - Member of the Management Board, CFO

Henryk Jaremek PhD, Eng - Deputy President of the Management Board

ADDRESS
AMC Campus
Meibergdreef 5
1105 AZ Amsterdam
The Netherlands

WEBSITE
www.caelushealth.com

E-MAIL
info@caelushealth.com

PHONE
+31 6 2297 9249

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2014

CAELUS HEALTH

COMPANY PROFILE

Caelus Health is an Amsterdam-based biotech company developing an entirely new class of Microbiome Therapeutics for the reduction of insulin resistance and prevention of Type 2 Diabetes (T2DM) in people with metabolic syndrome.

The company is dedicated to the commercialisation of functional food and pharma-biotic products for the prevention and early treatment of cardio metabolic diseases – based on the strong correlation between the intestinal microbiome and health.

Caelus Health builds on the experience of leading scientists in this field and is one of the very few companies that can effectively capture the value of Microbiome Therapeutics through their solid preclinical and early-stage clinical development approaches.

MANAGEMENT TEAM

Luc Sterkman, CEO

Willem M de Vos, CSO

PIPELINE PRODUCT 1:

CP-101 E. hallii

PIPELINE PRODUCT 1:

Prevention of early treatment of T2DM

PIPELINE PRODUCT 2:

CP-304 Intestinimonas

PIPELINE PRODUCT 2:

Prevention of T2DM'

Break down of AGEs

ADDRESS
Medicon Village
Scheelevägen 2
SE-223 81 Lund, Sweden

WEBSITE
www.cantargia.com/en

E-MAIL
info@cantargia.com

PHONE
+46 0 46 2756260

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2010

CANTARGIA AB

COMPANY PROFILE

Cantargia specialises in antibody-based cancer treatment. CAN04, the company's patented antibody treatment, has a dual mechanism of action. CAN04 fights cancer by activating the immune system and blocking signals that lead to tumour growth. Treatment with CAN04 has the potential to become an important part of modern immuno-oncology.

FOCUS ON LUNG AND PANCREATIC CANCER

Cantargia is developing antibody-based treatments specifically targeting the molecule IL1RAP with a potential to treat a number of different cancers. The lead candidate, CAN04, is initially focused on non-small cell lung cancer (NSCLC) and pancreatic cancer and clinical trials started in 2017. The aim is to develop a new drug with the potential to become an important part of future cancer treatment.

OUR PRODUCT CANDIDATE CAN04

CAN04 is designed to block the cancer cell's signalling via the interleukin-1 system. Thereby the tumour inflammation, which facilitates the growth of the tumour, can be counteracted. CAN04 is also designed to stimulate the body's immune system to eliminate cancer cells directly.

NEW PROJECT CANXX

Cantargia intends to develop and patent a new antibody against IL1RAP in order to treat autoimmune and inflammatory diseases, with the aim to have a product candidate selected by late 2018 or early 2019.

PIPELINE PRODUCT 1:

CAN04: Immuno-oncology antibody targeting IL1RAP in phase I/IIa clinical development for nonsmall cell lung cancer and pancreatic cancer.

PIPELINE PRODUCT 2:

CANxx in discovery phase.

PIPELINE PRODUCT 2:

Antibody against IL1RAP blocking IL-1, IL-33 and IL-36. Developed for autoimmune/ inflammatory disease

ADDRESS
Attenhoferstrasse 8b
8032 Zürich
Switzerland

WEBSITE
www.cellerys.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2015

CELLERYS AG

COMPANY PROFILE

Cellerys' mission is to induce antigen-specific immune tolerance in multiple sclerosis through peptide-coupled cell therapy. The company's flagship project "Establish Tolerance in MS" ("ETIMS") is currently in a Phase Ib clinical trial at the University of Zurich.

ETIMS aims to abrogate the myelin-specific autoimmune response at the root of MS while avoiding the sometimes serious side effects of currently approved immunomodulatory treatments. The patient's blood cells are coupled ex vivo with a cocktail of myelin peptides, which represent the most important target antigens in MS. After being given back to the patient, the peptide-coupled cells undergo natural cell death in the body and are presented in a tolerogenic manner in liver and spleen, thereby "teaching" the immune system to refrain from harmful responses to brain antigens.

A previous Phase Ib clinical trial conducted by Roland Martin and Andreas Lutterotti demonstrated the safety/tolerability of the approach and provided early indication of proof of mechanism (reduction/elimination of myelin-specific T cells). A new Phase Ib trial employing an improved and protected methodology for a semiautomatic GMP process is currently ongoing at the University of Zurich.

MANAGEMENT TEAM

Prof. Dr. Roland Martin, Co-Founder

Prof. Dr. Andreas Lutterotti, Co-Founder

Nicolas Martin, Managing Director

FINANCIAL SUMMARY

Cellerys is backed by the Wyss Zurich, a joint research and development center of the University of Zurich and the ETH Zurich (www.wysszurich.uzh.ch). Wyss Zurich has committed to support the clinical development of ETIMS by funding a Phase Ib and a Phase IIa clinical trial.

CELLESTIA BIOTECH

ADDRESS
Technology Park Basel
Hochbergerstrasse 60C
Basel, 4057
Switzerland

WEBSITE
www.cellestia.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2014

CELLESTIA BIOTECH AG

COMPANY PROFILE

Cellestia is a clinical stage biopharmaceutical company located in Basel and Lausanne, Switzerland, developing innovative first-in-class anti-cancer drugs originated from its discovery platform. The lead compound is in Phasel I-IIa study running in EU countries, IND will be filed during 2018. In addition to the clinical stage lead compound, Cellestia has established a comprehensive patient selection biomarker panel, which is validated and active in clinical testing. Data from first 93 patients are available.

Cellestia is leader in selective treatment of NOTCH pathway driven cancers, pursuing an integrated biomarker and drug development program. Utilising cutting edge tailored diagnostic technologies in combination with novel mode of action proprietary small molecule therapeutics, Cellestia ensures provision of personalized medicine with best in class anti-NOTCH cancer drugs.

MANAGEMENT TEAM

Dr Michael Bauer, CEO

Dr Rajwinder Lehal, CSO

Dr Dirk Weber, CMO

Dr Maximilien Murone, COO

Gaudenz von Capeller, CFO

Prof Freddy Radke, Chairman of the BoD

FINANCIAL SUMMARY

Cellestia is financed by private equity investors and PPF Group. Proceeds raised to date 11.7 million in SEED A-B-C rounds (8m) and ongoing SERIES A Financing Round.

PIPELINE PRODUCT 1:

CB-103 is in Phase I of clinical development, treating cancer patients in selected oncology indications with a high prevalence of NOTCH.

PIPELINE PRODUCT 1:

CB-103 is a highly selective oncogene transcription factor inhibitor selectively blocking oncogenic activation mediated by NOTCH pathway signalling. CB-103 binds to a specific protein in the transcription complex, preventing the expression of downstream target genes. This novel mode of action has been fully validated by a range of methods including high-resolution co-crystalliation of CB-103 bound to the target.

Acting as highly selective protein-protein-interaction inhibitor, CB-103 has an exceptional saftety profile, overcoming the limitations of first (GSIs) and second (ligand / receptor targeting mABs) generation NOTCH targeting agents, demonstrating excellent anti-cancer efficacy with superior safety profile in absence of the tpyical NOTCH targeting agent related side effects.

PIPELINE PRODUCT 2:

NOTCH targeting 2nd generation compound based on Cellestia technology, preclinical proof of concept confirmed. Target to reach preclinical development in 2019

PIPELINE PRODUCT 3:

Undisclosed target A, selective transcription factor inhibitor and undisclosed target B, selective transcription factor inhibitor

CELLESTIA BIOTECH

ADDRESS
Technology Park Basel
Hochbergerstrasse 60C
Basel, 4057
Switzerland

WEBSITE
www.cellestia.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2014

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

CB-103

OPPORTUNITY 1:

Clinical stage oncology drug, targeting clinically validated pathway with novel Mode of Action.



ADDRESS
Meditrina Building 260
Babraham Research
Campus Cambridge
United Kingdom

WEBSITE
www.crescendobiologics.com

E-MAIL
info@crescendobiologics.com

PHONE
+44 0 1223 497140

COMPANY TYPE
Private

SECTOR
Biotechnology
Drug Delivery
Pharmaceuticals/Licensing

YEAR FOUNDED
2009

CRESCENDO BIOLOGICS LTD.

COMPANY PROFILE

Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated multi-functional Humabody® therapeutics with novel modes-of-action, superior biodistribution and larger therapeutic windows compared to conventional IgG-approaches.

At the heart of its proprietary pipeline, Crescendo has developed CB307, a novel targeted T-cell engaging platform for delivery and activation of tumour-specific T-cells only in the tumour microenvironment. This unique format delivers highly potent tumour-specific killing whilst avoiding systemic toxicity and can be applied to a broad range of cancer indications by using appropriate tumour-specific targeting markers

The Company's ability to develop mono- and multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® VH) with superior biophysical properties and developability.

The Crescendo team can rapidly explore a vast range of 3D format space to identi-fy optimal therapeutic configurations. This fully modular plug & play approach lacks the constraints of traditional mAbs enabling the assembly and design of small multi-functional biologics capable of target engagement that is unachievable using regular mAbs. Humabody therapeutics can be applied across a broad range of therapeutic indications.

Crescendo is pursuing novel Humabody®-based product opportunities, through in-house development and strategic collaborations.

MANAGEMENT TEAM

Dr. Peter Pack, CEO

Theo Harold, CFO

Dr. Phil Bland-Ward, CSO

Dr. Brian McGuinness, BD

FINANCIAL SUMMARY

Funded by blue-chip investors (Sofinnova Partners, IP Group/Touchstone, Takeda Ventures, Astellas Ventures, EMBL Ventures

PIPELINE PRODUCT 1:

CB201, a biparatopic PD1 x PD1 antagonist which 'handcuffs' PD1 (late pre-clinical)

- available for partnering -

PIPELINE PRODUCT 1:

One "anchor" VH domain of the biparatopic Humabody binding and one "blocker" VH blocking PD1 from engaging with its ligands, CB201 demonstrates significantly enhanced in vivo efficacy over IgG-based PD-1 antagonists in a PDX tumour model in NSG mice.

Pipeline Product 2:

CB213 : PD1 x LAG3 dual blockade Humabody (late preclinical, PD1-insensitive patients)

- available for partnering -

ADDRESS
Meditrina Building 260
Babraham Research
Campus Cambridge
United Kingdom

WEBSITE
www.crescendobiologics.com

E-MAIL
info@crescendobiologics.com

PHONE
+44 0 1223 497140

COMPANY TYPE
Private

SECTOR
Biotechnology
Drug Delivery
Pharmaceuticals/Licensing

YEAR FOUNDED
2009

PIPELINE PRODUCT 2:

A novel and highly differentiated PD-1xLAG-3 bispecific Humabody (Ihalf-life extended) designed to deliver highly potent simultaneous dual checkpoint blockade in patients non-responsive to PD-1 blockade alone.

PIPELINE PRODUCT 3:

CB108: anti PSMA Biparatopic Humabody Drug Conjugate (late pre-clinical, prostate cancer)

- available for partnering -

PIPELINE PRODUCT 3:

A half-life extended paratopic Humabody Drug Conjugate binding PSMA with superior tumour targeting, enhanced internalisation and highly efficient accumulation in target-positive tumours with up to 30 percent ID per g recorded in a 72hr imaging study.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

CB001

OPPORTUNITY 1:

A first-in-class Humabody targeting IL-17 formulated for topical delivery for treatment of mild-to-moderate psoriasis

Dermadis

ADDRESS
Technopole d'Archamps
Av. Marie Curie 218
74160 Archamps
France

WEBSITE
www.dermadis.com

E-MAIL
info@dermadis.com

PHONE
+33 0 450 43 25 26

COMPANY TYPE
Private

SECTOR
Biotechnology
Pharmaceuticals/Licensing

YEAR FOUNDED
2010

DERMADIS SAS

COMPANY PROFILE

Dermadis is a biotechnology company focused on the development of a novel recombinant protein therapeutic for the treatment of a rare genetic skin disease (Netherton Syndrome) and atopic dermatitis. The lead program DM107 has completed Phase I clinical trials. A Phase 1b/2a program in Netherton patients is planned.

MANAGEMENT TEAM

Christoph Kündig (Managing Director)

Yves Sagot (Head of Operations)

Patrick Dupuy (Medical Director)

Sylvie Ryckebusch (Head of Business Development)

FINANCIAL SUMMARY

The company has been financed to date with seed funding from a family office and is currently seeking to raise a Series A financing.

PIPELINE PRODUCT 1:

DM107 / Phase 1b

PIPELINE PRODUCT 1:

DM107 has been tested in a Phase 1 study in healthy volunteers. Dermadis is now planning to conduct a Phase 1b/2a trial in pediatric and adult patients with Netherton Syndrome. An additional trial could also be conducted in atopic dermatitis.

EMERALD HEALTH PHARMACEUTICALS, INC.

ADDRESS
5820 Nancy Ridge Drive
San Diego, CA 92121
United States

WEBSITE
www.emeraldpharma.life

E-MAIL
info@emeraldpharma.life

PHONE
+1 858 361 4499

COMPANY TYPE
Public

TICKER
[CVE: EMH]

SECTOR
Biotechnology

YEAR FOUNDED
2017

COMPANY PROFILE

Emerald Health Pharmaceuticals (EHP) is a private drug development company focused on patented non-psychotropic cannabinoid analogues for the treatment of inflammatory, auto-immune, neurodegenerative, fibrotic, and metabolic diseases. The Company's portfolio of over twenty patented molecules are chemically-modified derivatives of cannabidiol (CBD) and cannabigerol (CBG), specifically designed to improve the therapeutic properties of these natural compounds by addressing multiple biological targets and physiologic pathways that have been demonstrated to play key roles in specific central nervous system (CNS), auto-immune, inflammatory, metabolic, and fibrotic diseases. The first two selected product candidates from this portfolio of molecules (EHP-101, a CBD analogue, and EHP-102, a CBG analogue) are being developed to address unmet medical needs in the treatment of multiple sclerosis, scleroderma, Huntington's Disease and Parkinson's Disease. EHP expects to begin human trials on EHP-101 in 2018 and on EHP-102 in 2019.

MANAGEMENT TEAM

Jim DeMesa, MD, MBA (CEO)
Eduardo Munoz, MD, PhD (CSO)
Alain Rolland, PharmD, PhD (VP, Product Development)
Jill Broadfoot (CFO)
Nancy Coulson (VP, Regulatory and Quality Affairs)
Mari-Luz Bellido, PhD, MBA (VP, European Operations)
Bernie Hertel (VP, Investor Relations)

PIPELINE GRAPHIC



emerald HEALTH PHARMACEUTICALS

ADDRESS
5820 Nancy Ridge Drive
San Diego, CA 92121
United States

WEBSITE
www.emeraldpharma.life

E-MAIL
info@emeraldpharma.life

PHONE
+1 858 361 4499

COMPANY TYPE
Public

TICKER
[CVE: EMH]

SECTOR
Biotechnology

YEAR FOUNDED
2017

PIPELINE PRODUCT 1:

Name: EHP-101 (or VCE-004.8 in the scientific literature)

Stage: GLP Preclinical Development

Indications: Multiple Sclerosis and Scleroderma

PIPELINE PRODUCT 1:

EHP-101 is an orally-formulated drug candidate. The active pharmaceutical ingredient is a patented cannabidiol (CBD) derivative (new chemical entity).

PIPELINE PRODUCT 2:

Name: EHP-102 (or VCE-004.8 in the scientific literature)

Stage: Formulation and manufacturing development

Indications: Parkinson's disease and Huntington's disease

PIPELINE PRODUCT 2:

EHP-102 is a drug candidate in which the active pharmaceutical ingredient is a patented cannabigerol (CBG) derivative (new chemical entity).

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

EHP

OPPORTUNITY 1:

EHP is currently preparing for a pre-IPO financing round.

ADDRESS
Itäinen Pitkäkatu 4 B
FI-20520 Turku
Finland

WEBSITE
www.forendo.com

PHONE
+358 4031 08000

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2013

FORENDO PHARMA LTD.

COMPANY PROFILE

Forendo Pharma is a privately held drug development company, with core competences in modulating tissue specific hormone mechanisms. Forendo is focused on developing novel oral treatment for endometriosis patients, with tissue-specific hormone inhibitors to rebalance local estrogen metabolism in endometrial tissues. The key differentiator of the company's lead HSD17B1 inhibitor compared to other drug treatments is the ability to act locally without impacting the systemic estrogen levels. This selective activity is expected to allow safer long-term treatment of this chronic disease.

The company was founded in 2013 by leading academic endocrinology experts and Finnish drug development pioneers. Forendo is supported by strong international investors: Novo Seeds, Karolinska Development, Novartis Venture Fund, Merck Ventures and Innovestor. The pipeline of the company includes HSD17B1 inhibitor (in late preclinical stage) for the treatment of endometriosis; dual HSD inhibitors (discovery) for the treatment of endometriosis , with poptential for other endocrinological diseases; and Fispemifene (phase 2), a novel SERM for the treatment of male urological conditions.

FINANCIAL SUMMARY

Financing to date: €3,5M seed round, €12M A round

PIPELINE PRODUCT 1:

HSD17B1 Inhibitor FOR-6219/ preclinical

PIPELINE PRODUCT 1:

Inhibition of HSD17B1 is a novel approach to the treatment of endometriosis. It gives an opportunity to decrease the intracrine estradiol level in specific target organs which are known for their own conversion of weak estrogen, estrone, to biologically active estrogel, estradiol.

Estrogen is the most important known factor that stimulates the growth of endometriosis, drives the growth of lesions and causes disease progression.

Current drug treatment is based on suppression of ovarian estrogen synthesis. These systemic therapies lead to estrogen deprivation but, unfortunately, have either modest efficacy or harmful safety profiles, like loss of bone density and several menopause-like side effects. Therefore, these drugs are suitable only for short term treatment in premenopausal women.

Forendo Pharma has developed a drug candidate, HSD17B1 Inhibitor, which is progressing into clinical development during early part of 2018. The key differentiator of the HSD17B1 inhibitor compared to other drug treatments is the ability to act locally without impacting the systemic estrogen levels. This selective activity is expected to allow safer long-term treatment of this painful, chronic disease.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

Investment opportunity

OPPORTUNITY 1:

HSD17B1 Inhibitor is a targeted treatment opportunity for millions of women suffering from endometriosis.

Forendo Pharma is raising a series A extension of €6M, to close by June 2018.

ADDRESS
78 Allees Jean Jaures
Le Pré Catelan – Bâtiment F
Toulouse, 31000
France

WEBSITE
www.gamamabs.com

PHONE
+33 05 31 61 60 69

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2013

GAMAMABS PHARMA SA

COMPANY PROFILE

GamaMabs Pharma is a clinical-stage immuno-oncology company developing optimized therapeutic antibodies for the treatment of cancer.

GamaMabs' lead project is the monoclonal antibody (mAb) GM102 which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in gynecological cancers.

The company develops low-fucose EMABling® antibodies with increased tumor cell killing properties through the activation of immune system cells.

MANAGEMENT TEAM

Stéphane Degove, CEO (co-founder)

Jean-François PROST, MD, VP R&D and Strategy (co-founder)

Isabelle Tabah-Fisch, MD, Chief Medical Officer

FINANCIAL SUMMARY

18;6m raised since inception in 2013

Lead investors are Edmond de Rothschild Investment Partners (€15m series-B leader) and Innobio/Bpifrance (€3,6m series-A leader)

PIPELINE PRODUCT 1:

GM102

Phase Ia/Ib trial is ongoing in gynecological cancers

PIPELINE PRODUCT 1:

GM102 is a first-in-class monoclonal antibody targeting AMHR2-expressing tumors. It exerts its anti-tumor activity through macrophage engagement resulting in tumor phagocytosis.

PIPELINE PRODUCT 2:

ADC program - Research phase

PIPELINE PRODUCT 2:

Collaboration between GamaMabs Pharma and Medimmune for a development of an ADC using Medimmune ' PBD technology

idppharma

ADDRESS
Barcelona Science Park
Baldiri i Reixac, 4
Barcelona, 08028
Spain

WEBSITE
www.idp-pharma.com

E-MAIL
s.esteban@idp-pharma.com

PHONE
+34 934 02 90 60

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2015

IDP DISCOVERY PHARMA S.L.

COMPANY PROFILE

IDP is a biopharmaceutical company focused on the development of first-in-class drugs (new chemical entities) for the treatment of incurable cancers.

Our products are directed to a novel class of therapeutic targets, intrinsically disordered bHLH transcription factors (bHLH TFs). The most advanced products (regulatory stage) target cMyc and Ascl1/Mash1 proteins, two holy grails in cancer.

MANAGEMENT TEAM

Santiago Esteban, PhD, CEO

Laura Nevola, PhD, CSO

Raúl INsa, MBA, MD, CBD

Jordi Petit, MBA, CFO

PIPELINE GRAPHIC



[1]Compounds are peptidomimetics (new chemical entities). [2]Both products can be expanded to several tumour types.

PIPELINE PRODUCT 1:

IDP-121 Regulatory (financed)

PIPELINE PRODUCT 1:

A new chemical entity (peptidomimetic, patent protected) directly targeting the transcription factor cMyc*.

Formulation is undergoing and exploratory toxicology performed. Regulatory studies to be performed in 2018.

No compound targeting cMyc protein has yet entered clinical trails.

*Myc is recognized as most wanted target for cancer therapy. Its role in disease has been validated in multiple transgenic mosue models. For example, activation of a MYC transgene induces multiple myeloma in conditional mouse models: Mice progress to an indolent multiple myeloma associated with the biological and clinical features highly characteristic of the human disease. Besides multiple myeloma, cMyc is involved in NSCLC, AML, Breast, pancreas, glioma, etc.

idppharma

ADDRESS
Barcelona Science Park
Baldiri i Reixac, 4
Barcelona, 08028
Spain

WEBSITE
www.idp-pharma.com

E-MAIL
s.esteban@idp-pharma.com

PHONE
+34 934 02 90 60

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2015

PIPELINE PRODUCT 2:

IDP-233 Regulatory (financed)

PIPELINE PRODUCT 2:

A new chemical entity (peptidomimetic, patent protected) targeting the transcription factor Ascl1/Mash1*.

Formulation is undergoing and exploratory toxicology performed. Regulatory studies to be performed in 2018.

Besides IDP-233, there are no compounds directly targeting Ascl1/mash1 protein.

*The transcription factor Ascl1 – a well known SCLC biomarker – plays a crucial in promoting malignant behaviour and survival of human SCLC cell lines. Its relevance as a therapeutic target has been recently validated: a transgenic mouse model showed that ASCL1 is present in mouse pulmonary neuroendocrine cells, and only ASCL1 is required in vivo for tumour formation in mouse models of SCLC. ASCL1 is also involved in neuroendocrine cancers, neuroblastoma and glioma.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

Series A 18,5 M EUR

OPPORTUNITY 1:

A Series A of 18,5 M€ investment round is open. Funds will allow completing two Phase I/II studies and bring 3 products to clinical stage (IND approved).

IGEM Therapeutics

ADDRESS
119 The Hub 300
Kensal Road
London, W10 5BE
United Kingdom

WEBSITE
www.igemtherapeutics.com

E-MAIL
info@igemtherapeutics.com

PHONE
+44 0 203 657 7612

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2016

IGEM THERAPEUTICS LTD.

COMPANY PROFILE

IGEM Therapeutics is a UK Immuno-Oncology company developing novel IgE antibodies to treat cancer. IgE has evolved to kill tissue-dwelling multicellular parasites endowing it with several key features that make it ideal for the treatment of solid tumours which also mostly reside in tissue. The epsilon constant region of IgE binds very tightly to its cognate receptor (Fc€RI) on the surface of immune effector cells including macrophages, monocytes, basophils and eosinophils. This interaction is up to 10,000 fold greater than the gamma chain of IgG has for its equivalent receptor and this results in the majority of IgE molecules being permanently attached to the surface of immune effector cells. The latter are therefore primed and ready to destroy cells expressing the antigen recognised by the IgE. As a result, IgE is able to permeate tissues more effectively than IgG and stimulate significantly greater levels of both ADCP (antibody-dependent cell-mediated phagocytosis) and ADCC (antibody-dependent cell-mediated cytotoxicity), the two main mechanisms by which immune effector cells can kill tumour cells. IgE also has a significantly longer tissue half life than IgG (2 weeks versus 2 – 3 days) which also suits it for a role in the destruction of solid tumours.

The company's lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently in a phase 1/2a trial to treat ovarian cancer. This is the world's first IgE therapeutic to enter the clinic.

IGEM is also developing a novel antibody platform technology based on protein and glyco-engineering of the epsilon constant region.

ADDRESS
GIGA B34
Avenue de l'Hôpital, 1
4000, Sart Tilman
Belgium

WEBSITE
www.imcyse.com

E-MAIL
p.vandepapeliere@imcyse.com

PHONE
+32 4 366 47 37

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2010

IMCYSE SA

COMPANY PROFILE

IMCYSE is a Belgian biotech company that is developing the next generation of auto-immune treatments: Imotopes™.

1. First technology with the potential to cure severe auto-immune diseases such as :

Type 1 Diabetes,

Multiple Sclerosis,

Rheumatoid arthritis,

2. Clear advantages compare to our competitors: a long-lasting efficacy after short treatment course.

3. Potential to replace existing therapies and to take over an auto-immune treatment market of over $57b, with the ambition to generate major blockbusters.

4. Simple, inexpensive chemical manufacturing process and pricing will allow gross margin >99%.

5. Clear business model based on:

€ partnering and licensing large projects (Type 1 Diabetes, Multiple Sclerosis, Rheumatoid arthritis)

- developing our own products in rare diseases (Myasthenia Gravis,...)

6. R&D collaboration with 3 big pharma's (GSK, Novartis, Pfizer) while keeping the IP.

7. Experienced and complementary management team with experience in large Pharmas and biotech start-ups.

FINANCIAL SUMMARY

IMCYSE was founded in 2010 as spin off of the KUL. With 22,5 million € already invested in the projects through dilutive and non-dilutive funding.

IMCYSE is now proposing an offering for ~ 516.529 Series-B shares at a price of 29,04€ /share to raise 15 million €.

Exit Strategy that best suits our business model will be or an IPO or an acquisition by a big pharma with a target Return on Investment of 10x+.

PIPELINE DOWNLOAD



PIPELINE PRODUCT 1: IMCY-098, T1D Imotope clinical Phase Ib, ongoing

PIPELINE PRODUCT 2: IMCY-MS, MS Imotope preclinical

PIPELINE PRODUCT 3: Imcy-RA, RA Imotope target idnetification

INCARDA THERAPEUTICS, INC.

ADDRESS
39899 Balentine Drive,
Suite 185
Newark, CA
USA

WEBSITE
www.incardatherapeutics.com

E-MAIL
info@incardatherapeutics.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2009

COMPANY PROFILE

InCarda Therapeutics, Inc. is a biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions and diseases by the inhalation route. The advantage of inhalation is that it delivers “first pass” to cardiac tissue, presenting a bolus of a drug directly to affected regions of the heart. This permits rapid-onset, lower off-target tissue exposure of the drug, lower continued/prolonged exposure to cardiac tissue and more importantly can be patient administered.

The lead product under development is an inhaled therapy to treat paroxysmal atrial fibrillation (PAF), a widespread atrial arrhythmia. InCarda employs a de-risked approach by using approved drugs with a long history of efficacy and safety in a new dosing paradigm.

INSPHERO AG

ADDRESS
Wagistrasse 27
Schlieren, 8952
Switzerland

WEBSITE
www.nsphero.com

E-MAIL
info@insphero.com

PHONE
+41 44 515 04 90

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2009

COMPANY PROFILE

InSphero provides superior biological relevance to in vitro testing with easy-to-use solutions for drug discovery and safety using highly organotypic 3D cell culture models. Our patented 3D cell culture technologies enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumor tissues. These models help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. Microtissues are available directly or through a menu of 3D InSight™ Standard Services, supported by a comprehensive panel of 3D-optimized culture media, assay protocols, and imaging solutions. Using our Akura™ Flow technology, different organoids can be combined on a microphysiological chip to mimic the interaction between organs. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HTS-DILI, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

MANAGEMENT TEAM

- Jan Lichtenberg, PhD, CEO, Founder and Delegate of the Board
- Oliver Krähenbühl, CFO/COO
- Patrick Guye, PhD, CSO
- Frank Junker, PhD, CBO

FINANCIAL SUMMARY

- Privately held
- CHF 25m in funding from Series A to C
- Revenue growth in 2017: 42%

PIPELINE PRODUCT 1:

3D InSight Liver Disease Platform NAFLD, Fibrosis and soon NASH (Commercial)

PIPELINE PRODUCT 1:

Based on InSphero's market leading 3D InSight Liver Microtissues, our 3D InSight Liver Disease Platform is the only automation-compatible, primary-cell, 3D disease model on the market. Highly uniform and functional, our liver-disease model can be driven towards different pathological states and delivers responses that reflect clinical compound data. The 96-well and 384-well solutions (the latter availale in Q3) are compatible with standard liquid-handling, imaging and assay technologies.

The platform integrates seamlessly in your lab, can also be accessed through service projects and allows much faster innovation cycles than competing technologies, including animal testing.

PIPELINE PRODUCT 2:

3D InSight Pancreatic Islet Platform (Commercial)

PIPELINE PRODUCT 2:

Our award-winning 3D InSight Pancreatic Islet Platform is the only automation compatible solition for the in-vitro assessment of:

- -cell function and insulin secretagogues
- -cell function and glucagon suppressors

ADDRESS
Wagistrasse 27
Schlieren, 8952
Switzerland

WEBSITE
www.insphero.com

E-MAIL
info@insphero.com

PHONE
+41 44 515 04 90

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2009

- Islet viability and apoptosis
- -cell proliferation
- -cell function under stress
- Glucolipotoxicity
- Cytokine induced injury
- Drug safety – drug-induced pancreatic endocrine injury

PIPELINE PRODUCT 3:

3D InSight Liver Toxicology Testing (Commercial)

PIPELINE PRODUCT 3:

InSphero offers several convenient options for hepatotoxicity testing using our next-generation 3D InSight™ Liver Microtissues, which are developed using human or animal primary hepatocytes, co-cultured with non-parenchymal cells.

Our standard services enable you to leverage the enhanced sensitivity and specificity of long-term (7-14 day) compound exposure, with protocols enabled by the improved longevity of primary hepatocytes when cultured in a scaffold-free 3D format.

Standard services are performed every two weeks and are used by top 20 pharma companies regularly.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

Series C2 round investment

OPPORTUNITY 1:

2nd closing of the C2 investment series, total amount CHF 10 m.

Use of funds:

- Launch of body-on-a-chip platform
- Expansion of the disease-model portfolio
- Expansion in US and Asian (China, Japan) markets

lipocalyx

WEBSITE
www.lipocalyx.de

COMPANY TYPE
Private

SECTOR
Biotechnology
Drug delivery

YEAR FOUNDED
2011

LIPOCALYX GMBH

COMPANY PROFILE

Lipocalyx, a leading developer of drug delivery systems for nucleic acids, has entered into a research and development agreement with BioNTech AG exclusive for certain fields. Under the agreement, Lipocalyx will apply its Viromer® technology for the delivery of certain mRNA's and BioNTech will assume responsibility for the development of the resulting mRNA therapeutics. Both parties will cooperate in the clinical development of Viromer-based mRNA formulations.

MANAGEMENT TEAM

Dr. Steffen Panzner, CEO

Dr. Christian Reinsch, Head of Development

FINANCIAL SUMMARY

3M Seed and Start-up

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

Series A

OPPORTUNITY 1:

We are looking for a Series A financing to
- Bring RNA delivery into GMP
- Validate Platform through Licensing
- Integrate Additional Delivery Technologies

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

Outlicensing: Delivery Solutions

OPPORTUNITY 1:

Lipocalyx is offering its Viromer(R) Delivery Technology for therapeutic mRNA.

ADDRESS
500 Cartier West Blvd.,
Suite 104 Laval
Québec
Canada

WEBSITE
www.mangogen.com

E-MAIL
admin@mangogen.com

PHONE
+1 514 800 6872

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2014

MANGOGEN PHARMA, INC.

COMPANY PROFILE

MangoGen is a biotech company with a mission to develop and market novel approaches to accelerate wound healing. Our lead product is a gene-delivering cardiac stent, and a topical cream to accelerate wound healing.

MangoGen was co-founded in 2014 by Professor Satya Prakash, Dr Paul Plested, Dr. Dominique Shum-Tim and Dr Arghya Paul.

The opportunity to develop a new bio-therapeutic gene-delivering cardiac stent is clearly apparent. The major stakeholders in the vascular stent market are looking for the following:

An effective stent that exhibits no in-stent re-stenosis (ISR) or thrombosis formation over time [Patients]

Provide cost effective, safe and long-term healthcare [Governments]

Confidence and efficacy of the product [Clinical Practitioners]

The future of the stent market is being driven towards inexpensive devices that have long-term efficacy, a lower requirement for prescribed anti-coagulants and a reduced need for future invasive cardiac surgery.

MangoGen's patented technology utilizes a novel approach of using baculovirus encapsulated in a biodegradable coating that is applied to a cardiac stent before being placed in situ.

MANAGEMENT TEAM

Professor Satya Prakash, President

Dr Paul Plested, CEO

Dr. Dominique Shum-Tim CMO

Alain Labbe, CSO

FINANCIAL SUMMARY

Seed investment in 2015 - US$1.67 million

Seeking a Series A Round of US$20 million

PIPELINE GRAPHIC



ADDRESS
500 Cartier West Blvd.,
Suite 104 Laval
Québec
Canada

WEBSITE
www.mangogen.com

E-MAIL
admin@mangogen.com

PHONE
+1 514 800 6872

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2014

PIPELINE PRODUCT 1:

Gene-Delivering Cardiac Stent

Prototype developmet

Next step - final animal experiments with stents coated under sterile conditions

PIPELINE PRODUCT 1:

Gene-Delivering Cardiac Stent

The current paradigm of Drug-Eluting Stents (DES) is to ignore the underlying wound to the endothelium (inner cell lining of the blood vessel), and deliver an anti-proliferative drug to prevent local cell growth in and around the stent. However, there are problems of scar tissue and thrombus formation and recent data has suggested that the biodegradable stents are not as effective. In fact, after billions of dollars spent on their development, companies such as Boston Scientific are reconsidering and scrapping their bioresorbable cardiac stents.

MangoGen is developing an innovative gene-delivering cardiac stent designed to rapidly repair the inner lining of the blood vessel (endothelium). MangoGen has shown that by delivering a local, transiently expressed gene to the tissue around the stent promotes and accelerates the "re-endothelialization" of the blood vessel leading to a significant reduction of possible complications such as in-stent restenosis. Furthermore, a fully functional endothelium will reduce/prevent scar tissue formation, and late-stent thrombosis.

PIPELINE PRODUCT 2:

Gene-Delivering Diabetic Ulcer Cream

PIPELINE PRODUCT 2:

Pipeline – Gene-Delivering Diabetic Ulcer Cream

MangoGen's pipeline includes a gene-delivering cream to accelerate diabetic foot ulcer repair. Here there is a huge unmet need. The current paradigm is tender loving care, preventing infection and over-the counter unapproved creams. The only FDA-approved cream is Ragranex, which is of limited use, expensive (>$500 per 15g tube) and has been given a black box (association with 5-fold increase in malignant tumor formation). Ragranex's active ingredient is recombinant platelet-derived growth factor-b (rPDGF-b). This is not a local approach.

MangoGen's approach is to develop a gel/cream that delivers targeted gene-delivery to only the cells in and around the ulcer or wound. The baculoviruses that enter the blood stream will be rapidly inactivated, thus systemic distribution of rPDGF-b will be negligible.

PIPELINE PRODUCT 3:

Gene-Delivering Suture (to accelerate wound repair and prevent scar tissue formation)

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1: Investment

OPPORTUNITY 1:

Gene-Delivering Cardiac Stent

Require investment of US12 million to reach first-in man studies

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 2: Investment

OPPORTUNITY 2: Gene-Delivering Diabetic Foot Ulcer Cream

Require US$6-7 million to complete all pre-clinical studies, formulation and perform human Phase I/II clinical trials

ADDRESS
Karlovarská třída 20
273 01 Kamenné Žehrovice
Czech Republic

WEBSITE
www.medicem.com

E-MAIL
institute@medicem.com

PHONE
+420 317 070 360

COMPANY TYPE
Private

SECTOR
Biotechnology
Medical Devices

YEAR FOUNDED
1992

MEDICEM INSTITUTE S.R.O.

COMPANY PROFILE

MEDICEM Institute, the R&D centre of MEDICEM Group, focuses on

developing proprietary bioanalogic hydrogel technologies and applying them to ophthalmic surgery, tissue regeneration and gynaecology.

MEDICEM Institute's laboratories are equipped with state-of-the-art instrumentation for conducting research into polymer science, visual and physiological optics, and biomaterial biocompatibility.

MEDICEM is developing intraocular lenses for the premium segment of the IOL. has developed a extended depth of focus lens that is CE marked and is awaiting EU approval for its pre-loaded injector. It is also developing a femtosecond laser adjustab;e lens that can be corrected non-invasively after implantation.

Continuing an investigative tradition dating back to Otto Wichterle, our current scientific team includes researchers with backgrounds in biophysics, chemistry, biochemistry and electrical engineering and experience from both academic and industrial institutions.

MANAGEMENT TEAM

Eugen Chicevič – CEO and Co-Founder

Vladimír Stoy – CSO and Co-founder

Martina Plisová - R&D Director

David Bailey - Strategic Advisor

PIPELINE PRODUCT 1:

Femtosecond laser adjustable intra-ocular lens, FSLA-IOL

PIPELINE PRODUCT 1:

Medicem's FSLA-IOL can be non-invasively and repeatedly adjusted in situ using a femtosecond laser. Unlike the currently available IOL materials, Medicem's proprietary WIGEL hydrogel platform was specifically designed for femtosecond laser modification (FSLM) and has a quencher/dopant ratio that has been optimised for FLSM. The FSLA-IOL lens will be capable of corrections greater than 3 diopters, with recent in vitro data already demonstrating 2 diopter corrections inscribed in WIGEL-IOL. In a collaboration with the University of Rochester, Medicem showed that the WIGEL material had the largest optical phase shifts ever observed in lens materials induced by femtosecond laser pulses.

There are high levels of patient dissatisfaction with sub-optimal visual outcomes (40% of patients) in the cataract surgery market. Increasing expectations for refractive accuracy and improved visual outcomes following cataract surgery is predicted to drive the adoption of technologically advanced lenses. The ability to repeatedly adjust IOLs has the potential to address 100% of the cataract patients if offered as an 'insurance policy' for predictable outcomes, and also offers the potential to unlock the untapped but very large elective-presbyopia market – there are only 775 thousand IOL procedures performed annually for presbyopia out of a potential 3.6 billion presbyopic eyes globally.

The technology is well protected by a family of patents through to 2036. A search completed by Fox Rothschild LLP indicated freedom to operate in the key areas of IOL design, IOL material, femtosecond modification method and inscribed lens design for the FSLA-IOL.

ADDRESS
Karlovarská tř€ida 20
273 01 Kamenné Žehrovice
Czech Republic

WEBSITE
www.medicem.com

E-MAIL
institute@medicem.com

PHONE
+420 317 070 360

COMPANY TYPE
Private

SECTOR
Biotechnology
Medical Devices

YEAR FOUNDED
1992

PIPELINE PRODUCT 1:

Extended-depth-of-focus (EDOF) intra-ocular lens, WIOL-CF

PIPELINE PRODUCT 1:

WIOL-CF is a Class IIb CE-marked bioanalogic lens made of WIGEL, which was inspired by the physical form and optical properties of natural crystalline lenses. Its hyperbolic shape creates an infinite number of focal points that extend depth of focus without diffractive zones. The lens features the largest optics in the industry (8.6-8.9mm), which ensures maximum light in the eye and enables vision under low light conditions. This provides excellent contrast sensitivity and improved peripheral vision.
WIOLF-CF has an extensive history of successful clinical studies demonstrating excellent distant and intermediate vision, as well as very good near vision. In the recently completed post-marketing clinical follow-up BOND study co-funded by Bausch + Lomb, the results show binocular visual acuity UDVA 0.01 logMAR, UIVA 0.06 logMAR and UNVA 0.2 logMAR. The investigation confirms that WIOL-CF has an EDOF profile of vision with high spectacle independence, low level of optical phenomena and stable performance in varying light conditions.
The WIOLF-CF lens is packaged in a pre-loaded system that is easy to assemble, decreasing potential issues during implantation. Medicem is looking to commercially launch the technology following the approval of the injector set (c. June 2018) and the team is currently pursuing discussions with interested parties to commercialise WIOL-CF for a 2018/19 launch in EMEA.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

FSLA and WIOL-CF

OPPORTUNITY 1:

Medicem Institute is seeking €12M to fund Medicem through the FSLA-IOL animal proof-of-concept, as well as support the launch of the EDOF lens through a commercialisation partner. Medicem and its principal investor KKCG are looking for experienced medical technology partners to help guide the development of the Company.

METYS PHARMACEUTICALS AG

ADDRESS
Leimenstrasse 57,
4051 Basel,
Switzerland

WEBSITE
www.metys-pharma.ch

PHONE
+41 79 408 79 82

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2013

COMPANY PROFILE

Metys Pharmaceuticals is developing MP-101 for the prevention of chemotherapy-induced painful peripheral neuropathy. In the US alone, more than 400'000 patients suffer from the neuropathy caused by their cancer treatment. No drug has been approved to prevent or treat this condition. MP-101 is an orally active, allosteric modulator of spinal NMDA-type glutamate signalling, with more than 120 subjects' safety and tolerability data of its racemate, dimiracetam. MP-101 and dimiracetam are highly effective in preventing and treating chemotherapy-induced neuropathy in rats. We have filed a composition-of-matter priority patent application for MP-101 in May 2017, based on an unusual medicinal chemistry preference for a certain range of non-racemic mixtures of its enantiomers. Patented successor compounds, with similar chemical structure and medicinal chemistry preferences, are in hand, and may be suitable candidates for additional CNS indications.

MANAGEMENT TEAM

Michael Scherz, PhD - Founder & CEO

Elisabet Lindberg, MD - Chief Medical Officer

Carlo Farina, PhD - Head of Chemistry & Patents

FINANCIAL SUMMARY

Funded by CHF 2.5 million seed investment, structured as convertible loans repayable in shares of the Company at a 20% discount to the pre-money valuation agreed with Series A investors.

PIPELINE PRODUCT 1:

MP-101 / Phase 2 - Prevention of chemotherapy-induced peripheral neuropathy

PIPELINE PRODUCT 1:

MP-101

MP-101 is an orally-active allosteric modulator of spinal NMDA-type glutamate receptors. It inhibits NMDA+glycine-induced release of pre-loaded 3H-D-aspartate from rat brain- and spine-derived synaptosomes. MP-101 is a specific non-racemic mixture of the enantiomers of dimiracetam. In keeping with specific FDA- and EMA-guidance, it is supported - without bridging studies of any kind - by the regulatory dossier of racemic dimiracetam. Racemic dimiracetam has a complete, ICH-compliant regulatory dossier supporting human clinical trials of up to 12-weeks duration. Its toxicological profile is benign; it's clinical safety- and tolerability-profile is placebo like. It is completely bioavailable by the oral route. It is not a substrate of, nor does it inhibit, cytochrome P450's; it is excreted, unchanged, entirely by the renal route, with a terminal elimination half-life of 6 h in humans. Human oral clinical formulations of tablets, capsules, and aqueous solutions are in hand; validated chiral and achiral analytical and bio-analytical (plasma and urine) methods are in hand. GMP manufacturing route of racemic dimiracetam provides 35-kg batches with 6-week cycle times. 110 kg of GMP-quality racemic dimiracetam are in hand. A non-GMP stereospecific synthesis of the eutomer has been performed at kg-scale, and is awaiting GMP scale-up to manufacture MP-101 by admixture with GMP racemic dimiracetam. Separately, scaleable, GMP-compliant chiral simulated moving bed column chromatography methods for separation of racemic dimiracetam into its enantiomers are also in hand.

METYS PHARMACEUTICALS

ADDRESS
Leimenstrasse 57,
4051 Basel,
Switzerland

WEBSITE
www.metys-pharma.ch

PHONE
+41 79 408 79 82

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2013

PIPELINE PRODUCT 2:

MP-102 / Pre-clinical - Major depressive disorder

PIPELINE PRODUCT 2:

MP-102 is a structural analog of dimiracetam, with similar medicinal chemistry preference for a certain non-racemic mixture of enantiomers. MP-102 has undergone evaluations to assess its suitability as preclinical development candidate.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

MP-101 / Phase 2

OPPORTUNITY 1:

MP-101 has been prepared for a Phase 2 dose-ranging proof-of-concept study for prevention of chemotherapy-induced peripheral neuropathy. The clinical trial will recruit 250 subjects into 4 groups of non-equal size, for 12 weeks of twice-daily oral administration of MP-101. The primary endpoint of the study is the patient-reported score on an 11-point numeric rating scale of the sensitivity to touching cold items (see Pachmann et al 2015, J Clin Oncol; PMID 26282635). Clinical trial conduct is planned with a mid-sized suitably-experienced CRO in western- and eastern Europe; US sites may also be included.

The study budget is estimated at CHF 8 - 10 million; and extension study for patients rolling over into an open label extensions study is expected to cost CHF 4 million. Other MP-101 development activities conducted in parallel to the Phase 2 trial are expected to add CHF 4 million.

A trade-sale to major pharma is foreseen after succesful completion of the study.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 2:

MP-102 / preclinical

OPPORTUNITY 2:

MP-102 is expected to be enter preclinical efficacy and safety profiling during the Phase 2 trial of MP-101; these activities have not yet, however, been budgeted.

MOLOGEN AG
THE POWER OF IMMUNOTHERAPIES

ADDRESS
Fabeckstrasse 30
Berlin, 14195
Germany

WEBSITE
www.mologen.com

PHONE
+49 30 84 17 88 0

COMPANY TYPE
Public

TICKER
[ETR: MGN]

SECTOR
Biotechnology

YEAR FOUNDED
1998

MOLOGEN AG

COMPANY PROFILE

MOLOGEN AG is a biopharmaceutical company and considered a pioneer in the field of immunotherapy on account of its unique active agents and technologies. Alongside a focus on immuno-oncology, MOLOGEN develops immunotherapies for the treatment of infectious diseases.

The immunotherapy lefitolimod (MGN1703) is the company's lead product and is regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this action mechanism, lefitolimod is an immune surveillance reactivator (ISR) and could potentially be used in various indications. The ISR lefitolimod is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. Key data of the phase II IMPULSE study in small cell lung cancer have been announced in April 2017. Detailed analyses of IMPULSE data and data from the extension phase of the TEACH study in HIV, published in August, are currently being conducted. In addition, lefitolimod is currently being investigated in a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy®) in various cancer indications. Along with various checkpoint inhibitors, lefitolimod, which is being investigated as part of a phase III clinical trial currently, is one of the few near-to-market product candidates in the field of immuno-oncology.

MANAGEMENT TEAM

Dr. Mariola Söhngen, Chief Executive Officer (CEO)

Walter Miller, Chief Financial Officer (CFO)

Dr. Matthias Baumann, Chief Medical Officer (CMO)

PIPELINE DOWNLOAD

Advanced Immunotherapy Pipeline: Late-Stage Lefitolimod & Follow-Up EnanDIM®



Notes: (1) Pipeline overview excludes MIDGE platform | (2) **Timeline** Denotes latest estimated timeline of upcoming milestones | (3) **Exclusivity** Denotes estimated minimum market exclusivity horizon based on patent and data protection
Legend: PC Pre-clinical | **Ph** Phase | **LPI** last patient in

MOLOGEN AG
THE POWER OF IMMUNOTHERAPIES

NETSCIENTIFIC PLC

COMPANY PROFILE

ADDRESS
6 Bevis Marks
12th floor
Bury Ct, London
United Kingdom

WEBSITE
www.netscientific.net

EMAIL
info@netscientific.net

PHONE
+44 20 3514 1800

COMPANY TYPE
Public

TICKER
[LON: NSCI]

SECTOR
Biotechnology

YEAR FOUNDED
2008

Overview:
NetScientific is a transatlantic healthcare IP commercialisation Group focused on sourcing, funding and commercialising technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people.

Strategy:
The Group sources opportunities from global institutions, leading technology incubators and its deep healthcare network. In the early stages of the company's development the Group provides extensive management support including technical guidance, administrative support, legal, IP and commercial expertise. As companies mature through key milestones the Group will recruit experienced industry leading CEOs to drive the next phase of growth, attract additional external capital and secure favourable exits.

Portfolio:
Our portfolio is split across three primary areas of focus: Digital Health, Diagnostics and Therapeutics.

Diagnostics (Glycotest, ProAxsis and Vortex):

Glycotest is a US-based liver diagnostics company seeking to commercialise new and unique blood tests for life threatening liver cancers and fibrosis-cirrhosis with exclusive world-wide rights to over 50 patent-protected serum protein biomarkers. Glycotest's lead product is its HCC panel, a biomarker panel driven by a proprietary algorithm for curable early-stage hepatocellular carcinoma (HCC), the most common form of primary liver cancer. The market for HCC testing is large and growing with currently three million patients and in excess of US$800m in the US alone.

ProAxsis is a medical diagnostics company based in Northern Ireland, developing a range of products for the capture, detection and measurement of active protease biomarkers of diseases. The rapid and easy-to-use tests ProAxsis has developed incorporate patented ProteaseTags®; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence.

Vortex Biosciences is a US-based cancer diagnostic company, developing a novel liquid biopsy automated instrument (VTX-1) and microfluidic cartridge for the isolation of circulating tumour cells from whole blood without the need for any pre-treatment.

Digital Health (Wanda):
Wanda is a San Francisco based digital health company commercialising advanced clinical decision support software. Wanda aims to significantly reduce hospitalisation risk, and improve the quality of life for people with chronic conditions, initially focused on congestive heart failure (CHF).

Therapeutics (PDS Biotechnology):
PDS is a clinical stage immunotherapy company developing a next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. Versamune® -its novel synthetic nanoparticle platform technology- activates multiple immunological mechanisms which direct the targeting of cancer and infectious disease by the immune system.

MANAGEMENT TEAM

Sir Richard Sykes, Non-Executive Chairman
Francois Martelet, CEO
Ian Postlethwaite, CFO

ADDRESS
Second Floor, Ashford House,
Tara Street, Dublin,
2 Ireland

WEBSITE
www.opsona.com

EMAIL
info@opsona.com

PHONE
+353 1 6770223

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2004

OPSONA THERAPEUTICS LTD.

COMPANY PROFILE

Opsona Therapeutics is a Dublin, Ireland based Biotech Company developing anti-inflammatory therapeutics targeting key structures of the innate immune system with specific focus on oncology.

The Company is in the midst of an open-label Phase I/II multiple dose trial of its lead program, OPN-305, for the treatment of MDS patients who have failed the standard of care.

OPN-305 is a first in class humanized IgG4 mAb TLR2 antagonist with a novel mechanism of action which involves both the blockade of ligand binding as well as the inhibition of receptor heterodimerisation. As a result, OPN-305 potentially has broader applicability to include pancreatic, gastric, melanoma and ovarian cancers, which are being studied preclinically.

To summarize the current trial, 44 patients have been treated so far and the Company has moved into the dose expansion part of the Phase 1/2 MDS study, which is conducted at MD Anderson, Moffitt, Montefiore and Cornell. OPN-305 has an overall response rate of 40% at the recommended dose of 10mg/kg with a 16% complete response rate. This response rate in this highly refractory and difficult to treat patient population is unprecedented at this stage.

OPN-305 has an excellent safety and tolerability profile based on a phase 1 in healthy volunteers, a single dose in renal transplantation (phase 2a/b) and the on-going multiple dose in MDS (phase 1/2).

Opsona has a strong international shareholder consortium including Amgen Ventures, Baxalta Ventures, BB Biotech Ventures, EMBL Ventures, Fountain Healthcare Partners, Novartis Venture Funds, Omnes Capital, Roche Venture Fund, Seroba Life Sciences and Sunstone Capital.

ORIGENIS GMBH

ADDRESS
Am Klopferspitz 19a
Munich, Planegg, 82152
Germany

WEBSITE
www.origenis.de

EMAIL
info@origenis.de

PHONE
+49 89 7801676 0

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2005

COMPANY PROFILE

Origenis is a privately-held German biopharmaceutical company developing brain-penetrating small molecule medicines and diagnostics for a variety of neurodegenerative and neuroinflammatory diseases.

Origenis leverages its unique capabilities in drug design, compound synthesis and characterization to engineer a continuous stream of proprietary IP-protected new chemical entities capable of permeating the blood-brain barrier. Origenis' approach has been validated by multiple partners resulting in significant IP and R&D portfolio that ensures strong patent protection until at least 2032. Origenis' lead product candidates address novel but clinically-validated targets Leucine Rich Repeat Kinase 2 (LRRK2) and Death Associated Kinase 1 (DAPK1), both of which are associated with neurodegeneration in a variety of chronic and acute brain diseases, including Parkinson's, Alzheimer's, dementia, and traumatic brain injury, among others.

Origenis' lead product candidates address novel but clinically-validated targets Leucine Rich Repeat Kinase 2 (LRRK2) and Death Associated Kinase 1 (DAPK1), both of which are associated with neurodegeneration in a variety of chronic and acute brain diseases, including Parkinson's, Alzheimer's, dementia, and traumatic brain injury, among others.

These two internal therapeutic key pipeline programs are complemented by Origenis proprietary PET tracer programs, that enable a precision medicine approach, open new avenues towards innovative, robust and shortened clinical development pathways with potential for conditional approval after Phase II, and represent a diagnostic tool on its own to enhance drug development and increase overall probability of success.

The combination of its therapeutic with the proprietary PET tracer programs not only forms a sound basis for further clinical development, but also differentiates Origenis from all of its competitors.

Origenis now is seeking to raise up to € 24 mill. in a Preferred Series A Equity Financing to advance two of its internal key pipeline candidates towards IND and clinical Phase I and is looking forward to building a transatlantic top-tier syndicate of institutional investors both in Europe and the US.

MANAGEMENT TEAM

Michael Almstetter, CEO
Dr. Michael Thormann, CSO
Dr. Andreas Treml, COO
Thomas Loeser, CFO

PIPELINE GRAPHIC:

AREA	TARGET	INDICATION	STATUS
CNS	LRRK2	Neurodegeneration	Candidate Selection completed
	DAPK1	Frontotemporal Dementia	Candidate Selection
	JAK	Multiple Sclerosis	Lead Optimization
	SYK	Alzheimer's Disease	Lead Optimization
	TYK2	Undisclosed	Lead Optimization
	NUAK1	Alzheimer's Disease	Lead Optimization

ORYZON

ADDRESS
Sant Ferran 74
Cornellà de Llobregat
Barcelona, 08940
Spain

WEBSITE
www.oryzon.com

EMAIL
info@oryzon.com

PHONE
+34 93 515 1313

COMPANY TYPE
Public

TICKER
[BME: ORY]

SECTOR
Biotechnology

YEAR FOUNDED
2002

ORYZON GENOMICS SA

COMPANY PROFILE

Oryzon is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics. With two compounds in clinical trials, ORY-1001, a highly potent LSD1 inhibitor with exquisite selectivity that has been granted orphan-drug status by EMA, in Phase I/IIA in oncology, and ORY-2001, a dual LSD1/MAO-B inhibitor in Phase I for the treatment of Alzheimer's disease and other neurodegenerative diseases, as well as another compound in preclinical development, ORY-3001, a selective LSD1 inhibitor for the treatment of non-oncological diseases, and additional programs in other cancer indications, the company has a broad and growing portfolio.

MANAGEMENT TEAM

Dr. Carlos Buesa, Chief Executive Officer
Dr. Tamara Maes, Chief Scientific Officer
Enric Rello, Chief Financial and Operating Officer
Neus Virgili, Chief Intellectual Property Officer
Dr. Roger Bullock, Chief Medical Officer
Emili Torrell, Chief Business Development Officer

FINANCIAL SUMMARY:

In 2015 the company raised € 16,5m and announced that the National Securities Market Commission (CNMV) approved the listing of Oryzon's shares on the Main Madrid Stock Exchange. Oryzon began trading on December 14, 2015 under the stock symbol ORY (ISIN Code: ES0167733015).

In early 2015 an additional funding with soft deb from Spanish commercial banks (€15,5m) was achieved.

In April 2017, the Company successfully completed a capital increase of 5,693,565 new common shares, with gross proceeds of approximately €18.2 The offering included institutional investors specialized in healthcare and life sciences from the US, Spain and rest of Europe. The majority of the funds were raised from international investors, reinforcing and diversifying the Company's shareholder base. The Company intends to use the net proceeds from the capital increase to finance its research and development of clinical pipeline candidates and for working capital and general corporate purposes. Guggenheim Securities, LLC and Bryan, Garnier & Co. acted as joint bookrunners for the International tranche. Solventis AV, S.A., Bankinter, S.A. through Bankinter Securities Sociedad de Valores, S.A. were the coordinators of the Spanish part of the transaction and GVC Gaesco Beka S.V.

ORYZON

ADDRESS
Sant Ferran 74
Cornellà de Llobregat
Barcelona, 08940
Spain

WEBSITE
www.oryzon.com

EMAIL
info@oryzon.com

PHONE
+34 93 515 1313

COMPANY TYPE
Public

TICKER
[BME: ORY]

SECTOR
Biotechnology

YEAR FOUNDED
2002

PIPELINE GRAPHIC:



(*) Phase I/IIA in Acute Leukemia has been done in the same trial

PIPELINE PRODUCT 1:

ORY-2001
•Phase II-A in Multiple Sclerosis
•Phase II-A in Mild to moderate Alzheimer's disease patients

PIPELINE PRODUCT 1:

ORY-2001 is an oral and brain penetrant small molecule that selectively inhibits a Lysine Histone demethylase, LSD1, an epigenetic modulator, which regulates chromatin structure and modulates gene expression patterns and MAOB an enzyme that catabolizes dopamine and other important neuroactive and vasoactive amines. ORY-2001 acts on several levels to restore the proper neuronal function. It reduces neuroinflammation and corrects cognitive impairment and memory loss. The molecule has neuroprotective effects against glutamate excitoxicity and produces a switch in the expression of genes in the hippocampus and frontal cortex that results in a reduction of aggressiveness and social withdrawal. Some of the genes modified in the animals are characteristically deregulated in AD patients ORY-2001 exerts a holistic action in the different alterations seen in patients with AD and other neurodegenerative disorders. Different experiments suggest that ORY-2001 acts as a disease modifying drug. In AD patients and other neurodegenerative disorders, cognitive deterioration is often accompanied by episodes of agitation, aggression, psychosis, apathy and depression. In preclinical studies, ORY-2001 not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice to normal levels and also reduces social avoidance in rat models maintained in isolation.
The drug has been tested in 6 month rat and 9 month dog GLP toxicology studies to enable long term Phase II studies. The safety and tolerability of ORY-2001 has been studied in a Phase I clinical trial with 106 young and elderly healthy volunteers, confirmed LSD1 target engagement and ORY-2001 brain penetration, and allowed to establish the doses for the Phase II dose finding studies in patients. The company recently started a Phase IIA with ORY-2001 in patients with multiple sclerosis and plans to start soon a Phase IIA clinical trial in patients with Alzheimer's disease.
Epigenetic approaches to modify the progression of various neurodegenerative diseases, which focus on the production of changes in gene expression patterns in brain cells, have generated interest in the pharmaceutical industry.

ADDRESS
Petite Halle
31 rue Gustave Eiffel
Grenoble, 38000
France

WEBSITE
www.pdc-line-pharma.com

PHONE
+33 6 34 36 77 47

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2014

PDC*LINE PHARMA SA

COMPANY PROFILE

Founded in April 2014 in Grenoble (France) as a spin-off of the French Blood Bank (Etablissement Français du Sang, EFS), PDC*line Pharma (www.pdc-line-pharma.com) is a Belgian-French biotech company that is developing a novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) loaded with HLA-A2-restricted peptides that are derived from target tumor antigens (Figure 1). In 2015, the EMA1 granted this class of immunotherapies (named PDC*vac) the ATMP2 classification within the somatic-cell therapy category.

Our breakthrough technology, PDC*vac is highly potent in priming and boosting fully functional antitumor CD8+ T cells displaying a strong cytotoxic activity against tumor cells. It is more easily scalable, more versatile and more potent than other dendritic-cell-based vaccines, and it is synergetic with the use of anti-PD-1 immune checkpoint inhibitors.

MANAGEMENT TEAM

M. Eric Halioua (MS, MBA), President & CEO.

M. Laurent LEVY (MS, MBA), co-founder & COO.

Dr. Joel PLUMAS (PhD), co-founder & CSO.

M. Claude Dedry (Industrial Pharmacist), Vice-President of Pharmaceutical operations & Quality.

Dr. Béatrice De Vos (MD, PhD), Chief Medical Officer.

PIPELINE PRODUCT 1:

PDC*lung: our leading candidate for non-small-cell lung cancer (NSCLC). This targets widely expressed shared antigens. A phase Ib/II trial evaluating its safety and biological activity, with and without anti-PD1, is currently being initiated.

PIPELINE PRODUCT 1:

Robust results already obtained for PDC*vac provide a strong preclinical validation, as well as ex vivo results on blood samples of 14 lung cancer patients. PDC*lung consists of PDC*line loaded with HLA-A*02:01-restricted peptides derived from 6 antigens matching with NSCLC tumor antigen overexpression. Over 95% of NSCLC patients, including both squamous (SQC) and adenocarcinoma (ADK) subtypes express at least one of these antigens.

PIPELINE PRODUCT 2:

PDC*neo: our next candidate. It is currently being developed at the preclinical stage.

ADDRESS
Theodor-Heuss-Str. 179
52428 Jülich
Germany

WEBSITE
www.priavoid.com

E-MAIL
info@priavoid.com

COMPANY TYPE
Private

SECTOR
Pharmaceuticals/Licensing

YEAR FOUNDED
2017

PRIAVOID GMBH

COMPANY PROFILE

Founded on the September 18th, 2017 Priavoid GmbH is headquartered in Jülich, near Düsseldorf, Germany.

Priavoid is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS).

We develop novel therapies for the treatment of neurological diseases based on all-D-peptides. The most advanced drug in our pipeline is PRI-002, a Phase I clinical trial candidate for the treatment of Alzheimer's disease. The treatment strategy of PRI-002 differs from conventional approaches in that the so-called „toxic oligomers" – that is the probable cause of the neurodegenerative disease – are eliminated in the presence of the drug candidate. The oral administration of PRI-002 leads to improved cognitive behavior in three different transgenic mouse models.

FINANCIAL SUMMARY

We are looking for investments by VC or partnering.

Investments are searched for the phase 2 PoC in humans for PRI-002, a drug candidate for treatment of Alzheimers.

PIPELINE GRAPHIC



PIPELINE PRODUCT 1:

The most advanced drug in our pipeline is PRI-002, a Phase I clinical trial candidate for the treatment of Alzheimer's disease. The treatment strategy of PRI-002 differs from conventional approaches in that the so-called „toxic oligomers" – that is the probable cause of the neurodegenerative disease – are eliminated in the presence of the drug candidate. The oral administration of PRI-002 leads to improved cognitive behavior in three different transgenic mouse models.

PIPELINE PRODUCT 2:

Another drug candidate, PRI-003, has proven pre-clinical PoC for treatment of ALS in a transgenic ALS mouse model.

ADDRESS
Ronda de Poniente
28760, Madrid
Spain

WEBSITE
www.proteinalternatives.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Diagnostics

YEAR FOUNDED
2006

PROTEIN ALTERNATIVES S.L. (PROALT)

COMPANY PROFILE

Protein Alternatives (ProAlt) is an early stage Spanish biotechnology company dedicated to the development of diagnostic and therapeutic products for the early recognition of colorectal cancer and the treatment of colon and melanoma metastatic tumors, respectively.

The company developed ColoDetect®, a biomarker-based assays for the diagnosis of early stage colorectal cancer based on the detection of specific autoantibodies against tumor associated antigens (TAAs; also known as neoantigens) in blood samples. ProAlt aims to validate ColoDetect® in 2018 to obtain CE marking approval (IVD).

For the treatment of colorectal and melanoma metastatic tumors the company has developed PA-0661, a cadherin 17 (CDH17) specific monoclonal antibody. By targeting the conserved CDH17-RGD domain, PA-0661 acts through a novel mode of action inhibiting integrin beta 1 activation, mediated by CDH17, thus affecting cell adhesion, proliferation and migration. In vivo proof of concept studies in murine models of metastatic disease showed significant improvement in survival rates of treated animals.

The company is seeking financing and partnerships to complete during the next three years the marketing of its colorectal cancer diagnostic test (ColoDetect®) and preclinical development of the therapeutic monoclonal antibody Anti-CDH17_RGD (PA-0661).

MANAGEMENT TEAM

Dr. Juan Ignacio Imbaud, COO and CSO.

Dr. Thomas Zürcher, Project Leader R&D.

ResoTher Pharma

RESOTHER PHARMA APS

ADDRESS
Næsseslottet
Dronninggaards Alle 136
2840 Holte
Denmark

WEBSITE
www.resotherpharma.com

E-MAIL
lone.veng@resotherpharma.com

PHONE
+45 41 88 95 70

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2016

COMPANY PROFILE

ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on developing peptide-based drugs as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role. Our current focus is on cardiovascular disorders and inflammatory disorders with a large unmet medical need.

The company's assets and discoveries are based on the highly renowned science of Professor Mauro Perretti at the Queen Mary University in London, UK. Professor Perretti is a pioneer in the area resolution therapy and has spent decades pinpointing the role of Annexin 1A and its receptors in the resolution of chronic inflammation. Our peptide drug candiates are potent agonists against the FPR2 receptor and have shown excellent efficacy in both animal models and human cellular systems of chronic, neutrophil-driven inflammation.

ResoTher Pharma has an experienced management team with a proven track record of succesful clinical development, validating novel targets in diesease of high unmet medical need, and providing rapid and meaningful ROI for our investors.

MANAGEMENT TEAM

Lone Veng, PhD - Chief Executive Officer

Thomas Jonassen, MD - Chief Science Officer

Jeppe Øvlesen, MBA - Chief Financial Officer

FINANCIAL SUMMARY

We have raised seed capital in 2017 and are now seeking Series A investment of Eur 12 Million.

PIPELINE PRODUCT 1:

RTP-025 - Preclinical Development

PIPELINE PRODUCT 1:

RTP-025 is 46 AA peptide drug that acts as a potent (7 nM) and selective agonist at FPR2 , a G-protein coupled R . RTP-025 potently modulates neutrophil activity, dampen inflammation and initiate innate reparative mechanisms. RTP-025 has demonstrated excellent cardioprotective activity in models of myocardial infarct, where it improves cardiac function following infarct and attenuates mortality .

RTP-025 is in preclinical development as in-hospital, IV therapy for for patients with acute myocardial infarct and/or undergoing percutaneous angiography. The development plan is anchored in well-defined success milestones and will utilize a novel biomarker to guide patient selection. The novel approach will ensure a lean cost structure and enable clinical proof-of-concept within 5 years, thus providing an early opportunity for partnering or sale of the asset.

RTP-025 is patent protected by a portflio of composition of matter and technology patents issued in major markets.

PIPELINE PRODUCT 2:

RTP-026 -Preclinical development

PIPELINE PRODUCT 2:

RTP-026 is 48 AA peptide drug that acts as a potent (20 nM)and selective agonist at FPR2. It is an analogue of RTP-025.

ResoTher Pharma

ADDRESS
Næsseslottet
Dronninggaards Alle 136
2840 Holte
Denmark

WEBSITE
www.resotherpharma.com

E-MAIL
lone.veng@resotherpharma.com

PHONE
+45 41 88 95 70

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2016

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

RTP-025

OPPORTUNITY 1:

- 46 AA peptide drug in preclinical development
- potent (7 nM) and selective agonist at FPR2
- modulates neutrophil activity, dampen inflammation and initiate innate reparative mechanisms
- excellent cardioprotective and anti-inflammatory activity

ADDRESS
Baltorpvej 154
DK-2750 Ballerup
Denmark

WEBSITE
www.saniona.com

E-MAIL
saniona@saniona.com

PHONE
+45 70 705 225

COMPANY TYPE
Public

TICKER
[STO: SANION]

SECTOR
Biotechnology

YEAR FOUNDED
2012

SANIONA AB

COMPANY PROFILE

Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Proximagen Ltd., Productos Medix, S.A and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq Stockholm Small Cap and has about 5,100 shareholders. The company's share is traded under the ticker SANION.

MANAGEMENT TEAM

CEO, Drejer, Jorgen

CFO, Feldthus, Thomas

Chairman, deBethizy, Don

FINANCIAL SUMMARY

Nasdaq Stockholm listing 2017

PIPELINE GRAPHIC



In addition to the active pipeline shown above, Saniona has a range of validated drug discovery assets as well as clinical stage assets positioned for partnering or spin-out.

PIPELINE PRODUCT 1:

Tesomet Ph2

PIPELINE PRODUCT 1:

Tesomet is a unique weight loss program for eating disorders including Prader Willi and binge eating and "metabolic disorders" including obesity, T2D, NASH

PIPELINE PRODUCT 2:

SAN711 Preclinical development

ADDRESS
Baltorpvej 154
DK-2750 Ballerup
Denmark

WEBSITE
www.saniona.com

E-MAIL
saniona@saniona.com

PHONE
+45 70 705 225

COMPANY TYPE
Public

TICKER
[STO: SANION]

SECTOR
Biotechnology

YEAR FOUNDED
2012

PIPELINE PRODUCT 2:

Saniona's GABA€2/€3 selective compounds including SAN711 have confirmed efficacy in animal models of neuropathic pain without sedative effect and are expected to re-build or improve the body's own pain regulating system in the spinal cord.

PIPELINE PRODUCT 3:

IK blockers, Candidate selection

PIPELINE PRODUCT 3:

IK channel antagonists represent a novel first in class anti-inflammatory treatment in inflammatory bowel disease (IBD). In preclinical colitis models selective IK channel antagonists have demonstrated robust pharmacological effect in different species. T-cell activity is regulated by modulation of IK channels that are up-regulated in activated T cells and generate the driving force during activation and proliferation of T-helper cells. Blocking IK channels is therefore a novel potential therapeutic strategy for the treatment of peripheral autoimmune/inflammatory indications such as IBD, asthma, COPD, rheumatoid arthritis, fibrosis and central neuro-inflammatory diseases such as multiple sclerosis

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

Tesomet - eating disorders

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 2:

SAN711 pain

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 3:

IK program IBD

ADDRESS
43 boulevard du 11 novembre 1918
69100, Villeurbanne,
Rhônes-Alpes
France

WEBSITE
www.signiatherapeutics.com

E-MAIL
contact@signiatherapeutics.com

PHONE
+33 0 478771037

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDER
2017

SIGNIA THERAPEUTICS

COMPANY PROFILE

Signia Therapeutics is a spin-off of Université Claude Bernard Lyon1, that has and will continue to develop a proprietary platform to identify new products for the respiratory tract virus market where new approaches are greatly needed. Signia Therapeutics benefits from well established academic and industrial partnerships of VirPath laboratory, which contribute to significantly de-risking the path to Research and Development, innovation and licensing revenues.

Signia Therapeutics proposes an innovative and versatile platform for antiviral drug discovery and repurposing based on globally targeting the host cell instead of specific viral molecular determinants. This novel proprietary development strategy has already a proven track record and is based on a solid set of proofs of concept. The Company's strategy is well adapted to the pathogenesis of respiratory acute infections and provides a novel approach for the identification of broad-spectrum effective antivirals. The innovative and proprietary platform will offer the minimization of drug resistance, with significant regulatory and financial benefits compared to the time-consuming and costly process of classical de novo molecule development.

Signia Therapeutics is well positioned with a clinical and preclinical pipeline of antivirals of interest to large and specialty pharma partners and targeted markets. Signia already has a Phase 2b trial fully funded for a product identified through its proprietary platform.

Proofs-of-concept were established, several FDA-approved drugs were validated for new antiviral indication and one clinical trial (FLUNEXT) will start in December 2018 for the evaluation of one very promising antiviral candidate in 300 Flu patients, with final results expected in 2020. This clinical trial is financed by the French Health Ministry. Ongoing programs are currently conducted by Signia Therapeutics and dedicated to the identification and validation of broad-spectrum antiviral compounds against Flu, RSV, hMPV and human Coronaviruses such as MERs-CoV. Three patents covering drugs for the treatment of severe influenza and MERS-CoV are under licensing to Signia Therapeutics.

PIPELINE PRODUCT 1:

Signia Therapeutics proposes an innovative and versatile platform for antiviral drug discovery and repositioning based on globally targeting the host cell instead of specific viral molecular determinants. The Company's strategy is well adapted to the pathogenesis of respiratory acute infections and provides a novel approach for the identification of broad-spectrum effective antivirals. The innovative and proprietary platform will offer the minimization of drug resistance, with significant regulatory and financial benefits compared to the time-consuming and costly process of classical de novo molecule development. Signia Therapeutics initial strategy focuses on the identification and repurposing of already FDA-approved drugs for new antiviral indication. The Company's proposes a novel strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs for new antiviral indication against one or several human respiratory viruses that could be evaluated in clinical trials.

PIPELINE PRODUCT 2:

Repositionned Diltiazem et Etilefrine as antivirals to treat Influenza. Validated and in Phase 2b trial.

PIPELINE PRODUCT 2:

Very few efficient vaccines or antiviral treatments have been reported in the medical literature to fight against respiratory pathogens, with the exception of those available against influenza viruses. Signia's platform has generated proofs-of-concept, confirming the exploitability of clinical samples directly obtained from infected patients for

ADDRESS
43 boulevard du 11 novembre 1918
69100, Villeurbanne,
Rhônes-Alpes
France

WEBSITE
www.signiatherapeutics.com

E-MAIL
contact@signiatherapeutics.com

PHONE
+33 0 478771037

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDER
2017

the determination of enriched signatures of infection in a "real life" pathophysiological scenario. The development of improved experimental models for antiviral screening/validation also contributed to the identification of a new generation of more effective FDA-approved drugs that were repurposed for a new antiviral indication. One clinical trial (FLUNEXT) whas started in December 2017 for the evaluation of one very promising antiviral candidate discovered with Signia's discovery platform in 300 Flu patients, with final results expected in 2019. This clinical trial is financed by the French Health Ministry. The Company is seeking licencing & partnership opportunities (including co-development) for its 3 patents for 5 repurposed drugs to treat Flu.

PIPELINE PRODUCT 3:

Confidential - Candidates A & B to treat MERS-CoV infections in preclinical stage.

PIPELINE PRODUCT 3:

Middle East respiratory syndrome is a viral respiratory disease caused by a novel coronavirus (MERS€CoV) that was first identified in Saudi Arabia in 2012. Although the majority of human cases of MERS have been attributed to human-to-human infections in health care settings, current scientific evidence suggests that dromedary camels are a major reservoir host for MERS-CoV and an animal source of MERS infection in humans. Health care associated outbreaks have occurred in several countries, with the largest outbreaks seen in Saudi Arabia (80% of total reported cases), United Arab Emirates, and the Republic of Korea. The Company is seeking licencing & partnership opportunities (including co-development) for 2 repurposed drugs to treat MERS-CoV currently in preclinical stage. Results show strong inhibition of viral replication in human lung epithelial cells, antiviral activity in the micromolar range and activity against other CoV.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

Antivirals/antimicrobial discovery and validation platform

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 2:

Repositionned Diltiazem et Etilefrine as antivirals to treat Influenza. Validated and in Phase 2b trial.

STALICLA SA

ADDRESS
Campus Biotech
Innovation Park
Avenue de Secheron 15
1202 Genève
Switzerland

WEBSITE
www.stalicla.com

E-MAIL
Lynn.durham@stalicla.com

PHONE
+41 78 812 68 98

COMPANY TYPE
Private

SECTOR
Biotechnology
Pharmaceuticals/Licensing
Diagnostics

YEAR FOUNDED
2017

COMPANY PROFILE

STALICLA is an autism spectrum disorder (ASD) focused, data guided, drug development biotech company. Today patients with autism spectrum disorder account for 1-1.5% of the world population. The condition remains a high unmet medical need. STALICLA has taken a unique approach to bringing personalized medicine to patients with ASD. It has developed an innovative algorithm based platform (DEPI) that uses robust sets of clinical signs and symptoms with big data analytics to identify subgroups of patients with ASD. By identifying these subgroups, STALICLA is advancing repurposed drugs that provide more effective, personalized treatment options. STP1, addresses a uniquely characterized sub-group of ASD patients which represent 15% of the total ASD population.

MANAGEMENT TEAM

- Lynn Durham, CEO and Founder
- Joseph Wettstein, Ph.D. - Acting Chief of Development and Strategy
- Luigi Boccuto, MD - Chief Scientific Officer
- Jean-Marc Hyvelin, Ph.D. - Research Project and Operations Manager

FINANCIAL SUMMARY

- Successful multi million initial financing round with Biotech Experienced investors
- Round A - Q3- Q4 2018 - CHF 15 million
- Round B - expected 2021 - CHF 50 - 70 million
- IPO - 2023
- Market entrance - targeted 2025

PIPELINE GRAPHIC



PIPELINE PRODUCT 1:

DEPI (Data EndoPhenotyping Patient Identification): STALICLA's innovation engine beta version

PIPELINE PRODUCT 1:

DEPI is an algorithm conceived as a mathematical probabilistic model that summarizes large databases in interpretable manner. DEPI's operating software evidences commonalities between ASD big data and non ASD biomedical data. Commonalities are then filtered through personalized patient data. The novelty of DEPI does not solely

STALICLA

ADDRESS
Campus Biotech
Innovation Park
Avenue de Secheron 15
1202 Genève
Switzerland

WEBSITE
www.stalicla.com

E-MAIL
Lynn.durham@stalicla.com

PHONE
+41 78 812 68 98

COMPANY TYPE
Private

SECTOR
Biotechnology
Pharmaceuticals/Licensing
Diagnostics

YEAR FOUNDED
2017

stand in applying big data resources to clinical development but in doing so by integrating clinical data that had previously not been considered in ASD (e.g. sets of phenotype specific signs and symptoms). This allows to establish therapeutic target hypotheses, and use these to identify safe repositionable drugs.

PIPELINE PRODUCT 2:

STP1 (STALICLA Therapeutic Package 1) - pre-clinical

PIPELINE PRODUCT 2:

STALICLA's first therapeutic package (STP1) is intended to serve a well-defined subgroup of the ASD population, so-called ASD Phenotype 1 (ASD Ph1). This sub-population is characterized by sets of signs and symptoms and by a lower level of a specific biomarker.

STP1 comprises:

- a companion diagnostic, which permits the identification of ASD Ph1 patient
- a patented combination of two repurposed drugs
- a monitoring assay

STALICLA's patented therapeutic compounds consist of a combination of two repurposed drugs, aiming to restore several intracellular processes.

STEP PHARMA SAS

ADDRESS
28 Cours Albert 1er
Paris, 75008
France

WEBSITE
www.step-ph.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2014

COMPANY PROFILE

Step Pharma is focused on the development of a novel class of oral nucleotide synthesis inhibitors targeting CTPS1 for the improved treatment of a range of autoimmune diseases. The company has identified several series of CTPS1 inhibitors, with the most advanced series currently undergoing lead optimization.

Step Pharma was founded in June 2014 by Kurma Partners, the Imagine Institute, and Sygnature Discovery based on the scientific discoveries of Dr Sylvain Latour's laboratory and Prof. Alain Fischer (UMR1163 Inserm unit). Step Pharma is based in Paris, France

MANAGEMENT TEAM

CEO : Geoffroy de Ribains

CSO: Tim Bourne

FINANCIAL SUMMARY

Raised close to €17M in equity in two rounds : Seed €2.4M (2015), series A €14.5M (2017).

Investors include :Kurma Partners, Bpifrance, Inserm Transfert Initiative, Pontifax, Sygil Group and Imagine Institute.

PIPELINE PRODUCT 1:

The most advanced compounds are small molecule CTPS1 selective inhibitors currently in lead optimisation.

UPSTREAM MEDICAL TECHNOLOGIES

ADDRESS
87 St David Street
9016, Dunedin
Otago
New Zealand

WEBSITE
www.upstreamdx.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2015

UPSTREAM MEDICAL TECHNOLOGIES LTD.

COMPANY PROFILE

Upstream Medical Technologies Ltd is a molecular diagnostics company specializing in human cardiovascular disease diagnostics. The IP secured biomarkers based on specialist protein peptides developed by an internationally recognized medical research team based in the Christchurch Heart Institute. Upstream's pipeline of molecular tests enable earlier (preventive) diagnostics for improved patient recovery.

MANAGEMENT TEAM

Ruth Appleby, Ph.D., CEO

Chris Pemberton, Ph.D., CSO

Roland Toder, Ph.D., Executive Director

Colin Dawson, BVSc,MBA,CFInstD., Executive Chairman

FINANCIAL SUMMARY

2015 Founded

2015 Founders round NZD 1100

2016/2017 Seed round NZD 1400

PIPELINE GRAPHIC



PIPELINE PRODUCT 1:

UA Score/Pre-clinical

PIPELINE PRODUCT 1:

Upstream Medical Technologies UA Score a screening tool for assisting with triage of chest pain patients presenting to the Emergency Department.

UA Score provides a rapid solution with a simple blood test to help solve ED congestion, providing improved patient outcomes and reducing health care costs.

There is an unmet medical need to identify patients at risk of heart attack who have not yet had a heart attack. Patients in this risk category along with heart attack patients have acute coronary syndrome (ACS).

About one third of ACS patients have unstable angina. The lack of a simple diagnostic test currently results in many more hospital admissions than necessary and the procedure is repeated testing with heart attack diagnostics to determine a change in patient condition.

UA Score is supported by a 500 patient clinical trial that demonstrated clinical value as a rule out test with a NPV of over 98%. A multi-centre international trial is planned to further validate this data and gain FDA 510K approval.

UPSTREAM MEDICAL TECHNOLOGIES

ADDRESS
87 St David Street
9016, Dunedin
Otago
New Zealand

WEBSITE
www.upstreamdx.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2015

The technology is based on the discovery of novel protein fragments in the blood, of the signal peptide class. Eight patent families secure a pipeline focussed on cardiovascular disease and disease associated with cardiovascular complications, such as diabetes and kidney disease.

All tests are immunoassays on blood samples and can be easily adapted for high throughput analysers.

Upstream Medical Technologies has patented the therapeutic use of the lead biomarker, large animal data demonstrating protection against ischemic reperfusion injury occurring in heart attack.

PIPELINE PRODUCT 2:

GHR/PNEUsp: Diagnostic for identification of Acute Decompensated Heart Failure with copresent pneumonia. Preclinical, 400 patient clinical trial

PIPELINE PRODUCT 2:

With a greater than 99% negative predictive value this test rules out the presence of infection overlapping with acute heart failure in these patients.

Approximately 15% of ED patients have Heart failure and of these up to 15% will have copresent pneumonia. The two conditions can be difficult to diagnose independently, with one masking the other. Failure to diagnose correctly and rapidly has adverse outcomes for the patient.

Upstream Medical Technologies', second in line test, meets the unment medical need and can identify acute decompensated heart failure and pneumonia when the patient has both conditions.

PIPELINE PRODUCT 3:

EPOsp - Kidney disease and sports doping, pre-clinical, 135 patient trial

PIPELINE PRODUCT 3:

EPOsp has immediate application as a marker of endogenous erythropoietin (EPO) levels and therefore detection of doping in athletes.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

Series A investment

OPPORTUNITY 1:

Seeking investment of USD 5 million on a pre-money valuation of USD 10 million.

Funds will be applied to the international clinical trial and be key to transitioning the company from pre-clinical to clinical. The trial and FDA submission process is anticipated to be complete after 18 months.

At this stage a significant value uplift of the company is anticipated. This will be through licensing to a major diagnostic company and securing the recognition of the novel peptide class as a new diagnostic tool proving the value of the pipeline products.

VAXIMM

ADDRESS
Technologiepark Basel
Hochbergerstrasse 60c
4057 Basel
Switzerland

WEBSITE
www.vaximm.com

EMAIL
info@vaximm.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2008

VAXIMM AG

COMPANY PROFILE

VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer.

VAXIMM's technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens.

The Company's lead product candidate, oral VXM01, currently in clinical trials, activates killer T-cells targeting tumor vasculature and certain immune-suppressive cells and causes increased inflammation in solid tumors.

VAXIMM completed a Phase I/II trial of VXM01 in advanced pancreatic cancer. Clinical trials are completed or ongoing in metastatic colorectal cancer and in recurrent glioblastoma (brain cancer). VXM01 has received orphan designation from the European Commission and from the US Food and Drug Administration(FDA) for the treatment of glioma. Additionally, VAXIMM has a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. to evaluate avelumab, a human anti-PD-L1 antibody, in combination with VXM01. Under the terms of the agreement, VAXIMM will be responsible for conducting two open-label Phase I/II trials – one in glioblastoma and one in metastatic colorectal cancer. Preclinical data support that adding VXM01 to treatment with a checkpoint inhibitor may increase survival.

The Company has several additional product candidates at various stages of preclinical development. These candidates can be developed as stand-alone therapies or in combination with other immunotherapies, including VXM01. In addition, VAXIMM is also using its platform technology to develop a personalized neoantigen approach. VXM NEO has already demonstrated immune proof of concept.

Investors in our company include: BB Biotech Ventures, Merck Serono Ventures, Sunstone Capital and BioMed Partners.

VAXIMM AG is headquartered in Basel, Switzerland with a wholly owned subsidiary, VAXIMM GmbH (Mannheim, Germany), from where the Company's development activities are orchestrated, and a laboratory in Regensburg, Germany.

MANAGEMENT TEAM

Dr. Thomas Hecht, Executive Chairman

Dr. Heinz Lubenau, COO

Dr. Marc Mansour, CBO

PIPELINE PRODUCT 1:

VXM01 targeting VEGFR-2.

VXM01 is in clinical phase I/II in various indications. A clinical combination study with the anti-PD-L1 checkpoint inhibitor in recurrent glioblastoma patients is in preparation.

PIPELINE PRODUCT 1:

VXM NEO targeting neonatigens.

VXM NEO is in the preclinical phase of development. The clinical first-in-human study is currently being prepared.

PIPELINE PRODUCT 2:

VXM10 targeting PD-L1.

VXM10 targeting PD-L1 is currently in the preclinical phase of development.

PIPELINE PRODUCT 2:

VXMXX targeting various tumor-associated antigens including WT-1, mesothelin, CEA, and others.

SILVER SPONSOR

EURONEXT

www.euronext.com

About Euronext

Euronext is the leading pan-European exchange in the Eurozone with nearly 1,300 listed issuers worth close to €3.6 trillion in market capitalisation as of end December 2017, an unmatched blue chip franchise consisting of 24 issuers in the Morningstar® Eurozone 50 Index and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM (formerly known as Alternext) and Euronext AccessTM (formerly known as the Free Market).

About the Euronext European Tech Initiative

In 2017, Euronext launched a European Tech SME initiative and opened new offices in four European countries outside its core markets, in Germany (Frankfurt, Munich), Italy (Milan), Spain (Madrid) and Switzerland (Zurich), to assist tech companies in developing their business on a greater scale through capital markets. With more than 330 listed Tech SMEs representing a total market capitalisation close to €60 billion, and over 750 active tech investors, Euronext is the primary venue for innovative companies in Europe. Since 2014, close to 90 tech companies have gone public on Euronext markets, of which eight were from the four new countries in Europe. Local Directors are working closely within these ecosystems to deploy initiatives aimed towards tech entrepreneurs.

To find out more go to https://tech.euronext.com/en/tech-hub.

SILVER SPONSOR

TORREYA PARTNERS, LLP

www.torreya.com

Torreya Partners, LLP is a leading boutique advisory firm that provides strategic advice and assistance with Mergers & Acquisitions, Partnering and Financings to life science companies worldwide. Torreya Partners provides the long-term thinking and objective advice required for life science companies to create lasting value. We take great pride in handling complex financial and strategic matters for some of the most sophisticated private and public life science companies in the world. Our reputation has been built on quality advice, excellence in deal execution and good outcomes for our clients. We bring the caliber of people and quality of relationships found in some of the largest investment banks along with the attentive, detailed service you expect from a boutique advisory firm. Torreya Partners has offices located in New York, Philadelphia and San Francisco.

SUPPORTING ORGANISATIONS

BIOPARTNER

www.biopartner.co.uk

BioPartner is an independent, government-accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. BioPartner's delegations promote the UK presence at major international biopharma conferences, and companies are assisted with access to government grants and heavily discounted entry fees. Through the BioPartner Programme, members receive extra benefits and support to effectively trade overseas.

SUPPORTING ORGANISATIONS

BIOTECHGATE

www.biotechgate.com

Biotechgate is a global, comprehensive, life science database covering the Biotech, Pharma and Medtech industries. There are currently over 36,000 company profiles on the Biotechgate database. Biotechgate is commonly used to find product pipelines, collaboration partners, in/out-licensing opportunities and information about technology platforms, management details, new business leads and financing rounds. In addition, our licensing deals database supports companies in negotiating their licensing agreements.

SUPPORTING ORGANISATIONS

Citigate Dewe Rogerson

CITIGATE DEWE ROGERSON

www.citigatedewerogerson.com

Citigate Dewe Rogerson is one of the most respected names in communications. We are experts in our fields, combining the expertise of bankers, fund managers, in-house investor relations, former journalists and creative communications professionals as well as sector and transaction specialists.

We are City-based but our business and perspective are international. We serve over 500 clients from new start-ups to some of the world's largest listed companies, governments and other organisations from our offices in London and in the US, Europe, the Gulf and Asia.

SUPPORTING ORGANISATIONS

EDISON

www.edisongroup.com

Edison is an international advisory firm with around 450 corporate clients and 110 people working from offices in London, New York, Frankfurt, Sydney and Wellington. The team consists of 80 analysts, investment and logistics professionals with experience in capital markets, investor roadshows and communications. Healthcare is Edison's largest sector, with 16 analysts covering over 100 biotech and medtech stocks across the UK, continental Europe, North America and Asia-Pacific.

SUPPORTING ORGANISATIONS

FREEMIND
Non-Dilutive Funding Experts

FREEMIND

www.freemindconsultants.com

FreeMind is a consulting group whose goal is to assist in maximizing potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind working with academics and Industry alike. FreeMind's proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date.

Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations. FreeMind's knowledgeable and experienced team of Client Strategists and Project Managers are dedicated to guiding non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of xperts will assist in making non-dilutive funding a key tool in a long-term financial strategy.

SUPPORTING ORGANISATIONS

INSTINCTIF PARTNERS

INSTINCTIF PARTNERS

www.lifesciences.instinctif.com

Instinctif Partners is an international business communications consultancy. With a track record of delivering truly creative programmes, the Life Sciences practice focuses on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering specialist expertise seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities. Our service offering covers all communications disciplines including strategic counsel, PR, IR, media relations, public affairs, crisis communications, internal communications, marketing, advertising, copywriting, design, research and event management. Our globally integrated and dedicated life sciences team serves clients around the world from our headquarters in London, and bases across Europe, AsiaPac and the USA.

SUPPORTING ORGANISATIONS

Plattform Life Sciences

THE LIFES SCIENCES-SERIES

www.goingpublic.de/lifesciences

The Life Sciences-Series - Launched in 2014 four issues of the Life Sciences-Series appear annually. Based on the three pillars – technology, financing, investment – the issues combine current topics of life sciences with knowledge and networking from corporate financing and capital market. The mission: Building a cross medial bridge between the life sciences and the financial industry by the help of the quarterly Life Sciences issues, the monthly digital newsletter LifeSciencesUpdate.

SUPPORTING ORGANISATIONS

SWISS BIOTECH™ National Thematic Network

SWISS BIOTECH

www.swissbiotech.org

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland's profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies.Swiss Biotechs' mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.

SUPPORTING ORGANISATIONS

TIBEREND STRATEGIC ADVISORS, INC.

www.tiberendstrategicadvisors.com

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics.We work with both public and private emerging growth companies:

1. To enhance valuation
2. To build visibility for partnerships and strategic alliances

SACHS ASSOCIATES

www.sachsforum.com

Sachs Associates is a long established international conference company with offices in Switzerland and the UK. It runs a limited number of high profile conferences in Europe and the USA which are focused on bio-pharma, medtech, and digital health. These conferences focus on licensing and investment opportunities and all provide presenting opportunities for companies and excellent meeting facilities for all delegates to network.

Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

THE BENEFITS OF CONFERENCE PARTICIPATION WITH SACHS ASSOCIATES MAY BE SUMMARISED AS FOLLOWS:

ONLINE ONE-2-ONE MEETING SYSTEM

In order to offer the best possible provision for networking opportunities and deal making Sachs Associates provides all delegates access to our online one-to-one meeting system, allowing you to set up, accept or decline private one to one meetings with other conference attendees. These meetings last for 20 minutes in duration. Individual passwords and logins are provided to allow immediate access and ensure full security.

CUTTING EDGE CONTENT WITH EMINENT SPEAKERS

Sachs Associates is committed to ensuring that its events continue to provide forums with the participation of the most eminent speakers from the public and private sectors. Through its reputation and its long-established local relationships, the Company has attracted very senior scientific and business personalities as speakers at its events.

SPONSORSHIP AND MARKETING OPPORTUNITIES FOR FORTHCOMING EVENTS

Sachs Associates has developed an extensive knowledge of the key individuals operating within the global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase your company position in this market. Sponsorship of any of our events allows you to raise your company's profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.

THE FOLLOWING SPONSORSHIP AND MARKETING OPPORTUNITIES ARE AVAILABLE AT FUTURE CONFERENCES:

- Conference Sponsor – including workshops and social events
- Exhibition stands
- Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities, please call Silvia Kar on +44 203 463 4890 or email Silvia@sachsforum.com.



SACHS
ASSOCIATES

www.sachsforum.com